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1. PSEUDOMONAS AERUGINOSA AND ACINETOBACTER 
BAUMANNII INFECTIONS 
Despite decades of intensive antimicrobial development, bacterial infections remain 
an important cause of morbidity and mortality in hospital. Meanwhile, the increasing 
bacterial resistance to conventional antibiotics further poses a considerable health 
threat worldwide. Pseudomonas aeruginosa and Acinetobacter baumannii are two 
Gram-negative pathogens which are frequently found in clinical samples. These 
nosocomial pathogens affect severely ill patients with compromised immune systems, 
and cause a wide spectrum of infections in wounds, urinary tract, bloodstream and 
lung. P. aeruginosa has long been recognized as a pathogen with notable virulence, 
while A. baumannii is less virulent, it is also increasingly associated with numerous 
outbreaks of infections, especially in the intensive care units (ICUs). Types of 
possible P. aeruginosa and A. baumannii infections are listed in Table 1.1.  
Table 1.1 Types of infections can be caused by P. aeruginosa and A. baumannii. 
Pathogens Infections 
P. aeruginosa Respiratory tract infection: ventilator-associated pneumonia, cystic fibrosis 
 Central nervous system infection: meningitis 
 Ear infection: chronic otitis media, malignant otitis externa 
 Eye infection: keratitis, endophthalmitis 
 Skeletal system infection 
 Gastrointestinal tract infection 
 Urinary tract infection 
 Skin and soft tissue infection: burns and chronic wound infection 
 Blood stream infection: bacteremia, sepsis 
 Endocarditis 
A. baumannii Respiratory tract infection: pneumonia 
 Blood stream infection: bacteremia, sepsis 
 Central nervous system infection: meningitis. 
 Wound and surgical site infections 
 Urinary tract infection 
 
Both of these pathogens are noted for their genetic potential to carry and transfer 
diverse antibiotic resistance mechanisms, leading to limited therapeutic options in the 
clinic. According to the global priority list of antibiotic-resistant bacteria released by 
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the World Health Organization (WHO) in 2017 [1], carbapenem-resistant A. 
baumannii is on top of the list, followed by carbapenem-resistant P. aeruginosa, both 
with critical priority (Table 1.2). Given the rapid emergency of resistant P. aeruginosa 
and A. baumannii strains, discovery of alternative treatment strategies for these 
pathogens has become an urgent priority. 
Table 1.2 Global priority list of antibiotic-resistant bacteria to guide research, discovery, and 
development of new antibiotics [1] . 
Priority 1: CRITICAL  
 Acinetobacter baumannii, carbapenem-resistant 
 Pseudomonas aeruginosa, carbapenem-resistant 
 Enterobacteriaceae, carbapenem-resistant, 3rd generation 
cephalosporin-resistant 
Priority 2: HIGH  
 Enterococcus faecium, vancomycin-resistant 
 Staphylococcus aureus, methicillin-resistant, vancomycin intermediate 
and resistant 
 Helicobacter pylori, clarithromycin-resistant 
 Campylobacter, fluoroquinolone-resistant 
 Salmonella spp., fluoroquinolone-resistant 
 Neisseria gonorrhoeae, 3rd generation cephalosporin-resistant, 
fluoroquinolone-resistant 
Priority 3: MEDIUM  
 Streptococcus pneumoniae, penicillin-non-susceptible 
 Haemophilus influenzae, ampicillin-resistant 
 Shigella spp., fluoroquinolone-resistant 
 
1.1 Pathogenicity of P. aeruginosa and A. baumannii 
As a successful opportunistic pathogen that takes advantage of a host with a weak 
immune system, P. aeruginosa shows high adaptability and can survive under 
nutrient-poor conditions and different stresses. The pathogenesis of P. aeruginosa is 
mediated by various virulence factors such as adhesins, proteases, secreted toxins 
and pigments which help P. aeruginosa to colonize and escape the host immune 
systems [2, 3]. The production of several virulence factors is closely related to the 
complex quorum sensing (QS) regulatory network. Type III secretion system (T3SS), 
a protein appendage found in several Gram-negative bacteria, is also a major 
determinant of virulence, which injects toxins directly into host cells during infections. 
However, the pathogenicity of P. aeruginosa varies from strain to strain, and 
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differential sets of pathogenicity factors and mechanisms are found in different 
isolates.  
A. baumannii has emerged as a highly troublesome pathogen in last decades, and 
similar to P. aeruginosa it can cause various types of infections, and spread quickly 
during hospital outbreaks. A number of virulence factors have been identified in A. 
baumannii including secretion systems, surface glycoconjugates and iron acquisition 
systems [4-6]. However, discernible toxins or molecular determinants which can 
account for the virulence potential of a particular A. baumannii strain are often absent, 
and a “persist and resist” strategy contributes to the success of A. baumannii [6]. The 
most striking fact about A. baumannii is its ability to acquire antibiotic resistance and 
the globally rapid emergence of multidrug resistance (MDR) strains. 
1.2 Antibiotic resistance in P. aeruginosa and A. baumannii 
P. aeruginosa and A. baumannii strains are resistant to many antimicrobials through 
inherent structural or functional characteristics, and they can also acquire resistance 
easily by mutations or acquisition of genetic material [7]. Different types of β-
lactamases have been identified in both P. aeruginosa and A. baumannii, such as 
AmpC cephalosporinases and metallo-β-lactamases [8]. Aminoglycoside-modifying 
enzymes are also commonly found in these two pathogens, attributing to the 
resistance to aminoglycosides [8]. Other important resistance mechanisms shared by 
P. aeruginosa and A. baumannii include mutations in porins and overexpression of 
efflux pumps. The accumulation of multiple resistance mechanisms leads to MDR 
strains which are resistant to almost all available antibiotics. Antibiotics cause a 
selective pressure by killing susceptible bacteria, allowing antibiotic-resistant bacteria 
to survive and multiply and leading to the emergence of MDR strains. These MDR 
strains can spread quickly resulting in prolonged outbreaks. As carbapenem-resistant 
P. aeruginosa and A. baumannii strains are increasing in the hospital worldwide, only 
a few treatment options are still available. Colistin has been regarded as the last-
resort antibiotic to treat P. aeruginosa and A. baumannii MDR strains, but resistance 
against colistin was also described and might spread worldwide [9, 10].  
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1.3 Biofilm formed by P. aeruginosa and A. baumannii 
Biofilms are structures formed by surface-attached bacteria embedded in an 
extracellular polymeric matrix consisting of proteins, nucleic acids and 
polysaccharides. Chronic infections such as pneumonia in cystic fibrosis patients, 
chronic wounds and implant- and catheter-associated infections are closely 
associated with biofilm formation [11]. Bacteria within biofilms are shielded from 
antibiotic treatment and host immune defense system. An altered microenvironment 
existing in biofilms with gradients of nutrients, pH and oxygen, and gene expression 
in biofilm cells is significantly distinct from those in planktonic cells. In addition, a 
relatively large population of persister cells, which are able to survive antibiotic 
treatment and resume their growth, can be found in biofilms [12, 13]. P. aeruginosa is 
frequently involved in biofilm-associated infections and has been used as a model 
organism to study biofilms in Gram-negative bacteria. The whole process of biofilm 
formation includes cell attachment, microcolony formation, maturation, expansion and 
dissemination (Figure 1.1) [14]. Rhamnolipids, secreted polysaccharides like Pel, Psl 
and alginate, and extracellular DNA (eDNA) play an important role in maintaining the 
structure of the biofilm and matrix in P. aeruginosa [14]. A. baumannii clinical isolates 
also possess a strong ability to form biofilms [15], both in tissues and on the surfaces 
of medical devices. A number of genes have been reported to be involved in 
adhesion and biofilm development of A. baumannii as reviewed by Longo et al. [16]. 
 
Figure 1.1 Biofilm formation and characteristics. The different stages of biofilm formation from free-
swimming cells (a), attachment to the surface (b,c), formation of microcolonies (d), formation of a 
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mature three-dimensional biofilm architecture (e), and dispersion (f,g). (Modified from Römling et al., 
2012 [13]) 
1.4 Wound infections caused by P. aeruginosa and A. baumannii  
Acute and chronic wound infections affect millions of people worldwide and represent 
a considerable healthcare burden [17]. Surgical or traumatic wounds and burns are 
typical acute wounds. Chronic wounds are those detained in the normal wound 
healing process, such as diabetic, arterial, venous and pressure ulcers. Although 
several factors contribute to wound healing, bacterial infections can significantly 
delay this process. Chronic wounds can be colonized by a wide range of bacteria and 
fungi, including P. aeruginosa and A. baumannii [18, 19]. A. baumannii wound 
infections have been reported with increasing incidences of outbreaks among victims 
of combat injuries and natural disasters [20]. It is also an infrequent cause of skin and 
soft tissue infections in intensive care unit patients [21]. P. aeruginosa is among the 
most common bacteria isolated from chronic wounds [22]; it also causes infections in 
burn wounds, leading to rapid clinical deterioration, systemic spread, and in some 
cases death within days or weeks [23]. 
Biofilms are prevalent especially in chronic wounds and are often composed of 
diverse bacterial species. Fungi like Candida albicans and the bacterial pathogen S. 
aureus are common species in wound infections. Biofilms formed by C. albicans and 
S. aureus revealed a unique architecture in which S. aureus is associated with the 
hyphae of C. albicans [24]. The simultaneous infection with S. aureus and P. 
aeruginosa can significantly impair wound closure as compared to monospecies 
biofilms in mouse and rabbit wound healing models [25, 26]. Polymicrobial infections 
involving P. aeruginosa and A. baumannii have also been frequently reported [27-29]. 
A better understanding of the precise mechanisms by which bacterial biofilms delay 
repair processes as well as optimizing methods for biofilm detection and prevention 
may enhance opportunities for chronic wounds healing. 
Wound biofilms raise difficult problems in clinical diagnosis and treatment. 
Debridement has been studied as an approach of wound cleansing which facilitates 
the wound healing by reducing wound biofilms [30]. Maggot debridement therapy 
(MDT), in which live and ‘medical-grade’ fly larvae (Lucilla sericata) are applied to the 
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patient's wounds to achieve debridement, disinfection and wound healing has 
recently received considerable attention [31, 32]. MDT mainly helps wound healing 
by debridement of necrotic tissue by both mechanical and biochemical means; a 
mixture of proteolytic enzymes can be secreted by the maggots and lyse nonviable 
tissue [33]. However, QS-regulated virulence factors of P. aeruginosa are toxic to the 
maggots, leading to the failure of MDT treatment in wound infections with P. 
aeruginosa [34]. 
 
1.5 Novel strategies against P. aeruginosa and A. baumannii 
infections 
To cope with the growing threat of resistant pathogens, several novel strategies have 
been proposed and are currently widely studied. Except for new antibiotics, anti-
virulence agents are considered as promising ways to disarm P. aeruginosa and A. 
baumannii during infections without interfering with bacterial viability and/or exterting 
a selective stress like conventional antibiotics. Inhibitors against specific virulence 
factors such as elastase, T3SS and lectins in P. aeruginosa have been reported, 
however, one such inhibitor alone may not be able to block the virulence of P. 
aeruginosa [35]. Iron chelation is also frequently discussed for both A. baumannii and 
P. aeruginosa [36, 37]. For each approach, many questions remain to be answered 
before application will be possible. In the following part of this thesis, we will focus on 
the QS regulation system, one of the most extensively studied anti-virulence targets 
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2. QUORUM SENSING 
2.1 General review of quorum sensing 
Research in QS started with the study of the growth-dependent bioluminescence in 
the marine bacteria Vibrio fischeri and Vibrio harveyi in 1970s [38, 39]. A specific 
substance (autoinducer) was assumed to accumulate and induce the synthesis of the 
luminescence system components in this “autoinduction” phenomenon [39], as 
bioluminescence is only observed at high cell population density. Autoinducers in 
both species were identified later as N-acyl-homoserine lactones (AHLs) [40, 41], 
which now have been recognized as the dominant signal molecules in QS of many 
Gram-negative bacteria. A typical QS cascade includes synthesis of signal molecules, 
signal detection and transduction, and transcriptional gene regulation. When the 
threshold concentration of autoinducers is exceeded, bacteria can alter their gene 
expression and behavior correspondingly on a population-wide scale [42-44]. QS 
synchronizes processes such as symbiosis, conjugation, biofilm formation, motility, 
virulence [45], as well as the production of public goods (secreted compounds that 
might provide more benefit at higher population densities) [46].  
So far, a collection of different chemical signals is known to be used in different QS 
systems (Figure 1.2), and more than one signal or pathway can be found in individual 
species of bacteria where they form a hierarchical QS network. Here, several typical 
QS systems are introduced briefly. 
2.1.1 LuxI/LuxR-type quorum sensing 
As mentioned above, AHLs are the most common autoinducers in many Gram-
negative bacteria. Their typical structure contains a core N-acylated homoserine-
lactone ring and an acyl chain (4-18 carbons) with an occasional hydroxy or olefinic 
double bond modification at the C3 position (Figure 1.2) [47]. Responsible for the 
production of AHLs, LuxI-type synthases can be found in hundreds of Gram-negative 
bacterial species [48]. In most cases, they synthesize AHLs from S-
adenosylmethionine (SAM) and acyl carrier protein which participates in fatty acid 
biosynthesis [49]. Short-chain AHLs like N-butyryl-L-homoserine lactone (C4-HSL) 
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can freely diffuse out of cells, whereas AHLs with longer fatty acid chains may also 
require transporters to be released from cells [50]. The concentration of AHLs 
increases along with the growth of the cell population. Binding of LuxR-type receptors 
only occurs when an intracellular AHL concentration threshold is reached, and then 
the LuxR-AHL complexes bind (or release) DNA promoter elements and regulate 
transcription of QS controlled genes [51]. An acyl binding pocket at the N-terminal 
domain of LuxR protein precisely accommodates the acyl chain of its cognate AHL 
signal, which ensures the specificity of the LuxR-AHL interaction [52]. The expression 
of LuxI can also be enhanced by the binding of AHL and LuxR, forming a positive 
regulatory feedback loop in these QS systems [53]. 
 
Figure 1.2 The structures of several common QS signal molecules. (Modified from Atkinson et al., 
2009 [44]) 
 
First identified in V. fisheri [54], LuxI/LuxR-type QS has also been reported and 
widely investigated in Agrobacterium tumefaciens (TraI/R) [55], Chromobacterium 
violaceum (CviI/R) [56], Erwinia carotovora (ExpI/R, CarI/R) [57, 58], Burkholderia 
cenocepacia (CepI/R) [59] and Yersinia enterocolitica (YenI/R) [60], as well as in 
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pathogens P. aeruginosa and A. baumannii which will be discussed in detail in the 
following part. Orphan LuxR-type receptors without an associated synthase are also 
frequently identified, such as TrlR in A. tumefaciens, QscR in P. aeruginosa and SdiA 
in Salmonella enterica and Escherichia coli [61]. These orphan receptors participate 
in the regulation of existing QS network, and could potentially respond to external 
environmental stimuli such as plant compounds that can be detected by TrlR in A. 
tumefaciens [61]. 
2.1.2 Peptide-mediated quorum sensing 
Unlike Gram-negative bacteria, Gram-positive bacteria employ auto inducing 
peptides (AIPs) ranging from 5 to 17 amino acids in length as QS signals. AIPs are 
cleaved or modified after ribosomal synthesis, and ATP-binding cassette transporters 
are involved in their secretion. Sensor kinases belonging to typical two-component 
adaptive response systems recognize AIPs, and the activity of the response regulator 
is influenced through a phosphorylation cascade [62, 63].  
Peptide-mediated QS was first reported in Lactococcus lactis and Streptococcus 
pneumoniae [64, 65]. The accessory gene regulator (Agr) system in the human 
pathogen Staphylococcus aureus has also intensively been studied [66, 67]; it 
positively regulates the expression of many toxins and degradative exoenzymes, and 
negatively regulates the expression of several colonization factors during infections. 
2.1.3 LuxS/AI-2-type quorum sensing 
A furanosyl borate diester [68], designated autoinducer-2 (AI-2), was first reported to 
co-regulate density-dependent luminescence by a Gram-positive-like two-component 
phospho-relay system in V. harveyi [69, 70]. Different from AHLs and oligopeptides, 
AI-2 is produced by many Gram-negative and Gram-positive bacteria with identical 
biosynthetic pathway, and might act as a universal signal in interspecies 
communication [69]. LuxS is the key enzyme involved in the synthesis of the linear 
form of AI-2, 4,5-dihydroxy-2,3-pentanedione (DPD). However, since LuxS is also an 
enzyme in an important central metabolic pathway, the activated methyl cycle (AMC), 
it is equally possible that in some species AI-2 is merely a metabolic by-product [71]. 
AI-2 regulates biofilm formation, motility and other virulence traits among Bacillus 
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cereus, E. coli, Haemophilus influenza and S. aureus [71], and it can also influence 
the biofilm formation of non-AI-2-producing P. aeruginosa [72]. 
2.1.4 Other types of quorum sensing  
It seems common that a single bacterial species uses multiple autoinducers, even 
from different types. In the complex network of V. harveyi, a third autoinducer CAI-1 
(a long-chain amino ketone) was identified [73], which forms a parallel QS circuits 
with AHL and AI-2 type QS [42].  
The molecule 2-heptyl-3-hydroxy-4-quinolone, termed PQS, has been found to be a 
specific signal in the P. aeruginosa QS cascade [74] which will be discussed in the 
following section.  
‘Diffusible signal factor’ (DSF) is a designation used for a collection of cis-2-
unsaturated fatty acids with differing chain length and branching pattern. It influences 
the virulence of a number of plant and human pathogenic bacteria including 
Xanthomonas spp., B. cenocepacia and P. aeruginosa [75].  
Other less prevalent QS signals have also been reported, e.g. pyrone in 
Photorhabdus luminescens [76] and AI-3 (of which the structure has not yet been 
identified) in Enterohemorrhagic E. coli (EHEC) [77]. 
 
2.2 Quorum sensing in P. aeruginosa 
As a notorious opportunistic human pathogen which causes severe and persistent 
infections in immune-compromised patients, one of the major factors responsible for 
the successful invasive behavior and persistence of P. aeruginosa is its high 
adaptability under different conditions. This adaptability is related to its complex 
regulatory signaling networks involving four connected major QS systems (Figure 1.3) 
as well as multiple known QS regulators. Approximately 5~10% genes in the genome 
of P. aeruginosa can be influenced positively or negatively by QS [78, 79].  
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Figure 1.3 QS network in P. aeruginosa. [80] 
 
2.2.1 las and rhl quorum sensing systems 
The AHL-based QS systems in P. aeruginosa have been intensively studied. In the 
first identified las system, LasI directs the synthesis of N-3-oxo-dodecanoyl-L-
homoserine lactone (3-oxo-C12-HSL). The LuxR homolog LasR acts as the 
transcriptional regulator which was initially identified to positively regulate the 
expression of elastase LasB [81-83]. The lasR gene is also responsible for regulating 
the production of alkaline protease and exotoxin A as a global virulence gene 
regulator [84]. 3-oxo-C12-HSL binding is necessary for LasR multimerization and 
LasR functions as a multimer in P. aeruginosa [85]. The MexAB-OprD efflux system 
is involved in active efflux of 3-oxo-C12-HSL from cells [86]. 
C4-HSL was later identified as a second AHL produced by P. aeruginosa [87]. Its 
receptor and synthase are RhlR and RhlI; they are encoded by the rhamnolipid 
synthase gene cluster rhlABR and rhlI, respectively [88, 89]. Compared to the wild 
type, rhlR and rhlI mutants showed defects in the production of elastase, LasA 
protease, rhamnolipid, and pyocyanin [89]. When regulating rhamnolipid biosynthesis, 
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RhlR binds to the promoter of rhlAB both in presence or absence of C4-HSL [90], but 
transcription can only be activated in presence of C4-HSL, whereas RhlR alone acts 
to repress transcription [90]. Besides the dual activator and repressor role of RhlR, a 
recent study also showed the possibility for RhlR to function in the absence of C4-
HSL, and crucial RhlR-regulated virulence factors can be expressed in the absence 
of RhlI [91], which indicates the possible existence of an alternative RhlR ligand 
besides C4-HSL. 
Transcriptome analyses of las and rhl mutant revealed “las-specific genes”, “rhl-
specific genes” and also genes of which the expression is controlled by both AHLs 
[78, 92, 93]. The molecular basis for the specific responses depends on the 
conserved palindromic sequences termed las-rhl boxes in target promoters binding to 
either one or both of the regulators [79].  
2.2.2 Quinolone signaling 
The Pseudomonas quinolone signal (PQS), 2-heptyl-3-hydroxy-4-quinolone, was 
identified as a third signal in QS system of Pseudomonas aeruginosa [74]. 4-
quinolones are secondary metabolites known for their potent antibiotic activity [75]. 
PQS synthesis is controlled by the adjacent pqsABCDE and phnAB operons, as well 
as by pqsH located separately on the chromosome [94]. These genes are also 
responsible for the synthesis of other alkyl-quinolones (AQs) [95]. phnAB genes 
encode an anthranilate synthase which provide primary precursors for PQS synthesis 
[95]. PqsA is an anthranilate-coenzyme A ligase and catalyzes the first step in PQS 
synthesis [96]. The resulting anthranilate-coenzyme A and a β-ketodecanoate are 
condensed to form 2-heptyl-4-quinolone (HHQ) via PqsBCD. As the direct precursor 
of PQS, HHQ can be converted to PQS by the mono-oxygenase PqsH [97, 98]. HHQ 
has been regarded as a messenger molecule in this pathway, and it can also bind to 
the PQS receptor PqsR (also known as MvfR) in a less potent way compared to PQS 
[99]. PqsR regulates the transcription of pqsA-E and phnAB [97], leading to more 
production of HHQ and PQS and forming a positive feedback loop. PqsE is not 
involved in the production of PQS but acts as an effector in response to PQS [100], 
and its role in virulence and interaction between other QS systems has been 
discussed in the review of Sams et al. [100]. However, it is noteworthy that PQS 
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seems dispensable for virulence since pqsH mutation does not attenuate virulence in 
mice [99], while mutants of pqsA, pqsR and pqsE showed reduced virulence [101].  
2.2.3 The integrated quorum sensing (IQS) system 
In 2013, a new cell-cell communication signal was identified and named as integrated 
QS (IQS) for its role in integrating the QS network and stress response mechanisms 
[102]. IQS is 2-(2-hydroxyphenyl)-thiazole-4-carbaldehyde, and its synthesis is 
controlled by the gene cluster ambBCDE which is conserved in various P. aeruginosa. 
Disruption of IQS biosynthesis reduces PQS and C4-HSL production and attenuates 
bacterial virulence in different animal models [102]. Intriguingly, IQS production is 
tightly controlled by las under normal culture conditions but is also activated by 
phosphate limitation, a common stress factor encountered during infections, and IQS 
was demonstrated to be able to partially take over the functions of the central las 
system [102]. Therefore, the IQS system was considered to connect the las system 
and phosphate-stress response mechanism to the pqs and rhl regulatory systems. 
More work is still needed to identify the IQS receptor and to elucidate the detailed 
mechanisms of interplay between las, rhl and pqs systems as well as the phosphate 
regulons. 
2.2.4 Interconnection of quorum sensing regulatory systems 
The las, rhl, pqs, and IQS systems form a sophisticated and interconnected QS 
network in P. aeruginosa, which enables the organism to efficiently regulate the 
production of virulence factors and secondary metabolites. Though more and more 
missing parts have been added to the QS puzzle of P. aeruginosa, there always 
seems more to be discovered. 
The interrelation of the two AHL QS systems has been explored shortly after they 
were discovered. Pesci et al. and Latifi et al. reported in the same year that rhlR 
transcription was positively regulated by LasR/3-oxo-C12-HSL [103, 104]. 3-oxo-C12-
HSL can block C4-HSL from binding to RhlR, indicating the existence of post-
translational control of RhlR by las [103]. However, RhlR has also been reported to 
induce the transcription of lasI in a LasR mutant, which means that the rhl system 
may take over the deficient las system under certain conditions [105].  
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The synthesis and bioactivity of PQS are tightly connected to both las and rhl 
systems [74], and the PQS system seems to play an indispensable and 
multifunctional role in the QS network of P. aeruginosa. Specifically, LasR regulates 
the expression of PqsH, thus controling the conversion of HHQ to PQS [94, 97]. LasR 
also activates PqsR transcription by binding to its promoter, and further influences 
the PQS production controlled by the pqsA-E operon [106, 107]. In addition, the 
transcription of PqsR is repressed by RhlR [106]. PQS production is dependent on 
the ratio of 3-oxo-C12-HSL to C4-HSL, allowing a precise regulatory balance 
between these three QS systems [106, 107]. In turn, PQS induces the expression of 
rhlI, thus regulating the rhl system [106]. PQS and rhl system have also been 
reported to be linked by PqsE, since PQS regulates the expression of pqsE, and 
PqsE could enhance the ability of RhlR and C4-HSL to positively regulate gene 
expression [108]. Additionally, PqsR was reported to contribute to the induction of 
both RhlR and LasR, challenging the current well-known QS model in which the las 
system is placed at the top of the QS hierarchy [109]. 
The IQS system also emphasizes the variable roles of these QS systems under 
different conditions, especially during infection. The interactions between QS systems 
are also highly dependent on the stage of growth. For instance, positive regulation of 
pqsR by LasR happens during exponential stage, but pqsR becomes LasR 
independent in the absence of LasR at later stage of growth [106]. Considering that 
compensations or partial replacement have also been reported between different QS 
systems [102, 105], the hierarchy in QS networks seems quite flexible to changes. 
2.2.5 Potential advantages of combining different QS systems 
A complex network combining different types of QS systems in V. harveyi and P. 
aeruginosa might help them to conteract the possible bias in a changing environment. 
If QS-regulated gene expression would be based on the detection of only one signal 
molecule, then bias could be simply achieved by inactivation of this signal [110]. For 
bacteria only used one AHL-type QS system, their QS system might be easily 
disturbed since the AHL molecule might be unstable at high pH or degraded by other 
quorum quenching enzymes producing organisms, resulting in the failure of infections. 
However, combination of different QS systems may allow replacement or 
complementation by other QS systems. In P. aeruginosa, the IQS system can 
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partially take over the functions of las system under phosphate limitation [102]. 
Additionally, in clinical LasR variant isolates, virulence factors usually considered to 
be LasR dependent can be produced through other means, such as via RhlR directly, 
or through activation of RhlR via quinolone signaling molecules [111]. Therefore, in 
bacteria with multiple QS systems, the effect due to the interference of one signal 
molecule may be minimized, and a functional QS network can be retained as far as 
possible under different conditions. 
2.2.6 Additional regulatory factors of quorum sensing 
As a global regulatory system, QS itself is embedded in an even more complex 
network of global regulation (Figure 1.4) [79]. Many QS-controlled genes seem not 
simply triggered by the accumulation of signal but also require additional factors [79]. 
Interactions between QS and other regulatory systems have been reported, and 
several well-known ones are discussed below. 
 
Figure 1.4 The interconnection of QS with other regulatory networks. [79] 
2.2.5.1 Transcriptional regulators 
The pivotal transcriptional regulator RsaL has been reported to repress lasI 
expression by binding to the promoter of lasI [112, 113] and is involved in maintaining 
3-oxo-C12-HSL homeostasis. RsaL affects transcript level of many genes either by 
repressing lasI or interacting with their promoters directly [114]. A positive QS 
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modulator VqsM can also bind to the lasI promoter region [115, 116]. A vqsM mutant 
showed repressed type III secretion and reduced virulence in a mouse model, 
however its biofilm formation and resistance to several antibiotics were increased 
[115], indicating the multifaceted regulatory mechanisms of this regulator. AlgR2 
(AlgQ) is also a global regulator modulating the levels of GTP (guanosine 
triphosphate), ppGpp (guanosine tetraphosphate), alginate and polyphosphate [117]. 
It negatively regulates the expression of lasR and rhlR by binding to their promoters 
[118]. MvaT is a repressor of AHL QS, and it was considered to be required for the 
appropriate timing of expression of the QS regulon [94]. The mvaT mutant exhibits 
increased and premature expression of QS-regulated genes [119]. Another 
transcriptional regulator AmpR positively regulates rhlR expression and negatively 
regulates lasI/R expression [120]. It is also involved in the positive regulation of 
AmpC and PoxB β-lactamase [120]. A TetR-like transcriptional repressor PA3699 
was shown to repress the lasR promoter and the production of LasR-dependent 
virulence factors [121].  
The two-component regulatory system BfmS/R has been reported to influence rhl 
system [122]. Deletion of the regulatory sensor bfmS leads to the activation of bfmR 
and decreases the expression of rhlR [122]. The response regulator CzcR in the two-
component regulatory system CzcRS (related to metal response) was found to 
interact with QS. Full expression of lasI and rhlI is impaired in the absence of CzcR, 
and CzcR is important for the expression of pyocyanin, LasB elastase and 
rhamnolipids [123]. The most extensively studied two-component regulatory system 
modulating QS is GacAS which positively control AHL production [124]. It affects QS 
post-transcriptionally through the small regulatory RNAs RsmY and RsmZ, and the 
RNA binding protein RsmA [125-127]. 
The cyclic adenosine monophosphate (cAMP) receptor protein Vfr has long been 
known as a QS regulator [128]. Vfr regulates a specific subset of virulence genes 
depending on cAMP levels, but its activation of the lasR promoter is cAMP-
independent [129]. Vfr can also regulate rhlR transcription directly by binding to rhlR 
promoter region and exerts a positive effect on rhlR transcription[130].  
QscR is an orphan LuxR-type regulator in P. aeruginosa which lacks a cognate 
synthase [131].  QscR can form heterodimers with LasR and RhlR at low AHL density 
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and by doing so inactivates LasR and RhlR [132]. A qscR mutant is hyper-virulent to 
Drosophila melanogaster [131]. QscR directly controls a specific regulon that 
overlaps with the LasR- and RhlR-dependent regulons using 3-oxo-C12-HSL [133], 
and it can also respond to multiple AHLs, sugguesting its potential role in interspecies 
signaling [134]. Another transcriptional regulator VqsR is similar to a LuxR-type 
protein but without the AHL-binding domain. A vqsR mutant displays reduced 
production of quorum signals and virulence factors [135]. VqsR itself can be activated 
by 3-oxo-C12-HSL [79], and expression of vqsR is positively affected by PQS 
signaling [136]. Another study showed that VqsR regulates las and rhl systems by 
direct inhibition of QscR [137]. 
Sigma factors are important transcriptional regulators since they confer promoter 
recognition specificity to the RNA polymerase and are essential for transcription 
initiation [138]. Two sigma factors have been found to be involved in the regulation of 
QS. RpoN negatively controls the las and rhl systems probably through its effect on 
other QS regulators such as GacA and Vfr [139]. Another stress and stationary-
phase sigma factor RpoS represses the expression of rhlI [140].  
2.2.5.2 Post-transcriptional regulators 
As mentioned above, the RNA-binding protein RsmA represses AHL production at 
the post-transcriptional level through small regulatory RNAs (RsmY and RsmZ) under 
the control of GacAS two-component system [126]. RsmY and RsmZ act jointly to 
antagonize the activity of RsmA and affect the level of free RsmA. GacA controls the 
expression of RsmY and RsmZ and therefore acts as a positive regulator of QS [126]. 
RsmA has been shown to play an important role during murine infection by 
influencing colonization, virulence, persistence, and pulmonary inflammation [141]. 
Another regulator DksA decreases rhlI transcription when overexpressed [142] and 
regulates the translation of lasB and rhlAB [143]. In E. coli, dksA has been suggested 
to be required for rpoS induction by the nutrient stress signal ppGpp [144], and the 
inhibition of rhlI by DksA in P. aeruginosa is therefore assumed to be an indirect 
effect by affecting the expression of rpoS [143]. 
A conserved flavin adenine dinucleotide-binding protein involved in tRNA 
modification, GidA, affects RhlR at post-transcriptional level [145]. It also affects rhlR-
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dependent QS phenotypes such as LasA, pyocyanin, and rhamnolipid production 
[145]. The precise molecular mechanism of GidA is yet to be elucidated. 
The pqs system is also regulated by several small RNAs. ReaL was recently 
identified to be negatively regulated by LasR and positively impacts the synthesis of 
PQS by a post-transcriptional effect on pqsC [146]. This is the first report about a 
small RNA involved in las-pqs connections. A reaL mutant is less virulent in a 
Galleria mellonella infection model, and is also affected in pyocyanin production, 
biofilm and swarming activity [146]. Another small RNA PhrS is an activator of PqsR 
synthesis, and its expression requires the oxygen-responsive regulator ANR in low 
oxygen conditions. Thus PhrS can be considered as a regulatory link between 
oxygen availability and QS [147].  
2.2.5.3 Summary 
Except for those QS regulators discussed above, there are also other modulators 
related to QS. For example, the ppk gene encodes a polyphosphate kinase 
responsible for the synthesis of inorganic polyphosphate from ATP, which positively 
influences QS and is essential for the virulence of P. aeruginosa [148]. In this even 
more complex network of QS regulators, their roles seem to be overlapping and 
interconnected, and in some cases highly dependent on growth stage and 
environmental factors. For most of these QS regulators, more detailed mechanisms 
behind their QS activation or inhibition effects are yet to be discovered. 
2.2.7 Role of quorum sensing in P. aeruginosa virulence and biofilms 
As discussed above, the absence of one or more functional genes in a particular QS 
system often results in significantly reduced virulence of P. aeruginosa in different 
animal models, indicating the important role of completely functional QS in P. 
aeruginosa pathogenicity. Typical virulence factors known to be regulated by QS 
include elastase [149], alkaline protease [84], exotoxin A [84], hydrogen cyanide 
[150], pyocyanin [151], rhamnolipid [88], lectins [152], catalase and superoxide 
dismutase [153]. 
Among these virulence factors, alkaline protease and two elastases, LasA and LasB, 
are important secreted proteases in P. aeruginosa which can cause tissue damage, 
Chapter I. Introduction 
22 
degrade immunoglobulins and fibrin and even help P. aeruginosa to avoid immune 
detection during infections [154, 155]. Expression of lasA and lasB are under the 
regulation of the las and rhl systems [149, 156]. Another secreted protein exotoxin A 
inactivates elongation factor 2, leading to inhibition of protein synthesis and cell death 
[157]. It represses host immune response and helps with bacterial invasion [158, 159]. 
The production of exotoxin A and alkaline protease are activated by LasR [84]. 
The biosurfactant rhamnolipid is important in the invasion and colonization of P. 
aeruginosa in infections, protecting the bacteria against polymorphonuclear 
leukocytes (PMNs) [160]. It also plays a major role in swarming activity [161] and 
maintenance of biofilm structure [162-164]. RhlR acts as a direct activator of rhlAB 
transcription which is responsible for rhamnolipid synthesis [165]. Besides, 
rhamnolipid production was also reported to be affected by the pqs system and other 
regulators such as RsaL and Vfr [165]. 
The blue-green pigment pyocyanin causes oxidative stress to the host, induces 
apoptosis in neutrophils, and inactivates host catalase and mitochondrial electron 
transport [166]. Two phzABCDEFG operons, together with phzH, phzM and phzS 
genes are responsible for the synthesis of pyocyanin [167]. Mutations in gene 
involved in the las, rhl and PQS systems lead to the loss of pyocyanin production [94]. 
The global regulator GacA has also been reported to influence pyocyanin production 
via affecting the las and rhl systems [124]. 
Another virulence factor, hydrogen cyanide (HCN), produced by P. aeruginosa is 
often considered as a biomarker for P. aeruginosa lung infections [168]. The fast 
killing of Caenorhabditis elegans by P. aeruginosa is dependent on HCN production 
[169]. The expression of HCN synthase gene hcnABC relies on a synergistic action 
between LasR, RhlR and the anaerobic regulator ANR [150].  
Iron chelation is essential for bacteria during infection since iron availability is low in 
host environment due to the sequestration by host iron binding proteins, and many 
aspects of P. aeruginosa behavior, including intercellular communication and biofilm 
formation, are influenced by the concentration of free iron [170]. Two important 
siderophores, pyoverdine and pyochelin, are produced by P. aeruginosa to acquire 
necessary iron for growth, and pyoverdine also acts as signal molecules triggering 
other virulence factors such as the protease PrpL and exotoxin A [171]. Pyoverdine 
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biosynthesis is controlled by the las system [172], and further evidence showed that 
pqs system is important for both pyoverdine and pyochelin production [173]. In 
addition, the QS regulator VqsR is required for the full expression of the pyoverdine 
and pyochelin biosynthetic locus [174].  
The type IV pili of P. aeruginosa are considered as virulence factors because of their 
role in adherence and colonization on mucosal surfaces[175], and they are important 
for biofilm formation since cells lacking type IV pili are unable to form microcolonies 
[176]. Twitching activity of P. aeruginosa also depends on type IV pili [177]. Both the 
las and rhl systems are required for normal twitching activity, and the rhl system is 
required for infection by pilus-specific phages and adherence to human bronchial 
epithelial cells [178]. 
Biofilms produced by P. aeruginosa are the main cause for persistent infections [179]. 
They are formed by attached bacteria embedded in a matrix of polysaccharide, DNA 
and proteins. Bacteria in biofilms are shielded from host defense and more tolerant to 
antibiotics, increasing the difficulties in treating infections. The links between biofilm 
formation and QS in P. aeruginosa were first reported by Davies et al.; a lasI mutant 
forms flat and undifferentiated biofilms compared to those of the wild-type [180]. 
Since then several aspects of P. aeruginosa biofilm formation have been reported to 
be affected by QS. As mentioned, QS-regulated rhamnolipids are involved in 
microcolony formation, maintenance of open channels, mushroom cap formation and 
detachment of cells from biofilms [181]. Bacterial migration in early and late stages is 
related to pili, flagella and rhamnolipids, and depends on nutritional conditions [181]. 
QS is essential for the transcription of the pel operon encoding a glucose-rich matrix 
exopolysaccharide present in the biofilm matrix [182]. The release of eDNA in P. 
aeruginosa also can be induced by QS; this eDNA is an important matrix component 
and provides the structural stability to biofilms [183]. Additionally, iron uptake and 
denitrification connected to QS can influence biofilm formation under specific 
environmental conditions [181]. However, different results about the importance of 
QS in P. aeruginosa biofilm formation have also been reported depending on the 
study and experimental conditions [184]. Therefore, although several links between 
QS and biofilm have been established, it is still challenging to understand the full 
involvement of QS in biofilm formation, since both QS and biofilms are highly 
impacted by the surrounding environment as well as other types of signaling. 
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Bis-(3’-5’)-cyclic-dimeric-GMP (c-di-GMP) is an intracellular secondary messenger in 
many bacterial species that impacts fundamental bacterial behaviors and is important 
for the lifestyle switch between motile and biofilm cells [185]. Both QS and c-di-GMP 
regulate virulence and biofilm formation, and it has been shown that the two signaling 
pathways may be linked in several species [186, 187]. In P. aeruginosa, the 
interactions between c-di-GMP signaling and QS are just beginning to be understood. 
The tyrosine phosphatase TpbA was shown to inhibit the activity ofTpbB, an enzyme 
involved in c-di-GMP synthesis, to reduce c-di-GMP levels and biofilm formation, and 
TpbA is positively regulated by the Las QS system [188]. This suggests that QS 
negatively influences c-di-GMP production in P. aeruginosa. However, more details 
such as the concentration of c-di-GMP and the role QS plays in controlling this has 
not yet been studied. Elucidating the interactions between QS and c-di-GMP might 
help us to better understand their roles in controlling biofilm and virulence in P. 
aeruginosa. 
In summary, QS regulates multiple virulence factors in P. aeruginosa, and influences 
biofilm formation through multiple mechanisms. QS has been shown to be critical for 
pathogenesis of P. aeruginosa in lung and burn infections (reviewed by Rumbaugh et 
al. [189]). Though a comprehensive understanding of the exact roles of QS in the 
distinct types and stages of infections still needs to be worked on, the currently 
available evidence suggests a great promise for novel therapeutics aimed at 
inhibiting the complex QS network of P. aeruginosa. 
2.3 Quorum sensing in A. baumannii 
Compared to the complicated QS network in P. aeruginosa, the known QS system in 
pathogen A. baumannii is simple and straightforward. However, QS in A. baumannii 
and genes under QS regulation are not as well-understood as in P. aeruginosa. So 
far only one LuxI-type AHL synthase and its cognate receptor were identified in A. 
baumannii [190]. In this part, we will discuss the current knowledge of the existing QS 
in A. baumanni and its role in the virulence of A. baumannii. 
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2.3.1 AbaI/AbaR quorum sensing system  
The first AHL synthase in A. baumannii strain M2 was identified and named as AbaI 
in 2008 [190]. The AbaI protein showed high similarity to members of the LuxI family, 
and genome sequencing of other A. baumannii strains indicated that AbaI might be 
the sole AHL synthase in A. baumannii [191]. Based on the genome sequence of A. 
baumannii LMG 17989, coding regions of the cognate receptor gene abaR and the 
open reading frame of unknown function (A1S_0110) adjacent to abaI are separated 
by 930 bp [190]. The primary AHL signal detected in strain M2 was N-(3-
hydroxydodecanoyl)-HSL (3-OH-C12-HSL), but minor amounts of at least five other 
AHLs were also identified which might be due to the acetyl transferases [190]. The 
abaI mutant failed to produce detectable AHL and the biofilm formation was reduced 
by approximately 40% [190]. Homologues of the AbaI/AbaR were identified in other 
Acinetobacter species [192]. Interestingly, different AHL profiles of Acinetobacter 
strains have been reported [193] and nosocomial strains tend to produce long chain 
AHLs (C10~C16) compared to soil isolates [194]. Whether the diversity of AHLs in 
strains from different origins indicates a role for QS in virulence has not been clearly 
revealed yet. AHL produced by A. baumannii strain AB 14 was observed to affect the 
cell wall of S. aureus and induce apoptosis in different cancer cell line [195], 
addressing the possible function of AHL in A. baumannii in interactions with other 
bacterial pathogens and infected mammalian hosts. 
2.3.2 Role of quorum sensing in A. baumannii virulence and biofilms 
A. baumannii has become one of the most successful pathogens responsible for 
hospital-acquired nosocomial infections in the last decades. Multi-drug resistance 
and persistence in the healthcare environment are major challenges in A. baumannii 
treatment. The virulence factors contributing to A. baumannii pathogenesis include 
capsular polysaccharides, lipopolysaccharides, phospholipases, outer membrane 
vesicles, metal acquisition systems, biofilm formation and protein secretion systems 
[5]. The established relationship between QS and several virulence factors in A. 
baumannii are discussed below. 
A. baumannii can adhere and form biofilms on both biotic and abiotic surfaces, 
leading to severe infections as well as to colonization on hospital equipment and 
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indwelling medical devices. Pili-mediated A. baumannii adherence to epithelial cells 
has been considered as the initial step for colonization and subsequent host infection 
[196]. As mentioned above, a QS mutant showed reduced in vivo biofilm formation in 
A. baumannii strain M2 [190]. The AHL synthase in A. baumannii LMG 17978 
showed higher expression in biofilm cells when compared to planktonic cells [197], 
suggesting a role of QS in A. baumannii biofilm formation. QS is hypothesized to 
affect pili formation which is important for biofilm formation, but the mechanism 
behind this remains unclear. One study showed that non-native AHL can enhance 
the expression of the chaperone-usher secretion system involved in pili synthesis in 
A. baumannii, and this expression is necessary for twitching motility [198]. These 
results confirm the importance of QS during attachment and development of biofilms. 
The notable antibiotic resistance of A. baumannii relies on several mechanisms 
involving acquirement of β-lactamases, up-regulation of multidrug efflux pumps and 
modification of aminoglycosides. Recent research showed that 3-OH-C12-HSL may 
be involved in regulating the expression of several drug-resistance genes responsible 
for β-lactamase production and efflux pump activity in A. baumannii [199], directly 
connecting QS with antibiotic resistance in A. baumannii. 
Catalase and superoxide dismutase (SOD) are two important antioxidant enzymes to 
help pathogens to deal with reactive oxygen species (ROS) in infection. The 
production of these two enzymes has been reported to be affected by QS in A. 
baumannii in a study on the interaction between P. aeruginosa and A. baumannii 
[200]. The QS mutant of A. baumannii showed lower survival when exposed to H2O2 
compared to the wild type strain [200]. Interestingly, the quorum quenching (QQ) 
enzyme AidA in non-motile A. baumannii strains also seems to be involved in this 
process as downregulation of AidA was observed under ROS stress, which might 
lead to higher activity of the QS system in A. baumannii [201]. 
As a global transcriptional regulation system, it is reasonable to assume that QS 
controls more virulence-related genes in A. baumannii besides those discussed 
above. Comprehensive transcriptome studies may shed new light on QS and 
virulence of A. baumannii, providing better approaches to combat this pathogen. 
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3. QUORUM QUENCHING ENZYMES 
Generally, bacterial QS circuits can be blocked by targeting the biosynthesis, 
accumulation and detection of the signal molecules. QQ enzymes represent a 
powerful weapon against QS by directly degrading or modifying signal molecules. In 
this way, signal molecules produced by bacteria will not accumulate to the threshold 
level to activate the QS system and QS-controlled virulence genes downstream. The 
first QQ enzyme, AiiA was identified in a Bacillus sp. strain in 2000 [202], and since 
then, dozens of QQ enzymes have been found in a wide range of bacteria and even 
in eukaryotes. QQ enzymes acting towards AHL have been intensively studied, and 
other QQ enzymes targeting at AI-2 or PQS have also been described [203, 204]. In 
this section, we will focus on different types of AHL-degrading QQ enzymes, as well 
as the current progress concerning their possible application in controlling infections 
of P. aeruginosa, A. baumannii and other Gram-negative pathogens. 
3.1 Diversity of QQ enzymes 
Although many QQ enzymes degrading AHLs have been reported so far, most of 
these enzymes can be categorized into two major types based on their cleavage 
sites, i.e. AHL-lactonases and AHL-acylases. AHL-lactonases can hydrolyze the 
lactone bond leading to an inactive acyl-homoserine molecule, while AHL-acylases 
act on the amide linkage between the fatty acid chain and homoserine lactone ring 
(Figure 1.5). AHL-lactonases can degrade a broad range of AHLs, but AHL-acylases 
typically show high substrate specificity based on the length of the acyl chains. 
 
Figure 1.5 Hydrolytic cleavage of AHLs by AHL lactonases and AHL acylases. (Modified from Fetzner, 
2015 [205]) 
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3.1.1 AHL-lactonases 
3.1.1.1 Metallo-β-lactamase (MBL) superfamily 
Most known AHL-lactonases belong to the MBL superfamily, and other lactonases 
have also been found in the phosphotriesterase (PTE) family, α/β hydrolase family 
and GDSL hydrolase family [49]. The first identified AHL-lactonase AiiA represents a 
typical lactonase from the MBL superfamily with a characteristic metallo-binding 
HXHXDH motif which has also been identified in other AHL-lactonases belonging to 
this family. Homologues of AiiA were then discovered in many Bacillus species [206], 
as well as in other genera including Agrobacterium [207], Rhodococcus [208, 209], 
Arthrobacter [210], and Chryseobacterium [211] (reviewed by Tang et al. [49] and 
Fetzner [205]).  
Among these lactonases, MomL, which is produced by Muricauda olearia strain 
Th120, represents a type of AHL-lactonases that shows relatively low identity (less 
than 30%) in amino acid sequence with AiiA and other MBL-type AHL-lactonases 
[212]. Similar lactonases with high identity to MomL were reported later in other 
marine bacteria from the Bacteroidetes phylum, such as Aii20J from Tenacibaculum 
sp. 20J [213] and FiaL from Flaviramulus ichthyoenteri Th78T [214]. MomL, Aii20J 
and FiaL, as well as several predicted AHL-lactonases in Bacteroidetes phylum 
formed a specific marine lactonase cluster (Figure 1.6). Both MomL and Aii20J can 
degrade unsubstituted and substituted AHLs of different acyl chain length, with a 
slight preference for long-chain AHLs, and both showed high thermostability [212, 
213]. A recently reported MBL-type AHL-lactonase QsdS from a Sphingomonas 
ursincola isolate recovered from an industrial cooling water system also clustered 
with MomL-type lactonases [215]. 
Another AHL-lactonase sub-cluster in the MBL superfamily is represented by AidC 
from Chryseobacterium, showing less than 20% amino acid identity with AiiA [211]. 
AidC has been reported to show a higher kcat/Km value (10
6 M−1s−1) compared to 
other QQ enzymes including AiiA and MomL (104~105 M−1s−1), indicating it might be 
more efficient at low AHL concentrations [194]. Another MBL with kcat/Km value of 10
6 
M−1s−1 was GcL from the thermophilic Geobacillus caldoxylosilyticus [216]. 
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Besides GcL, two other novel AHL-lactonases in the MBL family have been 
described, AiiT from the thermophilic bacterium Thermaerobacter marianensis [217] 
and AidP from Planococcus sp. recovered from Antarctica [218], and both of them 
showed high similarity to AhlS in Solibacillus silvestris [219]. These psychro- or 
thermo-tolerant MBL-type AHL-lactonases identified from bacteria in extreme 
environments extend our knowledge about QQ enzymes and might be important for 
applications under specific conditions. 
3.1.1.2 PTE-like lactonases (PLLs) 
PTEs are known for their role in organophosphate degradation, while PLLs can 
proficiently hydrolyze various lactones, especially AHLs, with much lower 
promiscuous PTE activities. PPH in Mycobacterium tuberculosis, AhlA in 
Rhodococcus erythropolis and SsoPox in Sulfolobus solfataricus were the first 
identified PLLs [220]. SacPox and SisLac are PLLs from species belonging to the 
archeael genus in Sulfolobus [221, 222]. Interestingly, many PLLs are identified in 
thermophilic bacteria or archaea, such as SsoPox, GkL in Geobacillus kaustophilus 
[223] and VmoLac in Vulcanisaeta moutnovskia [224]. The biotechnological 
properties of a SsoPox variant has been investigated recently [225], and it showed 
resistance to diverse harsh conditions such as heating, exposure to organic solvents, 
sterilization and immobilization. In addition, it was active at sub-zero temperature and 
resistant against bacterial secreted materials, making this SsoPox variant an 
attractive candidate for industrial and medical applications. 
3.1.1.3 α/β hydrolase family 
The known AHL-lactonases in the α/β hydrolase family include AiiM in 
Microbacterium testaceum [226], AidH in Ochrobactrum sp. [227] and DhlR in 
Sinorhizobium sp. [228]. The newly reported AHL-lactonase AidA in clinical strains of 
A. baumannii also belongs to the α/β hydrolase family [201]. 
3.1.1.4 Other lactonases 
Except for the three categories discussed above, QsdH from a Pseudoalteromonas 
byunsanensis strain was identified as the only AHL-lactonase in the GDSL hydrolase 
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family [229]. PON1, PON2 and PON3 are mammalian paraoxonases which can 
degrade various AHLs [230, 231]. Recently, a metagenome-derived AHL-lactonase 
HqiA has been classified in a new family related to the cysteine hydrolase group 
[232], indicating that there might be other types of AHL-lactonases beyond our 
current knowledge. 
 
Figure 1.6 Phylogenetic tree from the known protein sequences of bacterial AHL-lactonases. The 
phylogenetic tree was constructed with the ClustalW program in the MEGA6 (1000 bootstrap 
replicates). Scale bar, 0.1 substitutions per amino acid position. 
3.1.2 AHL-acylases 
Most of the known AHL-acylases belong to the N-terminal nucleophile-hydrolase 
superfamily, and these AHL-acylases group in four clusters: aculeacin A acylase, 
penicillin G acylase, penicillin V acylase and AmiE amidase family [233] (Figure 1.7). 
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AHL-acylases from α/β hydrolase family have also been reported [234]. The first 
isolated and characterized AHL-acylase was AiiD from Ralstonia sp. [235], and by 
now  AHL-acylases have also been identified from various species in the genera 
Pseudomonas, Acinetobacter, Agrobacterium and Streptomyces. (reviewed by Tang 
et al. [49] and Fetzner [205]). Unlike AHL-lactonases, AHL-acylases show distinct 
substrate specificities and many of them are active only towards long chain AHLs 
[233].  
Interestingly, cross-reactivity between AHL-acylases and penicillin acylases has been 
observed [236]; AhlD from Streptomyces sp. [237], HacB from P. aeruginosa [237] 
and PmrA from Pseudoalteromonas flavipulchra [238] showed activity on either 
penicillin G, penicillin V or ampicillin. Recently, a novel AHL-acylase MacQ from 
Acidovorax sp. further confirmed the possible bifunctional role of some AHL-acylases 
which can degrade both various AHLs and β-lactams [239, 240]. The MacQ-
expressing E.coli strain showed 2- to 16-fold higher minimum inhibitory concentration 
(MIC) values toward several β-lactam antibiotics (penicillin G, ampicillin, amoxicillin, 
carbenicillin, cephalexin, and cefadroxil) than the wild-type [239]. 
In P. aeruginosa, three AHL-acylases have been reported: PvdQ [241], QuiD [242] 
and HacB. These three AHL-acylases affect the AHL levels and virulence factor 
production in P. aeruginosa [242, 243], but the detailed mechanisms about how they 
interact with the complicated QS network in P. aeruginosa are not clear yet. The 
production of PvdQ was considered to be induced by iron limitation, since this 
acylase is also involved in the biosynthesis of pyoverdine [244]. QuiP is responsible 
for the utilization of long-chain AHLs as carbon source, while HacB is assumed to 
play a main role in controlling AHL accumulation [243]. 
3.1.3 AHL-oxidoreductases 
AHL-oxidoreductases are a few enzymes which can inactivate AHLs by reduction or 
oxidation activity. Rhodococcus erythropolis W2 [245] and Burkholderia sp. strain 
GG4 [246] showed the ability to reduce 3-oxo-AHLs to the corresponding 3-OH-AHLs, 
but the relevant genes have not yet been identified. BpiB09, an NADP-dependent 
reductase which derived from a metagenome library, was also capable of inactivating 
3-oxo-C12-HSL in P. aeruginosa [247]. CYP102A1, a widely studied cytochrome 
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P450 from Bacillus megaterium, can oxidise AHLs at the ω-1, ω-2, and ω-3 carbons 
of the acyl chain, and the oxidation products are much less active than the 
corresponding AHLs [248]. 
 
Figure 1.7 Phylogenetic tree from the known protein sequences of bacterial AHL-acylases [233]. The 
phylogenetic tree was constructed using the neighbor-joining method with the ClustalW (MEGA 
program, ver. 7). Number represents Bootstraps values based on 1000 replications. 
 
3.1.4 Physiological roles of QQ enzymes 
Except for their ability to degrade AHLs, the exact physiological roles of AHL-
lactonases or AHL-acylases are not clear by now. The potential functions of AHL-
acylases based on their AHL-hydrolyzing ability have been discussed by Utari et al., 
and include modulating the endogenous QS or interkingdom interactions and 
utilization of AHLs as nutrient sources [233]. These enzymes might be indispensable 
in the AHL turnover mechanism to allow a real-time monitoring of AHL concentration 
and population density [233]. However, it is also possible that the natural roles of 
these enzymes are unrelated to QS and might be different in different bacteria. 
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3.2 The use of QQ enzymes to interfere with virulence 
3.2.1 In vitro proof 
Since the identification of the first QQ enzyme AiiA, its anti-virulence effects against 
various pathogens have intensively been studied. Heterologous expression of AiiA 
successfully decreases extracellular pectolytic enzyme activities of a plant pathogen 
Erwinia carotovora, and attenuates soft rot symptom on different plants [202]. It has 
also been demonstrated that expression of AiiA in P. aeruginosa PAO1 reduced the 
concentration of both C4-HSL and C12-HSL, and production of elastase, rhamnolipid, 
HCN and pyocyanin were also severely decreased [249]. The swarming motility of 
PAO1 has also been strongly reduced, whereas no significant effect on twitching 
motility and adherence to a polyvinylchloride surface was observed in this study [249]. 
AiiA has also been investigated in Burkholderia cepacia complex strains which are 
important opportunistic pathogens in human with cystic fibrosis. In the large majority 
of these bacteria, protease production, swarming motility, and biofilm formation were 
reduced when aiiA was expressed heterologously [250]. However, several aiiA-
expressing Burkholderia cepacia complex strains in this study showed increased or 
unaffected biofilm formation when aiiA was expressed heterologously [250]. In 
addition, an aiiA-expressing Enterobacter cloacae strain showed enhanced protease 
production and was less adherent during biofilm formation [251]. 
Except for AiiA, many other QQ enzymes have been evaluated on P. aeruginosa by 
either heterologous expression or addition to the growth medium. AHL-lactonases 
such as MomL [212] and QsdS [215], and AHL-acylases such as AiiD [235], AmiE 
[252] and AhlM [237] have been reported to affect P. aeruginosa QS-controlled 
phenotypes. Metagenome-derived QQ enzymes such as Aii810 [253] and BpiB05 
[254] can also attenuate P. aeruginosa virulence and biofilm formation. Another study 
showed that human and murine serum containing PON1 prevents P. aeruginosa 
biofilm formation in vitro [255]. In a recent study, the effect of an engineered variant 
of SsoPox was tested in a series of P. aeruginosa clinical isolates from diabetic foot 
ulcers [256]. The results showed that proteolytic activity was decreased by at least 
half in 67% of these strains, pyocyanin production in 68% and biofilm in 82%, which 
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were significantly more effective compared to the QS inhibitors (5-fluorouracil and 
furanone C-30) tested [256]. 
Few QQ enzymes have so far been tested on A. baumannii. A thermostable 
engineered mutant of GkL was reported to reduce biofilm biomass and thickness of 
an A. baumannii clinical isolate [257], which suggests that application of QQ enzymes 
might also be an effective way to treat this increasingly resistant pathogen. 
3.2.2 In vivo proof 
To understand the pathogens-host interaction during infection, different models of 
evolutionary divergent hosts such as nematodes, insects and rodents are available 
for studying the pathogenicity of P. aeruginosa and other bacteria [242]. C. elegans is 
one of the simplest invertebrate models to study QS and virulence of P. aeruginosa 
[258], and its innate immunity pathway resembles that of mammals in some aspects 
[259]. Several different mechanisms are involved in the killing of C. elegans by P. 
aeruginosa depending on the experimental conditions. QS-controlled phenazines and 
HCN can cause rapid paralysis of C. elegans in hours, and pyoverdin induces a 
hypoxia response and death in a liquid medium. A slow killing of C. elegans for days 
by P. aeruginosa might also happen on a minimal medium [260]. Overexpression of 
PvdQ in P. aeruginosa PAO1 reduced its virulence and rescued more than 75% of 
the C. elegans from lethal paralysis [261]. Moreover, addition of purified PvdQ to C. 
elegans increased their life span, but the infection itself cannot be completely 
prevented [261]. Other QQ enzymes, such as MomL [212], AiiD [235] and BpiB09 
[247], have also been shown to attenuate the virulence of P. aeruginosa in the C. 
elegans infection model. 
G. mellonella (Wax Moth) larvae are alternative models to study microbial infections 
and are used by a growing number of researchers [262]. Compared to C. elegans, 
these larvae are larger in size and easier to keep and manipulate. A variant of PvdQ 
which can degrade C8-HSL has been reported to rescue G. mellonella larvae upon 
Burkholderia cenocepacia infection [263]. No data about the effect of QQ enzymes 
on P. aeruginosa infections are available in this model so far. 
The effect of PON1 on P. aeruginosa has also been evaluated in another infection 
model, Drosophila melanogaster (fruit flies). D. melanogaster does not express 
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PON or a PON homolog, and human PON1 was transgenically expressed in the 
flies. These PON1-producing flies were found to be protected from P. aeruginosa 
lethality, and this effect was confirmed to be dependent on the lactonase activity of 
PON1 [264]. 
3-oxo-C12-HSL produced by P. aeruginosa can exert effects on mammalian cells, 
including upregulation of pro-inflammatory mediators and induction of apoptosis [265]. 
Human intestinal epithelial Caco-2 cells transfected with pvdQ were shown to be 
effectively protected from 3-oxo-C12-HSL induced apoptosis [266], which indicates a 
potential therapeutic strategy to obviate injury from P. aeruginosa to mammalian cells. 
Migiyama et al. evaluated the effect of AiiM against P. aeruginosa infection further in 
a mouse model of acute pneumonia [267]. AiiM expression reduced lung injury and 
improved the survival rates by over 70%. The levels of proinflammatory cytokines 
and myeloperoxidase activity were also significantly lower [267]. Another study 
showed that inhaled SsoPox-I can increase the survival by 55% during P. aeruginosa 
infection in a rat pneumonia model, and the histological lung damage was 
significantly reduced with no difference in lung bacterial counts [268]. These in vivo 
data strongly support the hypothesis that QQ enzymes can reduce excessive 
inflammation and relieve P. aeruginosa infection.  
3.2.3 Combined use of QQ enzymes 
QS has been proved to influence biofilm formation and the tolerance of the biofilm to 
antimicrobial treatment [184], therefore QQ enzymes might help to increase the 
efficiency of conventional antibiotics in biofilm eradication during infections. 
Combining QQ enzymes and antibiotics was considered as an attractive option to 
treat the rising number of antimicrobial-resistant infections. However, compared to 
the abundant data on QS inhibitor/antibiotic combination, studies on QQ enzymes 
combined with antibiotics are not so frequent. The efficacy of a lactonase from 
Bacillus species in combination with ciprofloxacin in treating P. aeruginosa murine 
burn wound infection has been investigated by Gupta et al. [269]. Topical application 
of lactonase or ciprofloxacin alone prevents the systemic spread of P. aeruginosa 
and reduced the mortality, while in the group treated with lactonase and ciprofloxacin, 
all the animals survived [269]. The level of cytokines and inflammatory mediators 
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were also reduced significantly. There results indicate a promising prospect for 
further research on co-administration of QQ enzymes and antibiotics in treatment of 
infectious diseases. 
Besides, synergistic efforts of multiple anti-biofilm components could be a better way 
to clear resistant biofilms. From such perspective, the QQ enzyme MomL has been 
combined with glycoside hydrolases recently in a cell-based anti-infective device 
[270]. The device was designed with a synthetic AHL-sensor connected to a 
downstream module encoding glycoside hydrolases and MomL, and it was capable 
of detecting AHL level in P. aeruginosa clinical isolates. Combination of MomL and 
glycoside hydrolases enabled the designer cells to fully degrade AHLs, potentiate 
antibiotic susceptibility, substantially reduce biofilms and alleviate cytotoxicity to lung 
epithelial cells [270]. This technology was considered to be particularly useful for 
hindering biofilm formation around cell implants in future cell-based therapies [270]. 
The AHL-degrading enzyme SsoPox has been modified and explored to be 
combined with another QQ enzyme LsrK targeting the AI-2 signal, which might 
provide a new idea for simultaneously quenching two different QS signals. Modified 
SsoPox and LsrK were successfully attached to capsules of the charged polymers 
chitosan and alginate [271]. However, the capacity of these capsules to combat 
infections still needs to be verified in vitro and in vivo, and these capsules may be 
more effective in treating multispecies infections involving diversified QS activity. 
Attempts have also been made to equip the T7 phage with QQ enzymes to treat 
biofilms [272]. Bacteriophage treatment has been considered as an effective way to 
collapse bacterial biofilms. Polysaccharide depolymerases produced by phages can 
help them to get access to bacteria in biofilms. However, these depolymerases have 
narrow substrate specificities, thus may not be potent enough in biofilms with multiple 
polysaccharides. In addition, QS was reported recently to activate CRISPR-Cas 
immunity in P. aeruginosa, which is important for bacteria to defend themselves 
against phages [273]. Therefore, combining QQ enzymes and phages might have a 
more profound effect. An engineered AiiA-expressing phage was shown to be more 
capable in inhibiting mixed-species biofilms of P. aeruginosa and E.coli than the wild-
type T7 phage [272], indicating that such QQ phages might be of great interest for 
their antibiofilm function. 
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Nanoparticle-based approaches have been widely studied as potential therapeutics 
for controlling biofilm infection in recent decades [274, 275]. Nanoparticles were 
developed with intrinsic antimicrobial properties or used in controlled antimicrobials 
delivery. Besides, the QS inhibition activity of nanoparticles (NPs) has also been 
investigated [276, 277]. Vinoj et al. synthesized AuNPs coated with AiiA protein, and 
the AiiA AuNPs reduced the exopolysaccharide production and biofilm formation of 
multidrug-resistant Proteus species at a concentration without damaging the host 
macrophages [278]. The anti-biofilm activity of such nanoparticles with QQ enzymes 
might also be promising in treating other pathogens as P. aeruginosa. 
3.2.4 Exploring the application of QQ enzymes 
Although most studies on QQ enzymes mainly focus on their anti-virulence and anti-
biofilm effects in vitro and in vivo, several studies go futher to explore the possible 
application of QQ enzymes, such as coatings or membranes with QQ enzymes and 
inhalable powder of QQ enzymes. 
Developing anti-biofilm coatings with QS disrupting activity represents a new 
paradigm to prevent catheter and other medical device related infections. Ivanova et 
al. built multilayer coatings on silicone catheters composed of acylase from 
Aspergillus melleus and α-amylase in a layer-by-layer fashion [279]. Coatings of 
acylases alone suppressed the biofilm formation of P. aeruginosa [279, 280], and 
hybrid coatings with acylases in the outermost layer demonstrated higher anti-biofilm 
efficiency compared to the other assemblies. Additionally, these nanocoatings 
significantly reduced mixed-biofilm of P. aeruginosa and E. coli, and delayed the 
biofilm growth up to 7 days in an in vivo rabbit model [279]. In another study, this 
acylase was covalently immobilized in polyurethane coatings via multipoint covalent 
immobilization [281], resulting in around 60% reduction in P. aeruginosa biofilm 
formation. The acylase-containing coatings retained 90% activity when stored dry at 
37℃ for 7 days, and might be promising in the clinical management of catheter-
related infections [281]. 
Immobilization of SsoPox onto nanoalumina membranes has been investigated [282], 
and the addition of membranes containing SsoPox in bacterial cultures of P. 
aeruginosa successfully decreased the production of pyocyanin and elastase. The 
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membranes with immobilized QQ enzymes in this study provide a possible means to 
control undesirable bacterial activities on medical device. 
For the treatment of pulmonary P. aeruginosa infections, Wahjudi et al. tried to 
develop PvdQ into a dry, inhalable powder using mannitol, trehalose and inulin as 
excipient [283]. The activity of PvdQ can be fully retained during spray-freeze drying, 
and PvdQ incorporated in trehalose or inulin was stable for storage (55 ℃ for four 
weeks). These results provide a good starting point for the delivery of QQ enzyme in 
patients. 
 
4. QUORUM SENSING INHIBITORS 
QS inhibitors (QSIs) are typically small molecules that can interfere with the QS 
pathway in different ways. A large number of QSIs have been synthesized or 
identified from broad natural sources and compound libraries, and this number 
continues to increase (reviewed by [49, 284-289]). These QSIs have been 
considered to modulate QS and QS-related virulence without affecting the growth of 
bacteria, opening up the possibility to develop new anti-virulence drugs to which 
resistance is less likely to develop, despite the on-going debate about possible 
mechanisms to develop resistance against QS inhibition [290-292]. Currently, most 
QSIs for which the mechanism of action was elucidated are either analogues of 
signal molecules or blockers of the cognate QS receptor. However, the mechanism of 
action of the majority of natural QSIs remains unknown.  
Primary detection of the QSI activity involve the application of QS reporter strains 
normally combining a QS-controlled promoter and a specific reporter gene/operon 
expressed gfp, bioluminescence or β-galactosidase, as reviewed by Rai et al. [293]. 
However, screening of QSIs by such methods might induce false positive predictions 
[294], since the certain QS-controlled phenotypes in these reporter strains can also 
be affected by other factors or the metabolic activity. Therefore, further confirmation 
in various ways is strongly recommended. In the following section, we will discuss the 
current knowledge and progress mainly focusing on typical QSIs against Gram-
negative pathogens, as well as the in vitro and in vivo evidences for the anti-biofilm 
and anti-infectious effect of QSIs. 
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Figure 1.8 Examples of QSIs with activity against P. aeruginosa 
4.1 Diversity of QSIs 
4.1.1 Natural QSIs 
The widely distributed plant phenolic compounds are an abundant source for natural 
QSIs, and QSIs have been identified from different classes of phenolic compounds 
including flavonoids, coumarins, phenolic acids, curcuminoids and others [287]. 
Some of these QSIs were tested with QS reporter strains, and their effects on 
virulence factor production and biofilm formation in a wide range of bacteria were 
investigated [287]. However, the effects of these compounds vary greatly. 
Compounds like vanillin, tannic acid and (-)-epicatechin were shown to inhibit QS and 
virulence factor production in some species, but they can also increase the AHL 
production or biofilm formation in other species (or strains) at certain concentrations 
[287]. Other compounds like ellagic acid, curcumin, quercetin and baicalein not only 
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affect the QS and biofilm in Gram-negative bacteria, but also in Gram-positive 
bacteria and even yeast which employed totally different QS systems [287, 295, 296]. 
These observations indicate that such compounds may not simply inhibit QS or 
distinct mechanisms may be involved in their QS and biofilm inhibition activity in 
different bacteria. In addition, the possible antimicrobial activities of these compounds 
should be clearly distinguished from the QS inhibition activity. Therefore, uncovering 
the detailed mechanisms of these potential QSIs might be the first step towards their 
applications. A recent study reported that flavonoids such as quercetin and baicalein 
inhibit QS in P. aeruginosa via antagonism of AHL receptor and prevention of DNA 
binding [297], which provides primary mechanistic evidence for these flavonoid QSIs.  
Another well-studied QSI is ajoene [298], a sulfur-rich molecule isolated from garlic. 
Jacobson et al. recently revealed that ajoene represses different QS systems in P. 
aeruginosa via modulation of the expression of the small RNAs RsmY and RsmZ, as 
well as modulation of RNAIII expression in S. aureus [299]. Ajoene targets the 
Gac/Rsm part of the QS machinery in P. aeruginosa and results in low expression of 
RsmYZ, but how ajoene confers an effect on RNAIII transcript levels in S. aureus 
remains unknown [299]. Other sulfur-containing isothiocyanates such as 
sulforaphane and erucin have also been identified as QSIs against P. aeruginosa 
[300, 301], and iberin showed a similar effect as ajoene in P. aeruginosa through 
downregulation of the Gac/Rsm network [302]. 
Other natural QSIs have been reported from diverse sources such as sponges [303], 
fungi [304] and honey [305]. Farnesol, a sesquiterpene which can be produced by 
Candida albicans, decreased pqsA transcription in P. aeruginosa [306]. Clove bud oil 
has also been shown as an inhibitor for PqsA [307].  
4.1.2 Synthetic QSIs 
Most synthetic QSIs are derived from either natural AHLs or structurally unrelated 
natural products. These QSIs act as antagonists or agonists which effectively 
compete with the natural AHLs and prevent a sufficient stimulation of the receptors 
[308]. Several AHL analogs showed remarkable inhibitory activities in QS reporter 
strains [309, 310], and some of them can inhibit elastase and biofilm formation in P. 
aeruginosa [311]. In addition, high-throughput screening of compound libraries led to 
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the identification of structurally diverse QSIs [312]. Synthetic furanone compounds, 
especially C30, are intensively studied QSIs based on the structure of natural 
furanones in marine macroalga Delisea pulchra and similar to AHLs in structure [313, 
314]. However, the effect of synthetic QSIs targeting single receptor might be 
insufficient to inhibit the complete QS network and QS-related virulence in pathogens 
as P. aeruginosa which use different QS systems. Discovery of QSIs targeting 
multiple receptors (e.g. both LasR and RhlR in P. aeruginosa) or the combined use of 
different QSIs could be a better choice in these conditions. QSIs against PQS 
pathway in P. aeruginosa have also been reported, such as halogenated anthranilic 
acid analogs, targeting the synthesis of PQS (PqsA, PqsD) or the receptor PqsR 
[315-318]. 
4.1.3 Known drugs as QSIs 
The macrolide azithromycin has been widely studied as a QSI of P. aeruginosa at 
sub-inhibitory concentrations [319, 320]. Azithromycin down-regulates QS-regulated 
genes encoding pilus, flagellum, and oxidative stress response proteins in P. 
aeruginosa. Research into the mechanism of azithromycin as a QSI initially assumed 
that azithromycin influences the flux of 3-oxo-C12 by altering membrane permeability, 
but later it has been reported that azithromycin can inhibit expression of the GacA-
dependent sRNAs (RsmY and RsmZ), just like ajoene [320, 321]. Antibiotics as 
ceftazidime and ciprofloxacin also show QS inhibition effect against P. aeruginosa 
[320]. 
5-Fluorouracil, an analog of uracil, is a clinical approved anti-cancer drug, and it has 
been identified as a QSI via interrupting uracil synthesis which is important for QS 
and QS-regulated virulence [322]. Imperi et al. [323] found the anthelmintic drug 
niclosamide as an effective QSI for P. aeruginosa by screening a library of FDA-
approved compounds. A nonsteroidal anti-inflammatory drug, meloxicam, has been 
reported to repress QS and related phenotypes in P. aeruginosa [324]. These QSIs 
identified from commercial drugs might make their clinical application much easier 
than other QSIs. 
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4.2 QSIs as antivirulence drugs 
4.2.1 In vitro and in vivo proof 
A large number of synthetic and natural QSIs have been tested in vitro on the 
production of bacterial virulence factors, as well as in different in vivo models. Here 
we will mainly focus on those that have been evaluated on P. aeruginosa and A. 
baumannii.  
As the most efficient modified furanone compound, C30 partially or completely 
inhibits the production of QS-regulated protease, pyoverdine and chitinase in P. 
aeruginosa [314]. Additionally, biofilms formed in the presence of C30 are more 
susceptible to tobramycin [314]. In a mouse pulmonary model, C30 led to a rapid 
clearance of bacteria [314] and prolonged the survival of the mice [313]. These 
results confirmed that applications of QSIs may reduce virulence and prevent 
detrimental biofilm formation of P. aeruginosa during infections. 
Many QSIs have been shown to reduce pyocyanin, protease and elastase production 
in P. aeruginosa, as well as rhamnolipid and motility. Notably, Welsh et al. reported 
that modulation of RhlR by synthetic, non-native AHLs induced inverse regulation of 
pyocyanin and rhamnolipid production, which might be due to the suppression of 
PQS signaling [325]. These results indicate that small molecule disruption of QS in P. 
aeruginosa might lead to unexpected virulence phenotypes depending on the 
mechanism of QSI. 
The effects of QSIs on biofilm of P. aeruginosa have been intensively studied. QSIs 
such as mBTL (meta-bromo-thiolactone), 6-gingerol and oleanolic aldehyde 
coumarate were reported to reduce biofilm biomass in P. aeruginosa [326-328], and 
some studies also revealed that QSIs increase the susceptibility of biofilms to 
antibiotic treatments [298, 304, 329]. Moreover, studies on biofilms formed in flow cell 
systems showed that QSIs affect the architecture of the biofilm [330]. 
Research into the effects of QSIs in different in vivo models also showed promising 
results to reduce the virulence of P. aeruginosa. Representative examples are 
summarized in Table 1.3. QSIs in combination with antibiotics have been considered 
as a possible way to be applied clinically for human diseases, as QSIs may enhance 
Chapter I. Introduction 
43 
the efficiency of antibiotics in treating biofilm infections. In an intraperitoneal foreign-
body infection mouse model, furanone C30, ajoene or horseradish juice extract were 
tested in combination of tobramycin in an early stage of infection [331]. Synergistic 
effects on the bacterial clearance were observed for all QSIs, and early treatment 
showed more significant effects compared to late treatment [331]. 
Table 1.3 The effects of QSIs on P. aeruginosa virulence in in vivo models 
QSIs In vivo effects Reference 
Patulin Promotes a faster clearing of P. aeruginosa in a mouse 
pulmonary infection model 
[304] 
Ajoene Increases the clearance of P. aeruginosa in a mouse 
pulmonary infection model 
[298] 
Azithromycin Attenuates chronic P. aeruginosa infection in Cftr-/- 
mice and significantly clears a P. aerugionsa infection 
in a urinary tract infection mouse model 
[332, 333] 






Restrict P. aeruginosa systemic dissemination and 
mortality in mice 
[315] 
mBTL Inhibits P. aeruginosa PA14 virulence toward C. 
elegans and human A549 lung cells 
[326] 
6-Gingerol Reduces mice mortality agains P. aeruginosa [328] 
Phenyllactic acid Inhibits the initial attachment of P. aeruginosa in an 





Reduces paralysis of C. elegans during P. aeruginosa 
infections 
[327] 
Tea polyphenols Reduce P. aeruginosa pathogenicity in C. elegans; 
increases the wound contraction percentage in an 
excision mouse wound infection model and dcreases 
the colony-forming units (CFU) in the wound area 
[335] 
Baicalein Enhances P. aeruginosa clearance in a mouse 
peritoneal implant infection model 
[336] 
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Comparing to the many studies evaluating QSIs on P. aeruginosa, QSIs targeting A. 
baumannii are seldom investigated and tested in in vivo models. Several synthetic 
non-native AHLs were identified as AbaR antagonists and inhibit motility and biofilm 
formation of A. baumannii [337]. Flavonoid components from Glycyrrhiza glabra have 
been shown to reduce motility, biofilm formation and production of antioxidant 
enzymes in A. baumannii [338]. Streptomycin at subinhibitory concentrations 
decreases transcription of the abaI gene and reduces motility, but the mechanism is 
unknown [339]. In a recent study, virstatin and two unsaturated chain fatty acids were 
reported to inhibit QS in A. baumannii and inhibit motility and biofilm formations in 
several clinical strains [340]. 
4.2.2 Clinical trials with QSIs 
Though impressive in vitro and in vivo results obtained with QSIs have been 
published, few QSIs have been tested in clinical trials. In a randomized, double-blind, 
multicenter trial, the ability of azithromycin to prevent ventilator-associated 
pneumonia (VAP) in patients colonized by rhamnolipid producing P. aeruginosa 
isolates was accessed [341]. A trend towards reduced occurrence of VAP was 
observed in the azithromycin group, but the difference was not statistically significant 
[341]. In another randomized controlled trial with garlic capsules in cystic fibrosis 
patients infected with P. aeruginosa, the improvement in lung function, weight and 
symptom score with garlic therapy was also non-significant [342]. These preliminary 
clinical trial data indicated that QSIs alone may not be sufficiently effective during 
infections. In addition, larger clinical trials may help to further demonstrate the effect 
of QSIs. 
4.3 QSIs vs. QQ enzymes 
Both QSIs and QQ enzymes interfere with QS and virulence in many bacterial 
species.  However, QSIs and QQ enzymes each have advantages and drawbacks 
due to their entirely distinct molecular structures and functional mechanisms. 
Many synthetic QS inhibitors mainly target one specific signal receptor or several 
homologous receptors, such as the LuxR-like family, which might allow to developing 
drugs with narrow spectrum targeting the virulence of specific pathogens. In P. 
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aeruginosa, selective effect on certain QS receptor, such as RhlR, LasR and QscR, 
can be achieved and allow for a precise modulation of individual QS system [343-
345]. However, in the case of microbial infection with multiple pathogens, targeting 
one pathogen might be insufficient. Under these conditions, QQ enzymes which can 
degrade a wide range of AHLs may be more efficient, as they could possibly affect 
different Gram-negative pathogens such as P. aeruginosa, E. coli, A. baumannii, and 
B. cenocepacia. Nevertheless, the unintended effect of broad spectrum QQ enzymes 
on the commensal or benificial bacteria should be considered in a complex 
environment as intestine. 
Unlike QQ enzymes, the structures of QSIs are relatively simple and can be easily 
modified through synthetic methods. QSIs with low molecular weights may be 
administered orally or intravenously like other drugs. Furthermore, the 
nonproteinaceous nature of QSIs may prevent an antibody-based immune response 
compared to QQ enzymes. It could also be more difficult to develop formulations for 
delivering macromolecular QQ enzymes due to the low bioavailability of protein drugs. 
Barriers related to poor absorption, poor permeation, and degradation in the 
gastrointestinal tract need to be addressed for an effective QQ enzyme delivery 
The stability of both QQ enzymes and QSIs is also an important issue to be 
considered. Thermostable QQ enzymes with high stability during storage and 
immobilization [225] may hold promise for biotechnological applications. Coatings 
and dry powder with QQ enzyme in several study also showed well-retained QQ 
activity [281, 283]. However, the stability of both QQ enzymes and different QSIs 
needs to be further investigated under the complex in vivo conditions. 
Therefore, the choice between QQ enzymes and specific QSIs might take their 
effectiveness, stability and toxicity into consideration. The successful application of 
both QQ enzymes and QSIs may also rely on the precise diagnosis of the pathogens 
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As major bacteria responsible for nosocomial wounds, urinary tracts, lung and 
bloodstream infections, P. aeruginosa and A. baumannii are highly resistant to a wide 
range of antibiotics. The ability of P. aeruginosa and A. baumannii to form biofilms 
further increases the difficulty to treat these infections. Interfering with the QS 
system(s) of these pathogens has been proposed as an alternative to conventional 
antibiotics for the eradication of biofilms and treatment of these biofilm-related 
infections. Many different QQ enzymes and QSIs from various origins have been 
identified and tested. However, the effects of some QQ enzymes and QSIs on the 
virulence and biofilm formation of P. aeruginosa and A. baumannii are poorly 
characterized, especially under in vivo-like conditions. In addition, the mechanism(s) 
behind the activity of several QSIs are yet to be investigated in detail. The main aim 
of this dissertation was to provide more evidence for the possibility to use certain QQ 
enzymes or QSIs to combat P. aeruginosa and A. baumannii infections and to get 
more insights into the mode of action. 
First, we aimed to evaluate the anti-biofilm activity of the QQ enzyme MomL against 
P. aeruginosa and A. baumannii, and further investigate the effect of MomL under 
more complex conditions such as in dual-species biofilm and in a wound model 
system. The effect of MomL on virulence of A. baumannii was also tested in the C. 
elegans infection model. 
Secondly, the effects of a plant-derived QSI, coumarin, on the production of virulence 
factors and biofilm formation in several P. aeruginosa wound isolates were 
investigated. We also aimed to test the potential use of coumarin to increase the 
survival of Lucilia sericata when challenged with P. aeruginosa in the context of 
wound debridement therapy. In addition, transcriptome analysis was performed to 
reveal how coumarin affected QS and virulence in P. aeruginosa. 
Finally, we aimed to expand the knowledge about QSIs which were effective against 
A. baumannii. The effects of several known QSIs on A. baumannii motility and biofilm 
formation were tested. The most promising QSIs against A. baumannii were further 
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Abstract 
Background. The enzymatic degradation of quorum sensing (QS) molecules (called 
quorum quenching, QQ) has been considered as a promising anti-virulence therapy 
to treat biofilm-related infections and combat antibiotic resistance. The recently-
discovered QQ enzyme MomL has been reported to efficiently degrade different N-
acyl homoserine lactones (AHLs) of various Gram-negative pathogens. Here we 
investigated the effect of MomL on biofilms formed by two important nosocomial 
pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii. 
Methods. MomL was expressed in E.coli BL21 and purified. The activity of MomL on 
AHLs with hydroxyl substituent was tested. Biofilms of P. aeruginosa PAO1 and 
Acinetobacter strains were formed in 96-well microtiter plates. Biofilm formation was 
evaluated by crystal violet staining, plating and fluorescence microscopy. The effect 
of MomL on biofilm susceptibility to antibiotics was also tested. We further evaluated 
MomL in dual-species biofilms formed by P. aeruginosa and A. baumannii, and in 
biofilms formed in a wound model. The effect of MomL on virulence of A. baumannii 
was also tested in the Caenorhabditis elegans model. 
Results. MomL reduced biofilm formation and increased biofilm susceptibility to 
different antibiotics in biofilms of P. aeruginosa PAO1 and A. baumannii LMG 10531 
formed in microtiter plates in vitro. However, no significant differences were detected 
in the dual-species biofilm and in wound model biofilms. In addition, MomL did not 
affect virulence of A. baumannii in the C. elegans model. Finally, the effect of MomL 
on biofilm of Acinetobacter strains seems to be strain-dependent. 
Discussion. Our results indicate that although MomL showed a promising anti-
biofilm effect against P. aeruginosa and A. baumannii biofilms formed in microtiter 
plates, the effect on biofilm formation under conditions more likely to mimic the real-
life situation was much less pronounced or even absent. Our data indicate that in 
order to obtain a better picture of potential applicability of QQ enzymes for the 
treatment of biofilm-related infections, more elaborate model systems need to be 
used.  
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Introduction 
Quorum sensing (QS) is a widespread communication process that allows bacteria to 
coordinate their group behavior based on the production, detection and response to 
extracellular signal molecules [346, 347]. QS regulates gene expression related to 
biofilm formation, motility and production of virulence factors in many Gram-negative 
and Gram-positive pathogens, and interfering with QS has been intensively studied 
as a promising anti-virulence therapy to combat bacterial infections and antibiotic 
resistance [348-350]. Many natural and synthetic compounds have been found to 
inhibit QS, and several quorum quenching (QQ) enzymes mainly targeting N-acyl 
homoserine lactone (AHL) based QS in Gram-negative bacteria have been described 
as well [49, 205, 288, 351]. Some of these QS inhibitors (QSIs) and QQ enzymes 
have shown promising anti-virulence effects both in vitro and in vivo. For instance, 
furanones which resemble AHLs and are able to bind to QS receptors have been 
reported to reduce biofilm formation and enhance bacterial clearance in 
Pseudomonas aeruginosa lung infection in mice [313, 330]. Baicalin hydrate and 
cinnamaldehyde (QSIs targeting AHL-based QS in P. aeruginosa and Burkholderia 
cepacia complex) as well as hamamelitannin (a QSI targeting the peptide-based QS 
system present in Staphylococcus aureus) increase biofilm susceptibility to antibiotics 
and survival of infected Galleria mellonella larvae and Caenorhabditis elegans, as 
well as decrease the microbial load in a mouse pulmonary infection model [352]. As 
for QQ enzymes, an AiiM-producing P. aeruginosa mutant showed reduced lung 
injury and increased survival in an in vivo study on mice with pneumonia [267], and 
an inhaled lactonase SsoPox-I was also reported to reduce virulence of P. 
aeruginosa and mortality in rat pneumonia [268].  
Previously MomL, a novel AHL lactonase belonging to the metallo-β-lactamase 
superfamily was identified and characterized [212]. It has high degrading activities 
towards short- and long-chain AHLs with or without an oxo-group at the C-3 position 
[212]. MomL can reduce pyocyanin and protease production by P. aeruginosa and 
attenuated the virulence of P. aeruginosa in a C. elegans infection model [212], but 
its effect on biofilm formation of P. aeruginosa and other Gram-negative pathogens 
was not tested yet.  
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Besides P. aeruginosa, Acinetobacter baumannii has also been recognized as an 
increasingly prevalent Gram-negative opportunistic pathogen responsible for severe 
nosocomial infections [353, 354]. Resistance of P. aeruginosa and A. baumannii 
strains to multiple antibiotic classes complicates the treatment for these infections 
and poses considerable therapeutic challenges worldwide [355]. One of the main 
factors contributing to their reduced antibiotic susceptibility and to treatment failure is 
biofilm formation both on tissues and abiotic surfaces [356-358]. Biofilms of both P. 
aeruginosa and A. baumannii are known to be regulated by AHL-based QS. In P. 
aeruginosa, N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) and N-
butyryl-L-homoserine lactone (C4-HSL) are used by the Las and Rhl QS system, 
respectively [103], and these two AHLs can both be degraded by MomL [212]. One 
AHL synthase belonging to LuxI family, AbaI, has been reported to catalyze the 
synthesis of N-(3-hydroxydodecanoyl)-L-HSL (3-OH-C12-HSL) in Acinetobacter 
nosocomialis M2 [190], but other AHLs with varied chain lengths and substituents are 
also found in Acinetobacter strains [359, 360]. The biofilm-forming ability of an abaI 
mutant was reduced by around 40 % compared to the corresponding wildtype strain 
[190]. Compared to the extensive literature on inhibiting QS pathways and virulence 
in P. aeruginosa [314, 326, 361-363], there are fewer reports on inhibiting QS and 
biofilm formation in A. baumannii [257, 338, 339].  
In the present study, we tested the anti-biofilm activity of MomL against P. 
aeruginosa and A. baumannii, and further evaluated the effect of MomL under more 
complex conditions such as in dual-species biofilm and in a wound model system 
with the aim to obtain a better knowledge base regarding the possible development 
of QQ enzymes as anti-virulence therapy. 
 
Material & Methods 
Bacterial strains, culture conditions and chemicals 
P. aeruginosa PAO1, A. calcoaceticus LMG 10517, A. nosocomialis M2 and A. 
baumannii LMG 10520, LMG 10531 and AB5075 were cultured on tryptic soy agar 
(TSA) or in Mueller-Hinton broth (MH) at 37°C. Escherichia coli BL21(DE3) harboring 
MomL expression plasmid pET24a(+)-momL-(-SP) [212] was cultured on Luria-
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Bertani (LB) agar supplemented with kanamycin (50 μg/mL) at 37°C. The AHL 
biosensor Agrobacterium tumefaciens A136 (pCF218) (pCF372) [364] was 
maintained on LB agar supplemented with spectinomycin (50 μg/mL) and tetracycline 
(4.5 μg/mL), and grown in AT minimal medium [365] containing 0.5% (wt/vol) glucose 
for detecting AHLs in the liquid X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) assay. 3-OH-C12-HSL was purchased from Sigma-Aldrich and 
dissolved in dimethyl sulfoxide (DMSO) as stock solution (100 mM). Caenorhabditis 
elegans N2 (glp-4; sek-1) was propagated under standard conditions, synchronized 
by hypochlorite bleaching, and cultured on nematode growth medium using E. coli 
OP50 as a food source [366]. 
MomL expression and purification 
MomL was expressed and purified according to Tang et al., 2015. In brief, protein 
expression was induced by 0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside) 
when E. coli cells in LB reaching an optical density at 600 nm (OD600) of 0.5 to 0.7. 
The induction was carried out at 16°C with moderate shaking (150 rpm) for 12h. Cells 
were harvested and sonicated, and the obtained supernatant was loaded on NTA-Ni 
(Qiagen) columns for purification according to the manufacturer’s instruction. 
Desalting of the protein solution was accomplished by Amicon Ultra-15 centrifugal 
filter devices, and the purified MomL was stored at -20°C in Tris-HCl buffer (50mM, 
pH 6.5) with 25% glycerol. 
Detection for degradation of 3-OH-C12-HSL 
The amount of 3-OH-C12-HSL was quantified using A. tumefaciens A136 liquid X-gal 
assay and expressed as the normalized β-galactosidase activity as previously 
described [367]. The correction factor a and b were obtained and calculated for our 
experimental conditions, and the final formula to calculate the normalized β-
galactosidase activity is  
0.716×𝑂𝐷492−𝑂𝐷620
0.205×𝑂𝐷620−𝑂𝐷492
.  To test the degradation of 3-OH-C12-HSL 
by MomL, 3-OH-C12-HSL (10 μM) was mixed with MomL in different concentrations 
(0.05-5 μg/mL) and incubated at 37°C for 1h. No MomL was added in control. 
Afterwards the residual 3-OH-C12-HSL was quantified by adding 10 μL solution to the 
A136 biosensor, as described previously [367].  
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Biofilm formation assays 
Overnight cultures of P. aeruginosa and Acinetobacter strains in MH broth were 
diluted to contain approximately 5×107 CFU/mL. 90 μL of this diluted bacterial 
suspension was transferred to the wells of a round-bottomed 96-well microtiter plate. 
Uninoculated MH broth was used as blank controls. To test the effect of MomL on 
biofilms, 10 μL purified enzyme (in different concentrations) was added to the wells, 
while 10 μL Tris-HCl buffer (50mM, pH 6.5) with 25% glycerol was added to the 
control. The plate was incubated at 37°C for 4 hours before the supernatant was 
removed. The wells were rinsed once with sterile physiological saline (PS) and re-
filled with fresh media (90 μL) and MomL (10 μL). The plate was incubated at 37°C 
for an additional 20 hours. The biofilm biomass was quantified by crystal violet (CV) 
staining as described previously [368]. After rinsing the wells with sterile PS, the 
biofilm was fixed with 100 μL 99% methanol for 15 min and stained with 100 μL 0.1% 
CV for 20 min. The excess CV was removed by washing the plates under running tap 
water and bound CV was released by adding 150 μl of 33% acetic acid. The 
absorbance was measured at 590 nm.  
Biofilm susceptibility assays 
After a 24h-biofilm of P. aeruginosa or A. baumannii strains was formed as described 
above either in presence of MomL or not, the plate was emptied and biofilm cells 
were rinsed with sterile PS. Antibiotics were dissolved in PS and 90 μL of these 
solutions were added to treat the biofilm for another 24h, either with or without 10 μl 
MomL. Tobramycin (TOB; 4 μg/mL as final concentration), ciprofloxacin (CIP; 0.5 
μg/mL), meropenem (MEM; 16 μg/mL) and colistin (CST; 16 μg/mL) were used to 
treat the biofilm of P. aeruginosa PAO1; TOB (6 μg/mL), CIP (4 μg/mL), MEM (8 
μg/mL) and CST (16 μg/mL) were used to treat the biofilm of the A. baumannii strains.  
The supernatant was removed and the wells were washed once with sterile PS. To 
release bacterial cells from biofilm, two cycles of vortex (5 mins) and sonication (5 
mins) were performed, and the number of CFU/biofilm was determined by plating the 
resulting suspensions on TSA. 
Fluorescence microscopy 
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Biofilms of P. aeruginosa PAO1 or A. baumannii strains were formed in the absence 
or presence of MomL and treated with antibiotics as described above using a flat-
bottomed 96-well microtiter plates. 3 μL SYTO9 and 3 μL propidium iodide were 
diluted to 1mL in sterile PS, and 100 μL of this staining solution was transferred to 
each well. The plate was incubated for 15min at room temperature and fluorescence 
microscopy was performed with EVOS FL Auto Imaging System (Life Technologies). 
The red fluorescent signal was detected with 531/40 nm excitation filter cube and 
593/40 nm emission filter cube and the green fluorescent signal was detected with 
470/22 nm excitation filter cube and 510/42 nm emission filter cube. 
Dual-species biofilm formation 
Overnight cultures of P. aeruginosa and A. baumannii strains in MH broth were 
diluted to contain approximately 5×105 CFU/mL and 5×107 CFU/mL, respectively, 
and equal volume of suspensions of P. aeruginosa and A. baumannii were mixed. 
MomL (200 μg/mL) and tobramycin (6 μg/mL) were added as described above. To 
quantify CFU in the dual-species biofilm, Pseudomonas Isolation Agar (Difco) and 
TSA supplemented with 5 μg/mL cefsulodin were used as selective media for P. 
aeruginosa and A. baumannii respectively. 
Biofilm formation in wound model 
Artificial dermis composed of hyaluronic acid and collagen was used in our wound 
model, as described before [369]. Each disk of artificial dermis was placed in 24-well 
microtiter plate. One mL media containing Bolton Broth, heparinized bovine plasma 
and freeze-thaw laked horse blood cells was added on and around the dermis. 
Suspensions (10 μL) of P. aeruginosa or A. baumannii containing 104 bacterial cells 
were added on the top of dermis. Final concentrations of MomL added were 200 
μg/mL and 10 μg/mL for P. aeruginosa and A. baumannii, respectively. Tobramycin 
(10 μg/mL) was added after 8 h incubation at 37°C. After 24h, the infected dermis 
was washed with 1 mL PS and was transferred into 10 ml PS. Biofilm cells on the 
dermis were loosen and collected by three cycles of vortex (30 s) and sonication (30 
s). The number of CFU/dermis was quantified by standard plating techniques. 
C. elegans survival assay 
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The C. elegans survival assay was carried out as described before with minor 
modification [352]. Synchronized worms (L4 stage) were suspended in medium 
containing 95% M9 buffer (3 g of KH2PO4, 6 g of Na2HPO4, 5 g of NaCl, and 1 ml of 1 
M MgSO4∙7H2O in 1 liter of water) and 5% brain heart infusion broth (Oxoid), and 25 
μL of this nematode suspension was transferred to the wells of a 96-well microtiter 
plate. Overnight culture of A. baumannii was suspended in the assay media and 
added in a final concentration of 2.5x107 CFU/ml. MomL was added in a final 
concentration of 10 μg/mL.  The plates were incubated at 25°C for 24 h. The fraction 
of dead worms was determined by counting the number of dead worms and the total 
number of worms in each well. 
Statistics 
The normal distribution of the data was checked by the D'Agostino-Pearson normality 
test. Normally distributed data were analyzed by one-way ANOVA, and non-normally 
distributed data were analyzed by the Kruskal-Wallis test or the Mann-Whitney test. 




Figure 1. SDS-PAGE of purified MomL. Lane1, molecular mass markers; Lane 2, purified recombinant 
MomL with molecular mass of nearly 31 kDa 
Degradation of 3-OH-C12-HSL by purified MomL 
MomL was produced in E. coli and subsequently successfully purified (Fig. 1). 
Although MomL had been shown to degrade various AHLs [212], its activity on AHLs 
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with hydroxyl substituent at the C3 position was not tested yet. We could 
demonstrate that MomL, in a concentration of 1 μg/mL or higher, can degrade almost 
all 3-OH-C12-HSLs (10 μM) under the experimental conditions used in the present 
study (Fig. 2). 
 
Figure 2. Degradation of 3OH-C12-HSL by MomL. The amount of residual 3-OH-C12-HSL was 
expressed as the normalized β-galactosidase activity. Data shown are average of three replicates (n = 
3), error bars represent standard deviation. *, P < 0.05 when compared with non-MomL treated control 
(Kruskal-Wallis test). 
Effect of MomL on biofilm formation by P. aeruginosa and A. baumannii 
Following biofilm formation in 96-well microtiter plates and quantification by crystal 
violet staining, a significant difference was observed between P. aeruginosa PAO1 
control biofilms and biofilms grown in the presence of MomL (concentration > 50 
μg/mL) (Fig. 3A). When grown with 150 μg/mL MomL, an average decrease of 
approximately 35% was observed. MomL inhibited A. baumannii LMG 10531 biofilm 
formation at concentrations as low as 0.1 μg/mL, and the biofilm biomass was 
reduced by approximately 42% when exposed to 5 μg/mL MomL (Fig. 3B). No further 
decrease was observed when A. baumannii LMG 10531 biofilms were grown in the 
presence of higher concentration of MomL. 
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Figure 3 Effect of MomL on biofilm formation by P. aeruginosa PAO1 (A) and A. baumannii LMG 
10531 (B). Biofilms were quantified by CV staining and amount of biofilm left is expressed as CV 
absorbance (OD 590). Data shown are average of three independent experiments with variable 
numbers of replicates each (n ≥ 27), error bars represent standard deviation. *, P < 0.05 when 
compared with nonMomL treated control in Kruskal-Wallis test (A) or one-way ANOVA(B). 
 
Effect of MomL on biofilm susceptibility to antibiotics 
Application of MomL alone (200 μg/mL for P. aeruginosa PAO1 and 10 μg/mL for A. 
baumannii LMG 10531) reduced the number of cultivable biofilm cells by 
approximately 50% in both P. aeruginosa PAO1 and A. baumannii LMG 10531. For P. 
aeruginosa PAO1, combining CIP or MEM with MomL led to >70% more reduction 
compared to treatment with CIP or MEM alone (Fig. 4A). For A. baumannii LMG 
10531, MomL also increased killing of biofilm cells when antibiotics were used 
together with MomL (Fig. 4B). In case of TOB, cell number was reduced by 80% 
when used in combination with MomL compared to TOB alone. Consistent with 
results obtained by plating, fewer living cells were observed in fluorescence 
microscope images of biofilms treated with MomL, TOB, or a combination of both, 
compared to control biofilms (Fig. 5). 
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Figure 4. Effect of MomL on susceptibility of P. aeruginosa PAO1 (A) and A. baumannii LMG 10531 (B) 
biofilms to different antibiotics. Numbers of CFU/biofilm were determined by plating and shown as box-
whisker plots. Boxes span the interquartile range; the line within each box denotes the median, and 
whiskers indicate the minimum and maximum values. MomL was added in a final concentration of 200 
µg/mL for P. aeruginosa PAO1 and 10 µg/mL for A. baumannii LMG 10531. Data shown are from 
three independent experiments with three replicates each (n = 9). Mann–Whitney tests were 
performed to compare different groups (*, P < 0.05) 
 
Figure 5. Representative fluorescence images of biofilms of P. aeruginosa PAO1 and A. baumannii 
LMG 10531. Biofilms were treated with MomL alone, TOB alone or a combination of both and stained 
with Syto9 and propidium iodide. 40× Objective (numerical aperture: 0.75) was used and the final 
magnification is 1,200×. The scale bar represents 100 µm. 
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Effect of MomL on dual-species biofilm formed by P. aeruginosa and A. 
baumannii 
We also evaluated the effect of MomL on dual-species biofilm formed by P. 
aeruginosa PAO1 and A. baumannii LMG 10531. We found that P. aeruginosa PAO1 
inhibited growth of A. baumannii LMG 10531 in dual-species biofilm, and most A. 
baumannii LMG 10531 cells were killed by P. aeruginosa PAO1 after 48h (Fig. 6). 
When MomL was added, there was a reduction in A. baumannii LMG 10531 cell 
numbers; however no difference was observed in either total cell numbers or number 
of surviving P. aeruginosa PAO1 cells (Fig. 6A). MomL in combination of TOB was 
also tested, but no change in susceptibility to TOB was observed in the dual-species 
biofilm (Fig. 6B). 
 
Figure 6 Effect of MomL on dual-species biofilms. Total number of CFU/biofilm, number of P. 
aeruginosa PAO1 CFU/biofilm and number of A. baumannii LMG 10531 CFU/biofilm in each dual-
species biofilm were determined by plating and shown as box-whisker plots. Boxes span the 
interquartile range; the line within each box denotes the median, and whiskers indicate the minimum 
and maximum values. (A). 24 h-biofilm treated with MomL alone; (B). 48 h-biofilm treated with MomL 
alone, TOB alone or a combination of both. Data shown are from three independent experiments with 
three (A) or two (B) replicates each (n = 9 for A, n = 6 for B). Mann–Whitney tests were performed to 
compare total, P. aeruginosa PAO1 and A. baumannii LMG 10531 cell numbers respectively between 
untreated or MomL-treated dual-species biofilm (*, P < 0.05). 
 
Effect of MomL on other Acinetobacter strains 
We also tested MomL on four other Acinetobacter strains. However, only A. 
baumannii LMG 10520 showed reduction in biofilm biomass when treated with MomL 
at 50 μg/mL (Fig. 7). No significant difference was observed for A. calcoaceticus 
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LMG 10517, A. nosocomialis M2 and A. baumannii AB5075. The effect of MomL on 
susceptibility of A. baumannii LMG 10520 and A. calcoaceticus LMG 10517 biofilms 
was also tested. For A. baumannii LMG 10520, significant differences were detected 
when MomL was added alone or in combination with several antibiotics (Fig. 8). For 
A. calcoaceticus LMG 10517, no difference was observed between biofilms receiving 
MomL treatment and biofilms receiving the control treatment, either by plating or 
fluorescence microscope.  
 
Figure 7. Effect of MomL on biofilms formed by other Acinetobacter strains. Biofilms of A. 
calcoaceticus LMG 10517, A. nosocomialis M2, A. baumannii LMG 10520 and A. baumannii AB5075 
were treated with different concentration of MomL and quantified by CV staining. Data shown in box-
whisker plots are from three independent experiments with variable numbers of replicates each (n ≥ 
27). Boxes span the interquartile range; the line within each box denotes the median, and whiskers 
indicate the minimum and maximum values. *, P < 0.05 when compared to untreated control (Kruskal-
Wallis test). 
 
Effect of MomL in a biofilm wound model system and in the C. elegans model 
An in vitro wound model was used to mimic the conditions in an infected wound. For 
both P. aeruginosa PAO1 and A. baumannii LMG 10531, MomL had no effect on 
biofilm formation in this wound model (Fig. 9). 
The C. elegans model was used to further evaluate whether MomL can increase 
survival of nematodes infected with A. baumannii. However, no significant increase of 
C. elegans survival was found after treating nematodes infected with A. baumannii 
LMG 10520 or A. baumannii LMG 10531 with MomL (Fig. 10). 
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Figure 8 Effect of MomL on biofilm susceptibility of A. baumannii LMG 10520 and A. calcoaceticus 
LMG 10517. (A). Plating results for biofilms of A. baumannii LMG 10520 exposed to CIP, MEM, CST, 
TOB alone or in combination with MomL (50 µg/mL); (B), Plating results for biofilms of A. 
calcoaceticus LMG 10517 exposed to CIP, MEM, CST, TOB alone or in combination with MomL (200 
µg/mL). Data shown in box-whisker plots are from two independent experiments with three replicates 
each (n = 6). Boxes span the interquartile range; the line within each box denotes the median, and 
whiskers indicate the minimum and maximum values. Mann–Whitney tests were performed to 
compare control and MomL or antibiotic treatment alone and in combination with MomL (*, P < 0.05). 
(C). Representative fluorescence images of A. baumannii LMG 10520 and A. calcoaceticus LMG 
10517. Biofilms were treated with MomL alone or in combination with tobramycin and stained with 
Syto9 and propidium iodide. 20× Objective (numerical aperture: 0.65) was used and the final 
magnification is 599×. The scale bar represents 200 µm. 
 
Chapter III. Experimental work                                                                                    Paper I 
63 
 
Figure 9. Effect of MomL on biofilms of P. aeruginosa PAO1 and A. baumannii LMG 10531 formed in 
wound model. Data shown in box-whisker plots are from three independent experiments with two 
replicates each (n = 6). Boxes span the interquartile range; the line within each box denotes the 
median, and whiskers indicate the minimum and maximum values. Mann–Whitney tests were 
performed to compare control and MomL treatment, or TOB and TOB in combination with MomL. 
 
Figure 10. Effect of MomL on the virulence of A. baumannii strains in C. elegans. Percent survival of C. 
elegans infected by A. baumannii LMG 10520 and LMG 10531. Data shown in box-whisker plots are 
from three independent experiments with three replicates each (n = 9). Boxes span the interquartile 
range; the line within each box denotes the median, and whiskers indicate the minimum and maximum 
values. One-way ANOVA was performed, and no significant differences were found between control 
and MomL treatment in both uninfected C. elegans and those infected by A. baumannii strains. 
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Discussion 
QS disruption has been considered as a promising anti-infectious strategy to 
substitute or at least supplement treatment with antibiotics, and could inhibit 
production of virulence factors and the formation of biofilms [352]. Compared to QS 
inhibitors, QQ enzymes can degrade AHLs from different pathogens and might be 
more effective in treating multispecies infections. In addition, QQ enzymes do not 
need to enter the cells as they can act extracellularly, making it less likely resistance 
will develop [370]. The recently-discovered QQ enzyme, MomL, has strong degrading 
activity towards AHLs with different acyl-chain length and substituents (oxo or 
hydroxyl) [212], and this could be an advantage when targeting bacteria like 
Acinetobacter strains that produce various AHLs. MomL was reported to reduce the 
in vitro production of protease and pyocyanin by P. aeruginosa and attenuate the 
virulence of P. aeruginosa in a C. elegans infection model [212]. The further 
application potential of MomL was not determined yet. In the present study we 
investigated the possible use of MomL for treating biofilm infections, and evaluate its 
effect on two important Gram-negative nosocomial pathogens, P. aeruginosa and A. 
baumannii in different models. 
First we tested the effect of MomL on single-species biofilms of P. aeruginosa PAO1 
and A. baumannii LMG 10531 formed in microtiter plates; a reduction of biofilm 
biomass was observed for both strains. The maximum decrease in biofilm of A. 
baumannii LMG 10531 was achieved at a concentration of 5 μg/mL and no further 
decrease was observed with higher concentrations of MomL, which indicated the 
presence of other mechanisms besides QS regulating biofilm formation in A. 
baumannii. When used in combination with antibiotics, fewer biofilm cells survived 
compared to antibiotic treatment alone, both for P. aeruginosa PAO1 and A. 
baumannii LMG 10531. In addition, MomL showed no inhibition on planktonic cells of 
both P. aeruginosa and A. baumannii (Fig. S1), and all these in vitro results seem 
promising and suggest possible use of MomL to treat biofilm infections of P. 
aeruginosa and A. baumannii. 
We subsequently investigated the effect of MomL in a dual-species biofilm formed by 
P. aeruginosa and A. baumannii and in a wound biofilm model. MomL had no effect 
on the overall cell number in the mixed species biofilm and the same disappointing 
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results were obtained in biofilms formed in wound model system. In this wound model 
system, media containing plasma, serum, horse blood and heparin was used to 
reflect nutritional condition in wounds. An artificial dermis was used to mimic a wound 
like surface and an inoculum of 104 cells was used to reflect the microbial load of a 
wound prior to infection. Additionally, in contrast to what we observed for the mono-
species biofilms formed in 96-well microtiter plates, MomL did not potentiate the 
activity of TOB in this model system. Possible explanations for this are that 
component(s) present in this wound biofilm model protect AHL from degradation 
and/or interfere with the activity of MomL (potentially through interactions with 
proteins in the plasma), or that QS is not essential for biofilm formation and/or 
resistance in these conditions. Further experiments will be required to clarify this. 
Although MomL showed strong activity against 3-OH-C12-HSL in the medium used in 
the C. elegans model (Fig. S2), no effect of MomL on the virulence of A. baumannii 
was observed. As previously reported, an A. baumannii QS mutant did not differ from 
the wild type with regards to killing in a Galleria mellonella infection model [371]. 
These results indicated that although QS is known to play an important role in A. 
baumannii biofilm formation, it might have only limited influence on the general 
virulence to C. elegans and G. mellonella. 
Thus far, a series of promising results about in vivo application of QQ enzymes have 
been reported. Phosphotriesterase-like lactonase SsoPox-I has been reported to 
reduce biofilm formation of P. aeruginosa at a concentration higher than 170 μg/mL, 
and the early use of SsoPox-I reduced the mortality of rats with acute pneumonia 
from 75% to 20%  [268]. In another study, acylase-containing coatings on silicone 
urinary catheters reduced formation of P. aeruginosa biofilms and mixed-species P. 
aeruginosa-E. coli biofilms [279]. Our data obtained in a dual-species biofilm formed 
by P. aeruginosa and A. baumannii as well as in a wound model strongly suggest 
that the effect of MomL (and potentially also other QQ enzymes) on in vivo grown 
bacterial biofilms may be much less pronounced than the effect observed with 
biofilms formed under simple in vitro conditions. Factors affecting the anti-biofilm 
activity in more complex systems could include stability of the enzyme, penetration of 
the enzyme through the biofilm matrix, and the composition of the environment. 
Different outcomes were also observed when we evaluated the effect of MomL on 
different Acinetobacter strains, and no effects of MomL on biofilm formation was 
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detected for three out of five Acinetobacter strains tested. In addition, for A. 
baumannii LMG 10520, a considerably higher concentration of MomL was required to 
obtain a pronounced inhibitory effect than for A. baumannii LMG 10531. These 
results confirm that the anti-biofilm activity of QQ enzymes is strain-dependent, which 
is likely to reduce their clinical efficacy.  
Conclusion 
The results of the present study highlight that there are considerable hurdles to be 
cleared before QQ enzymes could potentially be used to combat infections. Our data 
indicate that demonstrating AHL degrading activity in vitro and/or anti-biofilm activity 
in simple in vitro biofilm model systems is not sufficient to predict an anti-biofilm effect 
in more complex systems.  
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Figure S1. The influence of MomL on cell growth of P. aeruginosa PAO1 and A. baumannii LMG 
10531. The growth of P. aeruginosa PAO1 and A. baumannii LMG 10531 was spectrophotometrically 
determined at OD 590 after being incubated with different concentrations of MomL at 37 °C for 24 h. 
No MomL was added in control. Data shown in box-whisker plots are from three independent 
experiments with two replicates each (n = 6). Boxes span the interquartile range; the line within each 
box denotes the median, and whiskers indicate the minimum and maximum values. 
 
 
Figure S2. Degradation of 3-OH-C12-HSL by MomL in C. elegans model medium 3-OH-C12-HSL (10 
µM) was mixed with MomL under the same medium condition in C. elegans model and incubated at 
37°C for 1h. No MomL was added in control. The amount of residual 3-OH-C12-HSL was quantified 
using A. tumefaciens A136 liquid X-gal assay and expressed as the normalized β-galactosidase 
activity. 
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Abstract 
As one of the major pathogens in wound infections, Pseudomonas aeruginosa 
produces several virulence factors and forms biofilms; these processes are under the 
regulation of various quorum sensing (QS) systems. Therefore, QS has been 
regarded as a promising target to treat P. aeruginosa infections.  In the present study, 
we evaluated the effect of the plant-derived QS inhibitor coumarin on P. aeruginosa 
biofilms and virulence. Coumarin inhibited QS in the P. aeruginosa QSIS2 biosensor, 
reduced protease and pyocyanin production in different P. aeruginosa strains, 
inhibited biofilm formation both in microtiter plates and in an in vitro wound model, 
and reduced P. aeruginosa virulence in the Lucilia sericata infection model. 
Transcriptome analysis revealed that several key genes involved in the las, rhl, 
Pseudomonas quinolone signal (PQS) and integrated quorum sensing (IQS) systems 
were down-regulated in the coumarin-treated biofilm of P. aeruginosa PAO1. 
Coumarin also changed the expression of genes related to type III secretion and 
cyclic diguanylate (c-di-GMP) metabolism. The cellular c-di-GMP level of P. 
aeruginosa PAO1 was significantly reduced by coumarin. These results provide new 
evidences for the possible application of coumarin as an anti-biofilm and anti-
virulence agent against P. aeruginosa in wound infections. 
 
Introduction 
The opportunistic pathogen Pseudomonas aeruginosa frequently causes diverse 
infections in immunocompromised patients [2, 372, 373]. P. aeruginosa is also 
involved in both acute and chronic wound infections associated with high morbidity 
and mortality. Chronic wounds such as diabetic ulcers, venous ulcers and pressure 
ulcers affect millions of patients worldwide and lead to high costs for the healthcare 
system (e.g. they represent an estimated cost of around 25 billion per year in the US 
alone) [374]. Infections in burn wounds also pose a heavy medical and economic 
burden in both developed and developing countries [375, 376]. Wound infections with 
P. aeruginosa are especially difficult to treat and are often associated with worse 
outcomes compared to other pathogens [377], due to the extensive arsenal of 
virulence factors and increasing antibiotic resistance [378, 379]. In addition, biofilms 
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formed by P. aeruginosa in wound infections further protect the bacteria from host 
immune defense and antimicrobials, impeding the healing process and triggering the 
shift to chronic wounds [380, 381]. Therefore, there is an urgent need to develop 
alternative strategies to combat biofilm-related P. aeruginosa infections. 
Quorum sensing (QS) is the intercellular communication process based on the 
production and detection of, and group-level response to, signal molecules [42]. The 
complex P. aeruginosa QS network has intensively been studied in the past decades 
as QS plays a crucial role in coordinating the production of several important 
virulence factors, including pyocyanin, protease, exotoxin A, hydrogen cyanide and 
rhamnolipid [382]. QS also affects biofilm formation and antibiotic resistance through 
multiple distinct mechanisms [181, 383-385]. So far, four interacting QS systems 
have been identified in P. aeruginosa, including the N-acyl-homoserine lactone 
(AHL)-based rhl and las systems, the Pseudomonas quinolone signal (PQS) system 
and the recently identified integrated QS (IQS) system [386]. This QS network allows 
P. aeruginosa to secrete extracellular virulence factors only when they can be 
produced at a sufficiently high level to overcome the host defense [387]. In addition, 
QS has been reported to be involved in the spread of P. aeruginosa in burn wound 
infections [388].  
QS inhibition has been proposed as a promising anti-virulence strategy which would 
allow to ‘disarm’ pathogens rather than killing them, and many potential QS inhibitors 
have been described [284, 288, 348]. A wide range of structurally different QS 
inhibitors (QSIs) targeting P. aeruginosa have been identified, both from natural and 
synthetic sources [285]. The first comprehensively studied QSI is the furanone 
compound C-30 [314], which increased P. aeruginosa biofilm susceptibility to 
tobramycin and led to more efficient clearance of bacteria in a pulmonary mouse 
infection model [313]. Ajoene, a sulfur-rich molecule from garlic, reduces expression 
of several QS-regulated virulence factors by activating the QS negative regulator 
RsmA through two small regulatory RNAs, RsmY and RsmZ [298, 299]. Many other 
QSIs such as 6-gingerol [328] and quercetin [389] have also been reported to reduce 
the virulence and biofilm formation of P. aeruginosa. These studies together 
demonstrate the possibility of using QSIs to control P. aeruginosa infections in vitro 
and/or in animal infection models. 
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Coumarin is a plant-derived phenolic compound and its derivatives are known for 
their anti-tumor and anti-inflammatory activities [328, 390, 391]. Coumarin has been 
described as an inhibitor of QS in P. aeruginosa and several other Gram-negative 
bacteria [392]. It was shown to inhibit biofilm formation, phenazine production and 
motility in P. aeruginosa strain PA14 [392]  and suppress virulence in Vibrio 
splendidus [393]. However, the mechanism by which coumarin inhibits QS has not 
been elucidated yet. 
The goal of the present study was to evaluate the potential role of coumarin in the 
treatment of P. aeruginosa-infected wounds. To this end, we determined the effect of 
coumarin on the production of virulence factors and biofilm formation in an in vitro 
wound model, using the P. aeruginosa reference isolate PAO1 as well as several P. 
aeruginosa clinical wound isolates. We also investigated the effect of coumarin on P. 
aeruginosa virulence to Lucilia sericata maggots, which are widely used in the 
debridement of chronic wounds [394]. The QS-regulated virulence factors of P. 
aeruginosa are responsible for killing of these maggots and often lead to the failure of 
maggot therapy [34]. Finally, transcriptome analysis in both planktonic and biofilm 
cells was performed to obtain a clear picture of molecular mechanisms involved in 
the inhibition of QS by coumarin. 
 
Material and methods 
Bacterial strains, chemicals and growth media 
P. aeruginosa strains 1803, 2063, 2091, 2549, 3120 were isolated from wound 
infections and obtained from the Ghent University Hospital, Belgium (with the original 
strain number described as 170407-1803, 170411-2063, 170303-2091, 170410-2549 
and 170406-3120). Reference strain P. aeruginosa PAO1 and these five wound 
isolates were routinely cultured in Luria-Bertani (LB) agar or broth (Lab M limited, UK) 
or Tryptic Soy Agar (TSA, Lab M limited, UK). The QS inhibition selector P. 
aeruginosa QSIS2 [395] was cultured in ABT minimal medium (AB medium, 
containing 2.5 mg/L thiamine) supplemented with 0.5% glucose, 0.5% casamino 
acids and 80 μg/mL gentamicin. All strains were grown aerobically at 37 °C. 
Coumarin was purchased from Sigma-Aldrich (Bornem, Belgium) and dissolved in 
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dimethyl sulfoxide (DMSO) (Alfa Aesar, Germany) as stock solutions (1 M). L. 
sericata maggots in BioBags were purchased from BioMonde (Germany), and were 
used immediately after receipt. 
QS inhibition assay 
The P. aeruginosa QSIS2 reporter strain is a lasI rhlI double mutant containing 
plasmid pLasB-SacB1 encoding an AHL-induced killing system [395]. The QS 
inhibition assay based on QSIS2 was performed as previously described, with minor 
modifications [396]. Briefly, an overnight culture of QSIS2 was diluted in ABT medium 
to an optical density at 590 nm (OD 590) of 0.1. 50 μL cell suspensions and 50 μL LB 
with sucrose (224 mg/mL) was added to 96-well microtiter plates, supplemented with 
gentamicin at a final concentration of 80 μg/mL. N-(3-oxododecanoyl)-L-homoserine 
lactone (3-oxo-C12-HSL) and N-butyryl-L-homoserine lactone (C4-HSL) (200 nM 
each, Sigma) were added to activate the QS system as positive controls, and sterile 
MilliQ ultrapure water was used as a negative control. To test the QS inhibition effect, 
coumarin was added in a final concentration of 1 mM and 2 mM. The microtiter plates 
were incubated for 10 h at 37 °C, and the absorbance was measured at 450 nm 
using an EnVision multilabel reader (Perkin Elmer, Waltham, MA). The difference in 
growth between the negative control without AHLs and the positive control with AHLs 
was considered as 100% QS inhibition. Three independent experiments were 
performed with three replicates each (n=9). 
Measurements of pyocyanin and protease production 
Overnight cultures of P. aeruginosa strains were standardized to OD590 0.5 and 1:50 
diluted in 10 ml LB with or without coumarin (2 mM). After 24 h incubation at 37 °C by 
shaking, the supernatant was collected and filter-sterilized. For the pyocyanin assay, 
chloroform (3 mL) was added to 5 mL P. aeruginosa culture supernatant and 
vortexed. The chloroform phase was kept after centrifugation (5000 rpm, 5 min), and 
mixed with 1mL HCl (0.2 M). The absorbance of the pink HCl layer was measured at 
520 nm with the EnVision multilabel reader after vortexing and centrifugation [397]. 
0.2 M HCl was used as a negative control in the measurement of absorbance. 
Protease production was tested by the azocaseine assay as described previously 
[398, 399] with modifications. 400 μL azocaseine (Sigma) solution (5 mg/mL 0.1 M 
Tris-HCl buffer) was mixed with 400 μL supernatant and incubated at 37 °C for 1 h. 
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The reaction was stopped by adding 100 μL 10% (w/v) trichloroacetic acid and the 
mixture was then centrifuged. 100 μL of the resulting supernatant was transferred to 
96-well microtiter plates and mixed with 100 μL 625 mM NaOH.  The absorbance 
was measured at 420 nm with the EnVision multilabel reader. Azocaseine solution 
with LB medium was processed following the same procedure and used as blank 
control. Two independent experiments were performed with three replicates each 
(n=6). 
The effect of coumarin on planktonic cell growth and on biofilm formation in 
microtiter plates 
Overnight cultures of P. aeruginosa strains were standardized to OD590 0.5 and 
inoculated in 10 mL of LB with 1:50 dilutions with or without coumarin (2 mM) at 
37 °C. The growth of planktonic cells was quantified by serial dilution and plating on 
TSA after 24 h. Three independent experiments were performed (n=3). 
Biofilm formation in microtiter plates was evaluated as described previously [396]. 
Briefly, overnight cultures of P. aeruginosa strains were diluted to approximately 
5×107 CFU/mL in LB broth. 100 μL of the suspension was transferred to the wells of 
a round-bottomed 96-well microtiter plate with coumarin in a final concentration of 1 
mM or 2 mM. 10 μL MilliQ with DMSO was added for the control. The plate was 
incubated at 37 °C for 4 h, and then the wells were rinsed once with sterile 
physiological saline (PS) and re-filled with fresh medium and coumarin. The plate 
was incubated at 37 °C for an additional 20 h. After removing the supernatant and 
washing the wells once with sterile PS, two cycles of vortexing (5 mins) and 
sonication (5 mins) were performed to release biofilm cells, and the number of 
CFU/biofilm was determined by plating. Three independent experiments were 
performed with three replicates each (n=9). 
The effect of coumarin on biofilm formation in a wound model 
The biofilm wound model used has been described before [400]. A spongy artificial 
dermis of 1 cm3 (upper layer: chemically cross-linked hyaluronic acid, lower layer: 
hyaluronic acid and collagen) is used as a substrate for biofilm formation to mimic 
biofilm formation at the air-liquid interface in real wounds. Each sheet of artificial 
dermis was placed in a 24-well microtiter plate. 300 μL medium containing Bolton 
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Broth, heparinized bovine plasma and freeze-thaw laked horse blood cells was 
added on dermis. Coumarin was added in a final concentration of 2 mM. P. 
aeruginosa suspensions (10 μL) containing approximately 104 bacterial cells were 
added on top of the dermis. After 24 h, the infected dermis was washed with 1 mL PS 
and was transferred into 9 ml PS. Biofilm cells on the dermis were collected by three 
cycles of vortexing (30 s) and sonication (30 s). The number of CFU/dermis was 
quantified by plating. Three independent experiments were performed with three 
replicates each (n=9). 
The effect of coumarin on P. aeruginosa virulence to L. sericata 
Blood agar (5% horse blood in LB agar) was prepared in 6 cm Petri dishes with 
DMSO as control or with coumarin (2 mM in a final concentration). P. aeruginosa 
bacteria (5×105 CFU) were spread on the blood agar and incubated overnight at 
37 °C before the assay. The maggots were aseptically transferred onto the blood 
agar (10 maggots per plate) and cultured at 37 °C in the dark (n=50 in total from two 
independent experiments). Maggot survival was assessed after 24 h. 
Immobile/inactive maggots were considered to be dead, and maggot death was 
verified by stimulating the maggots with an inoculation needle. 
RNA extraction, sequencing and analysis 
RNA sequencing was performed on coumarin treated (2 mM, 24 h) and untreated P. 
aeruginosa PAO1 biofilms. To detect the initial changes on gene expression due to 
the coumarin treatment also shortly treated (2 mM, 1 h) and untreated planktonic 
cultures were included. Suspensions of planktonic cells (5×107 CFU/mL) were added 
to a 96-well microtiter plate and treated with 2 mM coumarin or DMSO as control. 
After incubation at 37 °C for 1 h, cells were collected on ice for RNA extraction. 
Biofilms were formed in microtiter plates with 2 mM coumarin or DMSO and cells 
from 24h-biofilms were collected as described above. Subsequently, total RNA was 
extracted immediately using the Ambion RiboPure™ RNA Purification Kit (Life 
Technologies, Renfrewshire, UK) according to the manufacturer’s instructions. Three 
biological replicates were performed for each condition. 
RNA sequencing was performed as described previously [401]. Total RNA of each 
sample was depleted for ribosomal RNA using the Ribo-Zero Magnetic Kit for Gram-
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Negative Bacteria (Epicentre, Madison, WI, USA). Truseq stranded RNA library 
preparation kit (Illumina) was then used to create strand-specific cDNA sequencing 
libraries. Quality control of the libraries (DNA 1000 chip, Agilent Technologies, Santa 
Clara, US) was performed and the concentration was determined according to 
recommendations provided by Illumina. Sequencing was performed using an Illumina 
NextSeq 500, generating 75 bp unpaired reads. Fastq files were deposited at 
ArrayExpress under the accession number E-MTAB-6629. Using CLC Biosystems 
Genomic Workbench 10.1.1 (CLC Bio, a Qiagen company, Waltham, Mass), quality 
trimming was performed and the quality filtered reads of each sample were mapped 
(length fraction 0.8 and similarity fraction 0.8) against the genome sequence of P. 
aeruginosa PAO1 (the NCBI reference sequence with accession number 
NC_002516). Total gene read values are used by the Differential Expression for 
RNA-Seq tool based on a negative binomial generalized linear model (GLM) in CLC 
Workbench. Only genes that were significantly differentially regulated (the false 
discovery rate adjusted p-value < 0.05) and with at least 1.5-fold change compared to 
the control were considered. Gene descriptions were obtained from the 
Pseudomonas Genome Database [402]. 
C-di-GMP quantification 
Quantifications of c-di-GMP levels in P. aeruginosa PAO1 cells were performed as 
described previously [403]. Briefly, an overnight culture of P. aeruginosa PAO1 was 
standardized to OD590 0.5 and inoculated in 10 mL of LB with 1:50 dilutions with or 
without coumarin (2 mM). After 24 h, the cells were harvested by centrifugation at 
4 °C for 20 min from 5 mL culture suspensions. The wet weight of collected cells was 
measured. Cells were lysed in ice-cold extraction buffer consisting of 
acetonitrile/methanol/water (2/2/1, v/v/v), and incubated at 4 °C for 15 min. The cell 
suspension was then heated to 95 °C for 10 min and centrifuged. The extraction of 
the resulting pellet was repeated twice with 200 µL of extraction solvent at 4 °C 
omitting the heating step. The solvent of the combined supernatants was evaporated 
to dryness in a vacuum centrifuge. The pellets were dissolved in HPLC-grade water 
for analysis by liquid chromatography-coupled tandem mass spectrometry as 
described before [403]. Extractions were performed in triplicate or duplicate from two 
independent bacterial cultures as biological duplicate (n=5). 
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Statistical analyses 
Numerical data were analyzed using GraphPad Prism 6.0 and presented as mean ± 
standard deviation (SD). The normal distribution of the data was checked by the 
D'Agostino-Pearson normality test. Normally distributed data were analyzed by one-
way ANOVA or Student t-test, and non-normally distributed data were analyzed by 
the Kruskal-Wallis test or the Mann-Whitney test. 
Results 
Coumarin inhibits QS in P. aeruginosa QSIS2 biosensor 
The previously described QS inhibitory activity of coumarin was confirmed using the 
P. aeruginosa QSIS2 reporter strain. While 1 mM coumarin had no measurable effect 
on QS, at a concentration of 2 mM, QS inhibition could clearly be observed (average 
inhibition: 40.3%, standard deviation: 5.2%). 
Coumarin reduces pyocyanin and protease production in different P. 
aeruginosa strains 
Pyocyanin production was significantly decreased by coumarin in strains PAO1, 2063, 
2091 and 2549 (p<0.05), but not in strains 1083 and 3120 which produced virtually 
no pyocyanin in the experimental conditions used (Figure 1A). Coumarin also 
reduced protease production in P. aeruginosa PAO1 and the five clinical strains, to 
varying degrees (p < 0.05) (Figure 1B). These results indicate that coumarin inhibits 
the production of QS-regulated virulence factors in different P. aeruginosa clinical 
strains. 
 
Figure 1. Effect of coumarin (2 mM) on pyocyanin (A) and protease (B) production in different P. 
aeruginosa strains. Data shown are the mean (n=6), error bars represent standard deviation. *, p<0.05 
compared to the untreated control group. 
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The effect of coumarin on P. aeruginosa biofilms 
No significant effect on growth of planktonic cells of P. aeruginosa strains was 
observed when 1 mM or 2 mM coumarin was added (Figure S1). The effect of 
coumarin on biofilm formation of P. aeruginosa strains was tested in 96-well 
microtiter plates as well as in an in vitro wound model. In microtiter plates, biofilm 
formation of all P. aeruginosa strains investigated was significantly reduced in the 
presence of 2 mM coumarin (p < 0.05) (Figure 2A); for four strains (2063, 2091, 2549 
and 3120) this was also the case in the presence of 1 mM coumarin. 
In the wound model, statistically significant reduced biofilm formation in the presence 
of 2 mM coumarin was observed for P. aeruginosa PAO1, 2091 and 3210 (p < 0.05) 
(Figure 2B). Biofilm formation for the other three clinical strains showed a non-
significant decrease of approx. 30%. 
 
Figure 2. The effect of coumarin on P. aeruginosa biofilms. Data shown are the mean (n=9), error bars 
represent standard deviation. (A). Biofilms formed in microtiter plates. (B). Wound model biofilms 
treated with 2 mM coumarin. *, p<0.05 compared to the untreated control group. 
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The effect of coumarin on P. aeruginosa virulence to L. sericata 
As shown in Figure 3, the virulence of P. aeruginosa to L. sericata varied between 
different clinical isolates. P. aeruginosa 2549 appeared to be most virulent among the 
strains tested, as exposure of the larvae to this strain led to > 90% killing after 24 h. 
In the coumarin-treated groups, significant increase in L. sericata survival was 
observed for PAO1 and 1803, with 34% and 54% more survival compared to the 
control groups, respectively. For the other P. aeruginosa strains, coumarin increased 
the survival of L. sericata by 6~16% but this was not significant. It should however be 
noted that for two of these strains (2091 and 3120) survival already was quite high in 
the control group, suggesting these strains are less virulent in this model. 
 
Figure 3. The effect of coumarin (2 mM) on survival of L. sericata. Data shown are the mean (n=9), 
error bars represent standard deviation. *, p<0.05 compared to the untreated control group. 
Transcriptome analysis of P. aeruginosa planktonic and biofilm cells treated 
with coumarin 
In order to obtain insight into the mechanism(s) behind the QS inhibitory effect of 
coumarin, RNA sequencing was performed on P. aeruginosa PAO1 planktonic cells 
after 1 h coumarin treatment and biofilm cells grown in the presence of coumarin for 
24 h. In planktonic cells, 46 genes were down-regulated and 21 genes were up-
regulated by coumarin (Table S1). Nearly half of the down-regulated genes (21) were 
related to the type III secretion system (T3SS), including the key genes coding for the 
needle complex (pscF, pscJ, pscL), the translocation apparatus (pcrV, popB, popD), 
the chaperones (pcrH, pscG), as well as the effector proteins (exoS, exoT). Two sets 
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of two-component regulator systems were down-regulated (PA4774/PA4775 and 
pmrAB). An oxidative stress sensing regulator ospR was repressed, as well as gene 
PA2826 (encoding a glutathione peroxidase which is under the regulation of ospR) 
[404]. This result indicated that coumarin might affect the response of P. aeruginosa 
to oxidative stress. One HD-GYP domain phosphodiesterase (PDE) encoding gene 
(PA4781) was down-regulated; PA4781 has been reported to degrade c-di-GMP 
[405-407]. However, no significant changes in either QS or QS-regulated virulence 
genes were observed in coumarin-treated planktonic samples, except that phzG2 
involved in phenazine production was repressed by over 50-fold. 
In coumarin-treated biofilms, 399 genes were significantly downregulated (Table S2). 
Among them, several core genes involved in the four different QS systems of P. 
aeruginosa were repressed. The AHL synthase encoding genes lasI and rhlI were 
both downregulated, as was the receptor encoding gene rhlR. The expression of 
lasR was not significantly influenced. Gene pqsB and pqsC within the pqsABCDE 
operon (which controls PQS synthesis) were both downregulated, as was pqsH 
(involved in the conversion of 2-heptyl-4-quinolone to PQS). No difference was 
observed in the expression of the gene encoding the PQS receptor PqsR. Moreover, 
genes responsible for the synthesis of IQS (ambBCDE) were also significantly 
downregulated in coumarin-treated biofilms. In addition, genes involved in the 
production of QS-regulated virulence factors including alkaline protease, hydrogen 
cyanide, LasA protease, LasB elastase, phenazine, siderophores and rhamnolipids 
were significantly downregulated. These results confirm that coumarin interferes with 
the QS network of P. aeruginosa and the production of QS-related virulence factors. 
Genes involved in T3SS were repressed by coumarin in the biofilm cells (Table S2), 
including several genes encoding T3SS regulators (exsC, exsD and ptrA). The c-di-
GMP PDE encoding gene PA4781 was downregulated in coumarin-treated biofilm 
cells by 2-fold. 
In addition, 234 genes were up-regulated in the coumarin-treated biofilm cells (Table 
S3). PA2226 encoding a negative QS regulator QsrO was upregulated by 3.7-fold. 
Overexpression of QsrO has been reported to repress the las, rhl and PQS systems 
of P. aeruginosa, although the detailed mechanisms have not been elucidated yet 
[408]. Co-expression of PA2226 and PA2225 prevents the induction of T3SS [408], 
and PA2225 was found to be up-regulated by 2.0-fold in the coumarin-treated biofilm. 
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tpbA, encoding a tyrosine phosphatase that represses c-di-GMP production [188] 
was up-regulated by 4.0-fold in the coumarin-treated biofilm cells. No significant 
changes in the expression of other diguanylate cyclase (DGC) or PDE genes 
involved in c-di-GMP metabolism were found in coumarin-treated biofilm cells. 
Coumarin reduced c-di-GMP level in P. aeruginosa PAO1 
To confirm the influence of coumarin on c-di-GMP metabolism, we determined 
intracellular c-di-GMP concentrations of planktonic P. aeruginosa cells. The c-di-GMP 
concentration in untreated controls was 3.67±1.07 pmol/mg, while the c-di-GMP level 
of PAO1 treated with coumarin was significantly reduced (p<0.01) to 0.87±0.33 
pmol/mg (Figure 4).  
 
Figure 4. The effect of coumarin (2 mM) on c-di-GMP level in P. aeruginosa PAO1. Data shown are the 




Coumarin was previously described as a QS inhibitor in P. aeruginosa [392] and this 
was confirmed in the present study. In addition, coumarin reduced protease and 
pyocyanin production in different P. aeruginosa strains, as well as biofilm formation 
both in microtiter plates and in an in vitro wound model. We also demonstrated that 
coumarin increases the survival of L. sericata maggots in the presence of several 
clinical P. aeruginosa strains. A transcriptomic analysis demonstrated that the 
expression of a large number of genes (including genes involved in QS and T3SS) is 
regulated in response to coumarin, both in planktonic and sessile P. aeruginosa cells, 
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and intracellular c-di-GMP levels were lower in treated cells, compared to untreated 
controls. 
Several studies have shown that clinical P. aeruginosa strains display varying levels 
of virulence, and highlighted the importance to include clinical isolates when 
evaluating the effect of potential novel treatment approaches [256, 409]. We 
observed that different P. aeruginosa clinical isolates indeed vary significantly in their 
ability to produce protease and pyocyanin, as well as in their virulence towards L. 
sericata. Coumarin significantly inhibited biofilm formation in microtiter plates for all P. 
aeruginosa strains tested, whereas its biofilm-inhibitory effect in the wound model 
and its effect on virulence in L. sericata were partly strain-dependent, indicating that 
coumarin’s effect as QSI may be reduced in the more complex environment 
encountered in vivo. 
To obtain a global picture of effect of coumarin on QS, biofilm and virulence of P. 
aeruginosa, we performed RNA sequencing on P. aeruginosa PAO1 planktonic cells 
after 1 h of treatment with coumarin, as well as on biofilms treated with coumarin for 
24 h. The expression of genes involved in the QS system of P. aeruginosa was not 
significantly changed in planktonic cells after 1 h. In a previous study, coumarin (1.36 
mM) has been reported to reduce the expression of pqsA and rhlI in planktonic cells 
after 6 h and 24 h, respectively, while lasI expression was not affected either at 6 h or 
24 h [392]. In biofilm cells we found that lasI expression was down-regulated by 
coumarin, as well as rhlI, rhlR and genes within the pqsABCDE and ambBCDE 
operons. These results confirm that coumarin interferes with the P. aeruginosa QS 
network. The observation that the expression of QS-regulated virulence genes was 
downregulated in P. aeruginosa PAO1 was in line with the decreased protease and 
pyocyanin production and reduced virulence observed in L. sericata. Also qsrO, 
encoding a negative regulator of QS was overexpressed in coumarin-treated biofilms 
suggesting that this regulator contributes to the inhibition of QS by coumarin. 
T3SS in P. aeruginosa acts as a major virulence determinant that manipulates host 
cell responses and plays an important role in acute infections [410]. A microarray-
based analysis of P. aeruginosa QS regulons revealed that at least three genes 
involved in T3SS (pscQ, pscI, and pcrH) are negatively regulated by QS [411]. 
Bleves et al. has also reported that the expression of T3SS in P. aeruginosa is 
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negatively regulated by QS, especially by RhlR under low calcium levels [412]. These 
results raise the concern that interfering with QS might potentially increase the T3SS-
related virulence in P. aeruginosa [413]. However, transcriptome data obtained from 
P. aeruginosa treated with coumarin in the present study and 6-gingerol, another QS 
inhibitor [328] revealed that genes involved in T3SS were repressed. These results 
suggest that although QS has been reported to negatively affect T3SS expression, 
QS inhibition by certain QSIs may not necessarily induce T3SS-related virulence. In 
contrast, it is possible to inhibit QS and T3SS simultaneously by QSIs such as 
coumarin and 6-gingerol, although the underlying mechanisms remain to be 
elucidated. 
C-di-GMP regulates many bacterial behaviors, and a high intracellular c-di-GMP 
concentration has been reported to promote biofilm formation in P. aeruginosa and 
other bacteria [414]. The intracellular concentration of c-di-GMP is determined by 
GGDEF domain-containing DGCs (which synthesize c-di-GMP), and EAL or HD-GYP 
domain-containing PDEs (which degrade c-di-GMP) [414]. We found that coumarin 
affected two genes involved in c-di-GMP metabolism in P. aeruginosa PAO1, i.e. 
PA4781 and tpbA, and demonstrated that coumarin significantly reduced the c-di-
GMP level in P. aeruginosa. We hypothesize this is due to the upregulation of tpbA. 
TpbA acts as a negative regulator of c-di-GMP production, which deactivates the 
GGDEF-domain DGC TpbB responsible for c-di-GMP synthesis and indirectly 
reduces c-di-GMP levels in P. aeruginosa [188].  
Our results indicate that coumarin not only acts as a QSI but also reduces c-di-GMP 
levels, and these combined effects may explain the reduced biofilm formation 
observed. The connections between QS and c-di-GMP in P. aeruginosa have just 
begun to be elucidated. Mutants of P. aeruginosa PA14 without functional lasI, lasR 
or rhlR showed decreased expression of tpbA [188], leading to the assumption that 
QS negatively regulates c-di-GMP levels through TpbA/TpbB. However, our results 
showed that coumarin inhibits QS-related genes, but the expression of tpbA was 
significantly up-regulated by coumarin and led to reduced c-di-GMP level. Another 
study showed that rhl and PQS systems were expressed at a higher level in P. 
aeruginosa PAO1 with reduced c-di-GMP level due to overexpression of yhjH 
(encoding a PDE) than in a wspF mutant with elevated c-di-GMP levels [415]. This 
suggested that low c-di-GMP levels could increase expression of QS-related genes 
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and the production of QS-regulated virulence factors. In contrast, our results showed 
that coumarin reduced both c-di-GMP levels and QS-regulated virulence. These 
results might be explained by the different mechanisms leading to the reduced c-di-
GMP level. The distinct gene expression profiles (431 up-regulated genes and 595 
down-regulated genes) observed in the study of Lin Chua et al. is directly due to the 
loss of wspF and overexpression of yhjH, whereas in our study no change was 
observed in wspF expression.  
Several other compounds of the coumarin class have also been reported for their 
anti-QS and antibiofilm effects, e.g. esculetin, esculin and umbelliferone [416, 417]. 
Our research on the prototype coumarin molecule in this family revealed that 
coumarin can inhibit not only QS but also T3SS and c-di-GMP signaling, leading to 
reduced virulence and biofilm formation in P. aeruginosa. These results increase our 
understanding of the molecular mechanism(s) involved in the activity of coumarin and 
related molecules, and suggest these molecules could be useful to combat biofilm-
related infections. Structural modifications based on the coumarin scaffold may allow 
the development of more active coumarin-derivatives with potential application in the 
treatment of P. aeruginosa infections. 
Conclusion 
 Coumarin can reduce QS-regulated virulence and biofilm formation in P. 
aeruginosa strains. 
 Coumarin down-regulates the expression of key genes involved in the las, rhl, 
PQS and IQS systems in the biofilm of P. aeruginosa. 
 Coumarin reduces the expression of genes related to type III secretion, and 
decreases the cellular c-di-GMP level in P. aeruginosa. 
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Figure S1. The effect of coumarin on planktonic cell growth of P. aeruginosa strains at 24h. Data 
shown are the mean (n=3), error bars represent standard deviation. 
 
Table S1. Genes that are significantly down- or upregulated (cut-off: 1.5-fold change, FDR p-value 







Down-regulated genes (46) 
Type III secretion related (21) 
PA3841 exoS Exoenzyme S -1.69 
PA0044 exoT Exoenzyme T -1.71 
PA1697  ATP synthase in type III secretion system -2.27 
PA1699 pcr1  -2.21 
PA1700 pcr2  -2.07 
PA1703 pcrD Type III secretory apparatus protein -1.72 
PA1707 pcrH Regulatory protein -1.69 
PA1706 pcrV Type III secretion protein -1.69 
PA1708 popB Translocator protein -1.76 
PA1709 popD Translocator outer membrane protein -1.82 
PA1698 popN Type III secretion outer membrane protein -2.00 
PA1715 pscB Type III export apparatus protein -1.64 
PA1716 pscC Type III secretion outer membrane protein -1.51 
PA1719 pscF Type III export protein -1.65 
PA1720 pscG Type III export protein -1.72 
PA1722 pscI Type III export protein -1.53 
PA1723 pscJ Type III export protein -1.51 
PA1724 pscK Type III export protein -1.65 
PA1696 pscO Translocation protein in type III secretion -2.31 
PA1695 pscP Translocation protein in type III secretion -1.93 
PA1694 pscQ Translocation protein in type III secretion -2.02 
Polyamine transport related (3) 
PA3608 potB Polyamine transport protein -1.94 
PA3609 potC Polyamine transport protein -2.27 
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PA3610 potD Polyamine transport protein -2.19 
Two-component regulator system (4) 
PA4774   -3.51 
PA4775   -2.54 
PA4776 pmrA  -2.51 
PA4777 pmrB  -2.33 
Others (9) 
PA1321 cyoE Cytochrome o ubiquinol oxidase -1.63 
PA1838 cysI Sulfite reductase -1.70 
PA1634 kdpB Potassium-transporting ATPase -1.84 
PA2825 ospR Oxidative stress sensing regulator -1.91 
PA2826  Glutathione peroxidase -2.06 
PA3677 MexJ Efflux pump -1.69 
PA5365 phoU Phosphate uptake regulatory protein -1.50 
PA1905 phzG2 Probable pyridoxamine 5'-phosphate oxidase -50.75 
PA4781  Cyclic di-GMP phosphodiesterase -2.01 
Unknown function (9) 
PA1228   -2.51 
PA1402   -1.83 
PA2283   -1.94 
PA2284   -2.13 
PA2285   -2.31 
PA3445   -1.77 
PA4359   -2.13 
PA4773   -3.15 
PA4782   -2.30 
Up-regulated genes (21) 
Multi-drug efflux related (12) 
PA3719 armR Antirepressor for mexr 8.35 
PA0425 mexA Multidrug efflux membrane fusion protein 2.39 
PA0426 mexB Multidrug efflux transporter 2.06 
PA4599 mexC Multidrug efflux membrane fusion protein 3.04 
PA4598 mexD Multidrug efflux transporter 3.05 
PA0424 mexR Multidrug resistance operon repressor 2.03 
PA3721 nalC A probable repressor of the TetR/AcrRfamily 1.70 
PA4597 oprJ Multidrug efflux outer membrane protein 3.48 
PA0427 oprM Multidrug efflux outer membrane protein 1.78 
PA3718  Probable major facilitator superfamily transporter 3.06 
PA3720  Hypothetical protein 7.41 
PA4596 esrC An envelope stress-regulated repressor 3.12 
Other genes and genes with unknown functions (9) 
PA3126
  
ibpA Heat-shock protein 1.52 
PA4047
  ribA 
GTP cyclohydrolase II 
1.74 
PA1922  Probable TonB-dependent receptor 2.11 
PA2930  Probable transcriptional regulator 1.64 
PA4045   1.54 
PA4046   1.66 
PA4288  Probable transcriptional regulator 1.80 
PA4837  Probable outer membrane protein precursor 1.96 
PA4838   2.06 
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Table S2. Genes that are significantly down-regulated (cut-off: 1.5-fold change, FDR p-value < 0.05) in P. 
aeruginosa PAO1 24h-biofilm cells treated with coumarin (2 mM). 
Locus tag Gene 
name 
Description Fold changes 
QS network (11) 
PA1432 lasI AHL synthesis protein LasI -1.76 
PA3476 rhlI AHL synthesis protein RhlI -1.62 
PA3477 rhlR Transcriptional regulator RhlR -1.85 
PA0997 pqsB PQS synthesis -1.62 
PA0998 pqsC -1.62 
PA2587 pqsH -1.96 
PA4190 pqsL -1.91 
PA2305 ambB IQS synthesis -2.22 
PA2304 ambC -2.27 
PA2303 ambD -2.30 
PA2302 ambE -1.84 
major QS-regulated virulence factors (43) 
PA1249 aprA Synthesis and secretion of alkaline protease  -5.06 
PA1246 aprD -1.93 
PA1247 aprE -2.34 
PA1248 aprF -1.83 
PA1250 aprI -2.48 
PA2193 hcnA Hydrogen cyanide synthesis -2.75 
PA2194 hcnB -1.94 
PA2195 hcnC -1.75 
PA1871 lasA LasA protease -4.93 
PA3724 lasB LasB elastase -3.06 
PA2570 lecA Lectin -3.21 
PA4231 pchA Pyochelin biosynthesis -1.80 
PA4230 pchB -2.22 
PA4228 pchD -1.98 
PA4226 pchE -1.78 
PA4225 pchF -1.66 
PA4224 pchG -1.84 
PA4211 phzB1 Phenazine biosynthesis -2.24 
PA1900 phzB2 -3.19 
PA1901 phzC2 -1.93 
PA4213 phzD1 -1.81 
PA1902 phzD2 -1.92 
PA4214 phzE1 -1.98 
PA1903 phzE2 -1.97 
PA4215 phzF1 -2.17 
PA1904 phzF2 -2.18 
PA1905 phzG2 -3.36 
PA4217 phzS -1.80 
PA2386 pvdA Pyoverdine biosynthesis and transport -1.99 
PA2396 pvdF -1.71 
PA2425 pvdG -1.65 
PA2413 pvdH -2.12 
PA2394 pvdN -1.87 
PA2395 pvdO -1.85 
PA2392 pvdP -1.93 
PA2426 pvdS -1.72 
PA2390 pvdT -1.62 
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PA2391 opmQ  -1.69 
PA3479 rhlA Rhamnolipid production -2.57 
PA3478 rhlB -2.09 
PA2300 chiC Chitinase -6.93 
PA4236 katA Catalase -1.56 
PA4468 sodM Superoxide dismutase -2.38 
Type III secretion related (18) 
PA3841 exoS Exoenzyme S -1.70 
PA0044 exoT Exoenzyme T -1.57 
PA1697  ATP synthase in type III secretion system -2.18 
PA1699 pcr1  -1.68 
PA1710 exsC Exoenzyme S synthesis protein C precursor -1.99 
PA1714 exsD Type III secretion regulator -1.77 
PA1705 pcrG Type III secretion regulator -2.22 
PA1707 pcrH Regulatory protein -2.66 
PA1706 pcrV Type III secretion protein -2.06 
PA1708 popB Translocator protein -2.01 
PA1709 popD Translocator outer membrane protein -2.31 
PA1698 popN Type III secretion outer membrane protein -2.80 
PA1715 pscB Type III export apparatus protein -1.68 
PA1719 pscF Type III export protein -1.82 
PA1695 pscP Translocation protein in type III secretion -3.23 
PA1694 pscQ Translocation protein in type III secretion -1.93 
PA2808 ptrA Pseudomonas type III repressor A -2.00 
PA1711 exsE A regulator of ExsC -1.79 
C-di-GMP metabolism (1) 
PA4781  Cyclic di-GMP phosphodiesterase -2.00 
Others (121) 
PA5427 adhA Alcohol dehydrogenase -1.56 
PA1337 ansB Glutaminase-asparaginase -1.68 
PA5171 arcA Arginine deiminase -1.67 
PA5172 arcB Ornithine carbamoyltransferase -1.66 
PA5173 arcC Carbamate kinase -1.69 
PA2886 atuA Citronellol catabolism -1.67 
PA2887 atuB  -1.85 
PA2888 atuC  -1.71 
PA2889 atuD  -1.66 
PA2890 atuF  -1.73 
PA2891 atuG  -1.50 
PA2003 bdhA 3-hydroxybutyrate dehydrogenase -2.35 
PA2052 cynS Cyanate lyase -1.73 
PA2000 dhcB Dehydrocarnitine CoA transferase -1.52 
PA2008 fahA Fumarylacetoacetase -1.58 
PA4470 fumC1 Fumarate hydratase -2.83 
PA0854 fumC2 Fumarate hydratase -1.56 
PA1421 gbuA Guanidinobutyrase -1.58 
PA2446 gcvH2 Glycine cleavage system protein -1.56 
PA2445 gcvP2  -1.64 
PA2442 gcvT2  -1.59 
PA2153 glgB 1,4-alpha-glucan branching enzyme -1.77 
PA2144 glgP Glycogen phosphorylase -1.60 
PA2444 glyA2 Serine hydroxymethyltransferase -1.63 
PA5091 hutG Histidine utilization -1.63 
PA5098 hutH  -1.62 
PA5092 hutI  -1.69 
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PA5100 hutU  -2.03 
PA4694 ilvC Ketol acid reductoisomerase -2.10 
PA4695 ilvH Small acetolactate synthase subunit -1.91 
PA4696 ilvI Acetolactate synthase enzyme -1.67 
PA3792 leuA Leucine synthesis -2.93 
PA3118 leuB  -2.44 
PA3121 leuC  -4.10 
PA3120 leuD  -3.27 
PA4370 icmP 
Insulin-cleaving metalloproteinase outer membrane 
protein -1.67 
PA2863 lipH Lipase modulator protein -1.53 
PA4770 lldP L-lactate permease -1.82 
PA2007 maiA Maleylacetoacetate isomerase -1.51 
PA1927 metE Methionine synthesis -1.51 
PA0546 metK  -1.74 
PA5025 metY  -1.62 
PA0132  Beta-alanine:pyruvate transaminase -1.92 
PA0399  Cystathionine beta-synthase -1.81 
PA1041 wapB 1,2-glucosyltransferase -2.09 
PA1256 lhpO ABC transporter ATP-binding protein -2.06 
PA1641 gpsA Glycerol-3-phosphate dehydrogenase -1.57 
PA2321  Gluconokinase -1.57 
PA2414  L-sorbosone dehydrogenase -1.86 
PA4022 hdhA Hydrazone dehydrogenase -1.76 
PA4661 pagL Lipid A 3-O-deacylase -1.71 
PA5058 phaC2 Poly(3-hydroxyalkanoic acid) synthase 2 -1.84 
PA5161 rmlB dTDP-D-glucose 4,6-dehydratase -1.51 
PA0849 trxB2 Thioredoxin reductase 2 -2.40 
PA5419 soxG Sarcosine oxidase gamma subunit -1.83 
PA2279 arsC Arsenate reductase -1.51 
PA1863 modA Molybdate-binding periplasmic protein precursor -1.50 
PA0513 nirG Nitrite reductase -1.50 
PA1177 napE Periplasmic nitrate reductase protein -1.84 
PA0523 norC Nitric-oxide reductase subunit C -2.39 
PA0023 qor Quinone oxidoreductase -1.64 
PA3531 bfrB Bacterioferritin -1.72 
PA3407 hasAp Heme acquisition protein -8.13 
PA3408 hasR 
Heme uptake outer membrane receptor HasR 
precursor -1.88 
PA3530 bfd Bacterioferritin-associated ferredoxin  -1.62 
PA3676 mexK Efflux pump -1.58 
PA3677 mexJ Efflux pump -1.73 
PA4205 
mexG 
Membrane protein required for MexGHI-OpmD 
efflux -1.71 
PA4587 ccpR Cytochrome c551 peroxidase precursor -1.97 
PA1318 cyoB Cytochrome o ubiquinol oxidase subunit -1.83 
PA1319 cyoC  -2.61 
PA1320 cyoD  -2.09 
PA1321 cyoE Cytochrome o ubiquinol oxidase protein -2.04 
PA4133  Cytochrome c oxidase subunit -1.52 
PA3692 lptF Lipotoxon -1.99 
PA0122 rahU  -2.06 
PA5285 SutA A bacterial transcription factor -1.85 
PA0843 plcR Phospholipase accessory protein -1.63 
PA4776 pmrA Two-component regulator system -1.68 
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PA4777 pmrB  -1.85 
PA3790 oprC Outer membrane porin precursor -2.87 
PA1777 oprF Outer membrane porin precursor -1.54 
PA4067 oprG Outer membrane protein precursor -1.64 
PA1178 oprH Outer membrane protein H1 -1.69 
PA2853 oprI Outer membrane lipoprotein -2.08 
PA4761 dnaK DnaK protein -1.56 
PA4385 groEL GroEL protein -2.06 
PA4386 groES GroES protein -1.78 
PA4762 grpE Heat shock protein -1.57 
PA5053 hslV Heat shock protein -1.57 
PA1596 htpG Heat shock protein -1.93 
PA0852 cbpD Chitin-binding protein -4.54 
PA0139 ahpC Alkyl hydroperoxide reductase subunit C -1.67 
PA3550 algF Alginate o-acetyltransferase -1.66 
PA0723 coaB Coat protein B of bacteriophage Pf1 -1.91 
PA2717 cpo Chloroperoxidase precursor -1.63 
PA0694 exbD2 Transport protein -2.28 
PA4306 flp Type IVb pilin, Flp -2.03 
PA0867 
mliC 
Membrane-bound lysozyme inhibitor of c-type 
lysozyme -1.69 
PA4614 mscL Conductance mechanosensitive channel -1.87 
PA0766 mucD Serine protease mucd precursor -1.52 
PA0059 osmC Osmotically inducible protein -2.19 
PA4876 osmE Osmotically inducible lipoprotein -2.50 
PA0678 HxcU Alkaline phosphatase secretion related -2.15 
PA0683 HxcY  -2.89 
PA0779 asrA ATP-dependent protease -1.52 
PA1245 AprX  -3.34 
PA1259 LhpH  -1.51 
PA1657 HsiB2  -2.04 
PA1658 hsiC2  -1.67 
PA1665 Fha2  -1.70 
PA1668 DotU2  -1.58 
PA1830  Lon protease -1.58 
PA3891 opuC ABC transporter -1.75 
PA4916 nrtR Nudix-related transcriptional regulator -1.51 
PA0355 pfpI Protease PfpI -1.97 
PA4590 pra Protein activator -2.02 
PA4305 rcpC  -1.69 
PA3049 rmf Ribosome modulation factor -1.55 
PA4865 ureA Urease gamma subunit -2.30 
PA4868 ureC Urease alpha subunit -1.70 
Genes with general predicted or unknown functions (205) 
PA3672  
Probable ATP-binding component of ABC 
transporte -1.55 
PA4223  
Probable ATP-binding component of ABC 
transporter -1.75 
PA0400  Probable cystathionine gamma-lyase -1.75 
PA0656  Probable HIT family protein -1.58 
PA4131  Probable iron-sulfur protein -2.30 
PA1131  
Probable major facilitator superfamily (MFS) 
transporter -1.68 
PA4144  Probable outer membrane protein precursor -2.79 
PA4171  Probable protease -2.32 
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PA4143  Probable toxin transporter -3.21 
PA0236  Probable transcriptional regulator -1.96 
PA1403  Probable transcriptional regulator -1.51 
PA2588  Probable transcriptional regulator -1.89 
PA4341  Probable transcriptional regulator -1.86 
PA3963a  Probable transporter -2.43 
PA1737  Probable 3-hydroxyacyl-CoA dehydrogenase -1.56 
PA1869  Probable acyl carrier protein -2.71 
PA2815  Probable acyl-CoA dehydrogenase -1.63 
PA2158  Probable alcohol dehydrogenase (Zn-dependent) -1.52 
PA0366  Probable aldehyde dehydrogenase -1.51 
PA5097  Probable amino acid permease -1.62 
PA1617  Probable AMP-binding enzyme -1.69 
PA5094  
Probable ATP-binding component of ABC 
transporter -1.51 
PA5096  
Probable binding protein component of ABC 
transporter -2.06 
PA2069  Probable carbamoyl transferase -3.40 
PA1251  Probable chemotaxis transducer -1.96 
PA0459  Probable ClpA/B protease ATP binding subunit -1.59 
PA0223  Probable dihydrodipicolinate synthetase -2.67 
PA3940  Probable DNA binding protein -1.53 
PA2086  Probable epoxide hydrolase -1.85 
PA2165  Probable glycogen synthase -1.87 
PA2160  Probable glycosyl hydrolase -2.14 
PA2162  Probable glycosyl hydrolase -1.83 
PA2164  Probable glycosyl hydrolase -2.27 
PA5093  Probable histidine/phenylalanine ammonia-lyase -1.54 
PA1202  Probable hydrolase -1.71 
PA2067  Probable hydrolase -2.38 
PA2698  Probable hydrolase -1.65 
PA2068  
Probable major facilitator superfamily (MFS) 
transporter -2.30 
PA3441  Probable molybdopterin-binding protein -1.72 
PA4078  Probable nonribosomal peptide synthetase -1.79 
PA4172  Probable nuclease -1.68 
PA1875  Probable outer membrane protein precursor -1.71 
PA0147  Probable oxidoreductase -1.52 
PA1127  Probable oxidoreductase -1.51 
PA2592  
Probable periplasmic spermidine/putrescine-
binding protein -1.80 
PA3315  Probable permease of ABC transporter -1.55 
PA5095  Probable permease of ABC transporter -1.59 
PA3913  Probable protease -1.88 
PA4142  Probable secretion protein -4.35 
PA1344  Probable short-chain dehydrogenase -1.78 
PA2142  Probable short-chain dehydrogenase -1.64 
PA4098  Probable short-chain dehydrogenase -1.84 
PA2411  Probable thioesterase -1.58 
PA1285  Probable transcriptional regulator -1.61 
PA2096  Probable transcriptional regulator -1.59 
PA2312a  Probable transcriptional regulator -1.54 
PA3965  Probable transcriptional regulator -1.72 
PA4023  Probable transport protein -1.57 
PA2135  Probable transporter -1.55 
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PA2393  Putative dipeptidase -1.94 
PA0039  Hypothetical protein -1.62 
PA0050  Hypothetical protein -1.61 
PA0060  Hypothetical protein -1.53 
PA0062  Hypothetical protein -1.62 
PA0116  Hypothetical protein -1.55 
PA0187  Hypothetical protein -1.79 
PA0188  Hypothetical protein -1.83 
PA0250  Hypothetical protein -1.54 
PA0269  Hypothetical protein -2.26 
PA0270  Hypothetical protein -1.99 
PA0271  Hypothetical protein -1.71 
PA0307  Hypothetical protein -1.51 
PA0526  Hypothetical protein -1.72 
PA0529  Hypothetical protein -1.65 
PA0572  Hypothetical protein -2.47 
PA0741  Hypothetical protein -1.97 
PA0851  Hypothetical protein -1.60 
PA1123  Hypothetical protein -2.18 
PA1135  Hypothetical protein -1.53 
PA1198  Hypothetical protein -1.51 
PA1244  Hypothetical protein -1.71 
PA1323  Hypothetical protein -2.22 
PA1324  Hypothetical protein -2.30 
PA1353  Hypothetical protein -1.60 
PA1404  Hypothetical protein -2.43 
PA1414  Hypothetical protein -1.50 
PA1478  Hypothetical protein -1.57 
PA1592  Hypothetical protein -1.53 
PA1597  Hypothetical protein -1.59 
PA1784  Hypothetical protein -1.54 
PA1852  Hypothetical protein -1.72 
PA1870  Hypothetical protein -1.81 
PA1906  Hypothetical protein -1.62 
PA1913  Hypothetical protein -1.67 
PA2004  Hypothetical protein -2.25 
PA2026  Hypothetical protein -2.52 
PA2027  Hypothetical protein -4.67 
PA2030  Hypothetical protein -1.94 
PA2031  Hypothetical protein -2.02 
PA2033  Hypothetical protein -2.10 
PA2066  Hypothetical protein -1.88 
PA2134  Hypothetical protein -2.79 
PA2141  Hypothetical protein -2.18 
PA2142a  Hypothetical protein -1.58 
PA2143  Hypothetical protein -1.98 
PA2381  Hypothetical protein -2.83 
PA2146   -2.97 
PA2148   -1.75 
PA2149   -2.16 
PA2154   -1.51 
PA2159   -1.99 
PA2161   -2.44 
PA2163   -2.10 
PA2166   -2.49 
Chapter III. Experimental work                                                                                   Paper II 
92 
PA2169   -2.20 
PA2171   -2.03 
PA2172   -1.58 
PA2173   -1.55 
PA2176   -1.54 
PA2178   -1.50 
PA2180   -1.72 
PA2184   -2.05 
PA2190   -2.71 
PA2197   -1.80 
PA2274   -2.33 
PA2383   -1.66 
PA2384   -2.75 
PA2412   -1.95 
PA2415   -1.55 
PA2422   -1.56 
PA2427   -1.69 
PA2433   -2.23 
PA2448   -1.97 
PA2453   -1.78 
PA2566   -1.60 
PA2747   -1.77 
PA2785   -1.80 
PA2860   -1.72 
PA2927   -1.51 
PA3041   -1.73 
PA3042   -1.58 
PA3051   -1.57 
PA3119   -4.16 
PA3123   -1.51 
PA3130   -1.55 
PA3273   -1.78 
PA3274   -1.59 
PA3275   -1.72 
PA3313   -1.82 
PA3314   -1.64 
PA3370   -1.62 
PA3371   -1.60 
PA3412   -2.18 
PA3520   -2.86 
PA3532   -1.84 
PA3691   -1.91 
PA3734   -1.72 
PA3784   -1.77 
PA3785   -2.16 
PA3786   -1.52 
PA3791   -1.93 
PA3819   -1.65 
PA3904   -1.58 
PA3906   -1.82 
PA3907   -1.51 
PA3908   -1.91 
PA4129   -1.60 
PA4132   -1.70 
PA4139   -3.49 
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PA4141   -7.57 
PA4311   -1.51 
PA4313a   -1.65 
PA4346   -1.51 
PA4352   -1.55 
PA4384   -1.84 
PA4467   -1.94 
PA4469   -2.86 
PA4471   -1.62 
PA4570   -2.29 
PA4573   -1.52 
PA4578   -1.58 
PA4607   -1.95 
PA4702   -1.53 
PA4738   -1.87 
PA4739   -1.90 
PA4773   -2.32 
PA4774   -3.28 
PA4775   -2.18 
PA4782   -3.66 
PA4866   -1.72 
PA4874   -1.66 
PA4877   -1.73 
PA4925   -1.51 
PA5061   -1.70 
PA5101   -1.52 
PA5178   -1.61 
PA5212   -1.55 
PA5219   -1.58 
PA5220   -2.28 
PA5286   -1.51 
PA5424   -1.65 
PA5460   -4.02 
PA5461   -1.59 
PA5481   -1.86 
PA5482   -1.89 
 
Table S3. Genes that are significantly up-regulated (cut-off: 1.5-fold change, FDR p-value < 0.05) in P. 
aeruginosa PAO1 24h-biofilm cells treated with coumarin (2 mM). 




QS regulator (1) 
PA2226 qsrO QS negative regulator 3.70 
C-di-GMP metabolism (1) 
PA3885 tpbA Protein tyrosine phosphatase TpbA 3.95 
Others (85) 
PA2513 antB Anthranilate dioxygenase small subunit 2.03 
PA2514 antC Anthranilate dioxygenase reductase 1.85 
PA0866
  aroP2 Aromatic amino acid transport protein 1.98 
PA2507 catA Catechol 1,2-dioxygenase 1.81 
PA2508 catB Muconate cycloisomerase I 1.72 
PA2509 catC Muconolactone delta-isomerase 1.62 
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PA0286 desA Delta-9 fatty acid desaturase, DesA 1.81 
PA4888 desB Acyl-CoA delta-9-desaturase, DesB 1.56 




PA1384 galE UDP-glucose 4-epimerase 1.86 
PA3152 hisH2 Glutamine amidotransferase 1.68 
PA4406 lpxC UDP-3-O-acyl-N-acetylglucosamine deacetylase 1.64 
PA0208
  mdcA Malonate decarboxylase 2.21 
PA0210 mdcC  2.89 
PA0211 mdcD  2.97 
PA0212 mdcE  3.28 
PA4898
  opdK Histidine porin OpdK 1.96 
PA0216 madM Malonate transporter 1.77 
PA0603 agtA 4-aminobutyrate and 5-aminovalerate uptake 2.70 
PA0604 agtB  1.97 
PA0605 agtC  2.08 
PA0606 agtD  1.70 
PA0654 speD S-adenosylmethionine decarboxylase proenzyme 2.34 
PA0298 spuB Glutamylpolyamine synthetase 1.81 
PA5118 thiI Thiazole biosynthesis protein 1.67 
PA2515
  
xylL Cis-1,2-dihydroxycyclohexa-3,4-diene carboxylate 
dehydrogenase 
2.55 
PA2518 xylX Toluate 1,2-dioxygenase alpha subunit 1.52 
PA2516 
xylZ 
Toluate 1,2-dioxygenase electron transfer 
component 1.78 
PA2082 kynR Lrp/AsnC-type transcriptional regulator 1.92 
PA1175 napD Protein of periplasmic nitrate reductase 1.52 
PA3879 narL Two-component response regulator NarL 1.64 
PA4745 nusA N utilization substance protein A 1.69 
PA1779  Assimilatory nitrate reductase 1.66 
PA5291 betT2 Glycine betaine-specific importer 1.77 
PA1260 lhpP ABC transporter periplasmic-binding protein,  1.97 
PA0455 dbpA RNA helicase DbpA 1.54 
PA5239 rho Transcription termination factor Rho 1.85 
PA4242 rpmJ 50S ribosomal protein L36 1.59 
PA4264 rpsJ 30S ribosomal protein S10 1.74 
PA4563 rpsT 30S ribosomal protein S20 2.11 
PA0579 rpsU 30S ribosomal protein S21 1.98 
PA4727 pcnB Poly(A) polymerase 1.59 
PA4281 sbcD Exonuclease 1.77 
PA2619 infA Initiation factor 1.86 
PA4743 rbfA Ribosome-binding factor A 1.68 
PA4159 
fepB 
Ferrienterobactin-binding periplasmic protein 
precursor  1.66 
PA0472 fiuI  1.64 
PA3410 hasI  1.64 
PA3899 fecI  1.52 
PA4156 fvbA  3.53 
PA5531 tonB1 (Ferri)pyoverdine signal transduction 1.68 
PA1099 fleR Two-component response regulator 1.63 
PA1085 flgJ Flagellar protein 1.70 
PA1104 fliI Flagellum-specific ATP synthase 1.67 
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PA1105 fliJ Flagellar protein flij 1.57 
PA4649 cupE2 Pilin subunit  1.74 
PA4650 cupE3 Pilin subunit  2.06 
PA0408
  pilG Twitching motility protein 2.37 
PA4554
  pilY1 Type 4 fimbrial biogenesis protein PilY1 1.67 
PA3719
  armR Antirepressor for MexR 3.60 
PA3721 nalC  1.74 
PA4596 esrC Repressor of the mexCD-oprJ multidrug efflux 2.05 
PA5512 mifS NtrC-like transcriptional regulators 1.59 
PA0087 tssE1  1.69 
PA0172 siaA  1.51 
PA0845 cerN  1.54 
PA1509 tplEi Immunity protein  1.54 
PA1510 tplE Type 6 PGAP1-like effector,  1.83 
PA4033 mucE  2.10 
PA4674 higA Antitoxin  1.79 
PA4844 ctpL  1.58 
PA5325 sphA  1.59 
PA2258
  ptxR Transcriptional regulator 1.73 
PA4034 aqpZ Aquaporin Z 2.34 
PA3266 capB Cold acclimation protein B 2.02 
PA0993 cupC2 Chaperone 2.92 
PA0199 exbD1 Transport protein ExbD 1.88 
PA5267 hcpB Secreted protein Hcp 1.58 
PA3007 lexA Repressor protein 1.61 
PA0320 carO Calcium-regulated OB-fold protein 2.22 
PA0327 carP Calcium-regulated beta-propeller protein 1.56 
PA0930  Two-component sensor 1.61 
PA4276
  secE 
Secretion protein 
1.69 
PA3153 wzx O-antigen translocase 1.96 
Genes with general predicted or unknown functions (147) 
PA0214  Probable acyl transferase 2.22 
PA4979  Probable acyl-CoA dehydrogenase 1.59 
PA1601  Probable aldehyde dehydrogenase 1.6 
PA3865a  Probable amino acid binding protein 1.79 
PA5503  
Probable ATP-binding component of ABC 
transporter 
1.59 
PA2840  Probable ATP-dependent RNA helicase 2.25 
PA1541  Probable drug efflux transporter 2.49 
PA4980  Probable enoyl-coa hydratase/isomerase 2.25 
PA1385  Probable glycosyl transferase 2.53 
PA3573  
Probable major facilitator superfamily (MFS) 
transporter 
1.7 
PA1602  Probable oxidoreductase 1.79 
PA1739  Probable oxidoreductase 1.6 
PA4889  Probable oxidoreductase Add 1.51 
PA0295  Probable periplasmic polyamine binding protein 1.62 
PA3189  Probable permease of ABC sugar transporter 1.67 
PA0733  Probable pseudouridylate synthase 1.74 
PA4896  Probable sigma-70 factor, ECF subfamily 1.7 
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PA0942  Probable transcriptional regulator 1.93 
PA1283  Probable transcriptional regulator 1.89 
PA2100  Probable transcriptional regulator 1.5 
PA2220  Probable transcriptional regulator 1.52 
PA2221  Probable transcriptional regulator 2.38 
PA2276  Probable transcriptional regulator 1.61 
PA2577  Probable transcriptional regulator 1.61 
PA2957  Probable transcriptional regulator 1.59 
PA3067  Probable transcriptional regulator 1.69 
PA3341  Probable transcriptional regulator 1.64 
PA5437  Probable transcriptional regulator 2.45 
PA0730  Probable transferase 2.66 
PA2480  Probable two-component sensor 1.56 
PA3206  Probable two-component sensor 1.58 
PA2666  Probable 6-pyruvoyl tetrahydrobiopterin synthase 2.08 
PA0224  Probable aldolase 1.6 
PA1964  
Probable ATP-binding component of ABC 
transporter 
1.66 
PA2104  Probable cysteine synthase 1.95 
PA1391  Probable glycosyl transferase 1.55 
PA1569  




Probable major facilitator superfamily (MFS) 
transporter 
1.59 
PA1225  Probable NAD(P)H dehydrogenase 2.05 
PA4514  
Probable outer membrane receptor for iron 
transport 
1.71 





PA3188  Probable permease of ABC sugar transporter 1.68 
PA0975  Probable radical activating enzyme 1.64 
PA0491  Probable transcriptional regulator 2.19 
PA0876  Probable transcriptional regulator 1.78 
PA1836  Probable transcriptional regulator 1.52 
PA2047  Probable transcriptional regulator 1.66 
PA2497  Probable transcriptional regulator 1.58 
PA3458  Probable transcriptional regulator 2.23 
PA4288  Probable transcriptional regulator 2.53 
PA2479  Probable two-component response regulator 1.65 
PA0006   1.61 
PA0013   1.54 
PA0040   1.57 
PA0046   1.61 
PA0069   1.69 
PA0128   1.54 
PA0142   1.87 
PA0201   2.25 
PA0209   3.27 
PA0234   1.59 
PA0239   1.63 
PA0388   1.78 
PA0457   1.52 
PA0466   1.88 
PA0539   1.57 
Chapter III. Experimental work                                                                                   Paper II 
97 
PA0560   1.58 
PA0561   1.7 
PA0589   1.53 
PA0596   1.63 
PA0734   1.57 
PA0758   1.71 
PA0805   1.86 
PA0874   2.32 
PA0924   2.41 
PA0976   1.75 
PA0986   3.6 
PA1030   1.77 
PA1090   1.62 
PA1116   1.64 
PA1170   1.69 
PA1392   1.56 
PA1415   1.64 
PA1428   1.73 
PA1539   1.7 
PA1542   2.58 
PA1639   1.52 
PA1741   1.61 
PA1743   2.08 
PA1744   2.08 
PA1768   1.59 
PA1769   1.61 
PA1865   2.08 
PA2048   1.86 
PA2049   1.68 
PA2101   1.6 
PA2225   2.02 
PA2228   1.57 
PA2282   1.65 
PA2288   1.72 
PA2418   1.79 
PA2439   1.7 
PA2440   2.19 
PA2457   1.67 
PA2481   1.56 
PA2501   1.53 
PA2763a   2 
PA2767   2.06 
PA2910   2.11 
PA2929   1.98 
PA2941   1.8 
PA3056   1.52 
PA3057   1.67 
PA3237   1.78 
PA3292   1.6 
PA3390   2.25 
PA3413   2.86 
PA3414   2.45 
PA3424   1.57 
PA3489   1.78 
PA3720   2.21 
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PA3979   1.83 
PA4087   2.12 
PA4278   1.83 
PA4338   2.32 
PA4353   1.71 
PA4517   4.05 
PA4518   1.56 
PA4523   1.66 
PA4574   1.68 
PA4582   3.06 
PA4583   3.37 
PA4584   2.1 
PA4630   1.64 
PA4658   1.67 
PA4746   1.98 
PA4817   1.66 
PA4849   1.5 
PA4881   3.21 
PA5087   1.66 
PA5209   1.65 
PA5248   1.62 
PA5284   2.09 
PA5404   2.02 
PA5406   1.79 
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The effects of potential quorum sensing inhibitors on biofilm, motility and 
virulence of Acinetobacter baumannii 
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Abstract 
Acinetobacter baumannii is a nosocomial pathogen that causes a wide array of 
infections, and it has been considered as a global threat in the health-care setting 
due to its remarkable ability to acquire multidrug resistance. Quorum sensing (QS) 
has been proposed as a promising target for antivirulence therapy and QS inhibition 
has been studied as an effective way to interfere with biofilm formation and virulence 
in many pathogens. However, only limited QS inhibitors (QSIs) have been tested in 
A. baumannii so far, and few QSIs have been evaluated on A. baumannii in relevant 
in vivo models. In the present study, we investigated the effects of several known 
QSIs on biofilm formation and motility of A. baumannii. Some of these QSIs showed 
inhibition of biofilm formation and twitching motility in A. baumannii. Among these 
QSIs, curcumin and quercetin significantly reduced both biofilm formation and 
motility, and these two QSIs also increased the survival of Galleria mellonella infected 
by A. baumannii. 
 
Introduction 
Acinetobacter baumannii is an opportunistic pathogen associated with hospital-
acquired infections in immunocompromised patients [418]. It can cause severe skin, 
bloodstream, urinary tract and other soft tissue infections [353]. Outbreaks of A. 
baumannii infections have been frequently reported in soldiers during wartime [419, 
420], and A. baumannii is responsible for up to 20% of infections in intensive care 
units [421]. Virulence factors such as phospholipases, lipopolysaccharides, capsular 
polysaccharides, secretion systems and iron-chelating systems have been identified 
in A. baumannii [5, 6]. In addition, many clinical isolates of A. baumannii can form 
biofilms [15], which contributes to the persistence in infections and tolerance to 
antimicrobials and host defense. Rapid development of resistance in A. baumannii 
strains also contributes to the success of this pathogen, and the spread of multidrug 
resistant (MDR) A. baumannii strains worldwide has become a cause for serious 
concern [422]. The prevalence of MDR A. baumannii strains leaves few therapeutic 
options with antibiotics [423, 424], and there is an urgent need to develop alternative 
treatments against A. baumannii infections. 
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Quorum sensing (QS) has been studied as an important regulatory system controlling 
the virulence in a wide range of bacteria [45, 349, 425, 426]. QS in A. baumannii is 
composed of the N-acyl homoserine lactone (AHL) synthase AbaI and the 
corresponding receptor AbaR [190]. N-(3-hydroxydodecanoyl)-HSL (3-OH-C12-HSL) 
is the primary signal molecule detected in A. baumannii strains, while other AHLs can 
also be detected in different A. baumannii strains [359]. QS regulates biofilm 
formation in A. baumannii, and an abaI mutant showed 40% reduction in biofilm 
production compared to that of the wild-type strain [190]. Interfering with the QS 
system in pathogens has been considered as a promising way to inhibit virulence and 
biofilm formation; many quorum quenching (QQ) enzymes and QS inhibitors (QSIs) 
have been identified and evaluated on different pathogens [49, 288, 427, 428]. 
However, the effects of these QQ enzymes and QSIs on A. baumannii have not been 
studied in detail [429]. QQ enzymes MomL and engineered GkL have been shown to 
reduce biofilm formation in A. baumannii strains [257, 430], and several synthetic 
non-native acyl homoserine lactones (AHLs) can inhibit motility and biofilm formation 
in A. baumannii [337]. Glycyrrhiza glabra flavonoids, streptomycin at subinhibitory 
concentrations, virstatin and two unsaturated fatty acids have also been reported to 
disrupt QS system in A. baumannii and affect QS-controlled phenotypes [338-340]. 
The effects of other known QSIs for Gram-negative bacteria such as furanone C-30, 
curcumin and quercetin on A. baumannii are not reported yet. 
In the current study, we tested the effects of several known QSIs on biofilm formation 
and twitching motility of A. baumannii strains, aiming to expand the current 
knowledge of QSIs against A. baumannii. The most effective QSIs for A. baumannii 
were further evaluated in a Galleria mellonella infection model. 
 
Material and methods 
Bacterial strains, growth media and chemicals 
A. baumannii LMG 10520 and AB5075 were grown on Tryptic Soy Agar (TSA, Lab M 
limited, UK) or in Luria-Bertani (LB) broth (Lab M limited, UK) aerobically at 37°C. 
QSIs were purchased from Sigma-Aldrich (Bornem, Belgium), except for esculetin 
that was purchased from Acros Organics (Geel, Belgium). All compounds were 
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dissolved in dimethyl sulfoxide (DMSO) (Alfa Aesar, Germany) as stock solutions and 
diluted in MilliQ water. A control solution containing only DMSO was made in MilliQ 
water. Detailed information about these QSIs can be found in Table 1. 
Table 1. QSIs tested in this study. 
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Effect of QSIs on the growth of A. baumannii strains 
Overnight cultures of A. baumannii LMG 10520 and AB5075 were diluted 1:100 in 
fresh LB broth. QSIs were supplemented in a final concentration as shown in Table 1. 
100 μL bacterial suspesions were added to 96-well microtiter plates and cultured at 
37°C for 24h. The absorbance at 590 nm was measured at 1h intervals using an 
EnVision multilabel reader (Perkin Elmer, Waltham, MA). 
Biofilm formation and quantification 
Overnight cultures of A. baumannii strains were diluted to approximately 5×107 
CFU/mL in LB broth. 100 μL of the suspension was transferred to the wells of a 
round-bottomed 96-well microtiter plate with QSIs in a final concentration shown in 
Table 1. MilliQ with DMSO was added to the control. The plate was incubated at 
37 °C for 4 h before the supernatant was removed. The wells were rinsed once with 
sterile physiological saline (PS) and re-filled with fresh media and QSIs. The plate 
was incubated at 37 °C for an additional 20 hours. The number of living cells in the 
biofilm was quantified using the resazurin assay (CellTiter-Blue, CTB) [368]. Briefly, 
wells were rinsed after 24 h biofilm formation. 100 μL physiological saline and 20 μL 
CTB solution (Promega, Leiden, Netherlands) were added in each well. After 1 h 
incubation at 37 °C in dark, the fluorescence (excitation and emission filters of 486 
nm and 535 nm) was measured using the EnVision multilabel reader. The experiment 
was performed with ten replicates. 
Fluorescence microscopy 
Biofilms of A. baumannii LMG 10520 were formed in the absence or presence of 
QSIs as described above using a flat-bottomed 96-well microtiter plates. 3 μL SYTO9 
and 3 μL propidium iodide were diluted in 1 mL sterile PS, and 100 μL of this staining 
solution was transferred to each well. The plate was incubated for 15 min at room 
temperature and fluorescence microscopy was performed with the EVOS FL Auto 
Imaging System (Life Technologies). 
Twitching motility 
The effects of QSIs on twitching motility of A. baumannii AB5075 were investigated 
as previously described, with minor modifications [338]. Briefly, LB plates (0.8% agar) 
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supplemented with DMSO or QSIs in final concentrations as shown in Table 1 were 
prepared. 10 μL overnight culture of A. baumannii AB5075 was inoculated to the 
bottom of the agar, and the plates were incubated at 37 °C for 48 h. Subsequently, 
the agar was gently discarded and the plates were stained with 0.1% crystal violet for 
2 min and washed gently with water to remove excess crystal violet. Diameters of the 
crystal violet stained zone were measured. Three independent assays were 
performed, each in triplicate. 
G. mellonella survival assay 
G. mellonella larvae were purchased from BioSystems Technology (Exeter, UK) and 
were stored in the dark at 15°C prior to use. Cells of A. baumannii AB5075 were 
washed with phosphate buffered saline (PBS) and then diluted to a concentration of 
107 CFU/mL in PBS. Curcumin and quercetin were added to the bacterial suspension 
at a concentration of 10 μM before inoculation into the larvae. DMSO was added to 
the control. 10 μL of solutions were injected in the last left proleg of G. mellonella. 
Larvae were placed in the dark at 37°C and were scored as dead or alive every 24 h 
until 120 h. Larvae showing no movement in response to shaking or touch were 
considered dead. Experiments that had one or more dead larvae in control groups 
were discarded and repeated. 15 larvae were injected for each treatment, and three 
independent experiments were performed. 
Statistical analyses 
Numerical data were analyzed using GraphPad Prism 6.0 and presented as mean ± 
standard deviation (SD). The normal distribution of the data was checked by the 
D'Agostino-Pearson normality test. Normally distributed data were analyzed by one-
way ANOVA, and non-normally distributed data were analyzed by the Kruskal-Wallis 
test. Survival curves were analyzed by using a Log-rank (Mantel-Cox) test. 
Results 
Effect of QSIs on planktonic cell growth of A. baumannii strains 
As shown in Figure 1, coumarin (250 μM) inhibited the planktonic cell growth of both 
A. baumannii LMG 10520 and AB5075 during stationary phase, and the final OD at 
24 h is approximately 15% lower compared to the untreated control. 4-Nitropyridine-
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N-oxide (10 μM) slowed down the growth rate of LMG 10520 and AB5075. The final 
OD of AB5075 after 24 h treated with 6-CABA (500 μM) was approximately 20% 
lower compared to the untreated control. No significant inhibition on planktonic cell 
growth was observed with other QSIs with the tested concentrations in both A. 
baumannii LMG 10520 and AB5075. 
 
Figure 1. Effect of QSIs on planktonic growth of A. baumannii. (A). A. baumannii LMG 10520. (B). A. 
baumannii AB5075. 
Effect of QSIs on biofilm formation of A. baumannii strains 
Baicailin hydrate, coumarin, curcumin, esculetin, esculin hydrate and quercetin 
significantly reduced biofilm formation of both A. baumannii LMG 10520 and AB5075 
(Figure 2). Baicailin hydrate, coumarin and quercetin reduced biofilm formation by 
approximately 30~40 % in both A. baumannii strains tested. Curcumin, esculetin and 
esculin hydrate also reduced biofilm formation of AB5075 by 30~40%. Biofilm 
formation of AB5075 was reduced by about 10% when treated with 6-CABA, which 
might be due to its inhibition on the planktonic cell growth of AB5075. No significant 
inhibition was observed with (+)-catechin hydrate, 4-nitropyridine-N-oxide, furanone-
C30, indole and L-canavanine in either A. baumannii strain. 
Fluorescence microscopy was performed to confirm the effect of these QSIs on 
biofilm formation of A. baumannii LMG 10520. As shown in Figure 3, reduction in 
biofilm formation was observed following baicailin hydrate, coumarin, curcumin and 
quercetin treatment. 
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Figure 2. Effect of QSIs on biofilm formation of A. baumannii. Data shown are the mean values (n=10), 
error bars represent standard deviation. *, p<0.05 compared to the untreated control group. 
 
 
Figure 3. Representative fluorescence images of A. baumannii LMG 10520 biofilms treated with QSIs. 
The scale bar represents 400 μm. 
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Effect of QSIs on twitching motility of A. baumannii 
(+)-Catechin hydrate, curcumin, indole and quercetin inhibited twitching motility of A. 
baumannii AB5075 (Figure 4). No significant inhibition of twitching motility was 
observed for the other QSIs tested. 
 
Figure 4. Effect of QSIs on twitching motility of A. baumannii AB5075. (A). Data shown in are the mean 
values (n=9), error bars represent standard deviation. *, p<0.05 compared to the untreated control 
group. (B). Representative images shown the inhibition of twitching motility by QSIs. 
 
Effect of curcumin and quercetin on survival of G. mellonella following 
infection with A. baumannii 
We further evaluated two QSIs which inhibited both biofilm formation and twitching 
motility of A. baumannii in a G. mellonella infection model. Curcumin and quercetin 
showed no toxicity to G. mellonella at the concentrations used (data not shown). As 
shown in Figure 5, curcumin and quercetin significantly increase the survival of G. 
mellonella infected by A. baumannii AB5075 (p<0.0001 in Log-rank test). After 120 h, 
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the survival of infected larvae in control group was 18.9±6.0%, while the survival of 
curcumin and quercetin treated larvae was 69.0±7.5% and 51.2±7.9%, respectively. 
 
 
Figure 5. Survival curve of G. mellonella infected by A. baumannii AB5075. The data were presented 
as mean ± standard error. 
 
Discussion 
QS systems have intensively been studied as potential antivirulence targets in many 
bacterial pathogens [348, 435]; research on QS and QS inhibition of the emerging 
pathogen A. baumannii is however still in an early stage [429]. In the current study, 
we evaluated the effects of 12 compounds on biofilm formation and twitching motility 
of A. baumannii. These compounds included several plant-derived flavonoids ((+)-
catechin hydrate, baicailin hydrate and quercetin) as well as other phenols (curcumin, 
coumarin, esculetin and esculin hydrate) which have been reported to inhibit QS and 
biofilm formation in Pseudomonas aeruginosa [336, 389, 392, 416, 431, 432]. 
Synthetic QSIs like furanone C30, 4-nitropyridine-N-oxide and 6-CABA [313, 315, 
395] were also included in the present study. In addition, the arginine analog L-
canavanine, which inhibited QS in Sinorhizobium meliloti was tested. Another QSI 
tested in our study was indole, which has been reported to destabilize the QS 
receptor and inhibit QS in Acinetobacter oleivorans [433]. 
Baicailin hydrate, curcumin and quercetin significantly reduced biofilm formation of A. 
baumannii, as demonstrated by CTB staining and fluorescence microcopy. Although 
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coumarin also reduced biofilm formation, 15% inhibition of planktonic cell growth was 
observed at the concentration tested. No reduction in biofilm formation was observed 
with (+)-catechin hydrate and indole, but these two QSIs were found to significantly 
inhibit the twitching motility. In contrast, baicailin hydrate and coumarin which 
reduced biofilm formation showed no effects on twitching motility of A. baumannii. 
Only two QSIs, curcumin and quercetin, significantly inhibited both biofilm formation 
and twitching motility of A. baumannii. 
Twitching motility of A. baumannii relies on Type IV pili, and these surface 
appendages also participate in natural transformation and adherence to abiotic/biotic 
surfaces [436]. Although the relationship between QS and Type IV pili in A. 
baumannii has not been clarified yet, a study showed that AHL enhances pili 
assembly, twitching motility and biofilm formation of A. baumannii ATCC19606 [198]. 
In another study, an abaI mutant of A. baumannii M2 showed impaired twitching 
motility compared to the wild-type, and flavonoid extracts of G. glabra which inhibit 
QS of A. baumannii reduced twitching motility in the wild-type [338]. These results 
strongly suggest that QS positively regulates twitching motility. However, not all QSIs 
tested in our study inhibit both biofilm formation and twitching motility of A. 
baumannii, which might be due to the distinct mechanisms behind their inhibition 
effects on biofilm and motility in A. baumannii. 
Curcumin, the major ingredient from Curcuma longa, has been reported to inhibit QS 
in P. aeruginosa, reducing QS-regulated virulence and biofilm formation [437]. It also 
increased survival of Caenorhabditis elegans following infection with P. aeruginosa 
and Burkholderia pseudomallei [437, 438]. Curcumin-loaded liposomes were shown 
to interfere with QS and affect QS-regulated phenotypes of Aeromonas sobria [439]. 
Biofilm formation of pathogens as Escherichia coli, Proteus mirabilis and Serratia 
marcescens can also be inhibited by curcumin [432]. The natural flavonoid quercetin 
is another effective QSI that reduces biofilm formation and production of virulence 
factors in P. aeruginosa [389], probably by allosteric inhibition of QS receptors [297]. 
In our study, curcumin and quercetin were shown to inhibit QS-controlled 
phenotypes, biofilm formation and twitching motility, in A. baumannii. Both of them 
increased the survival of G. mellonella infected by A. baumannii AB5075 and to the 
best of our knowledge, this is the first report of QSIs reducing A. baumannii virulence 
in an in vivo infection model. Although a previous study showed no difference in G. 
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mellonella killing between wild-type and QS mutant of A. baumannii M2 [371], our 
results showed QS might be an important determinant in the virulence of A. 
baumannii to G. mellonella. The inconsistent results might be due to different A. 
baumannii strains and experiment conditions used in these two studies. 
In summary, we evaluated the effect of different known QSIs on A. baumannii. 
Curcumin and quercetin were identified as possible QSIs which effectively inhibited 
both biofilm formation and twitching motility of A. baumannii, and they reduced the 
virulence of A. baumannii in a G. mellonella infection model. These results indicated 
that QS inhibition can be an effective way to inhibit A. baumannii virulence and 
infections. Both curcumin and quercetin are currently applied as dietary supplements 
[440, 441], and they may be good choices for further investigations on safe and 
efficiency QSIs to treat A. baumannii clinical infection. 
 
Conclusion 
QSIs such as curcumin and quercetin can effectively inhibit biofilm formation, motility 
and virulence of A. baumannii, and these QSIs might be promising in treating A. 
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1. The need for antivirulence drugs 
According to the report released by WHO in April 2014, a 'post-antibiotic' era in which 
common infections and minor injuries can kill, may become a reality in the 21st 
century if no effective actions are taken against the increasing antimicrobial 
resistance [442]. Data gathered from 129 member states of the WHO showed that 
extensive resistance to antibiotics is emerging in every region of the world [442]. This 
growing threat caused by antimicrobial resistance reduces the efficiency of known 
drugs, resulting in more difficult and costly treatment for patients worldwide. The first 
study on the burden posed by antibiotic resistant bacteria in 2013 revealed that 2 
million people become infected with resistant bacteria and at least 23,000 people die 
each year as a consequence in the US alone, leading to a cost of over $20 billion in 
health care and $35 billion for the loss of productivity [443]. Globally, at least 700,000 
deaths are caused by drug resistance in illnesses such as bacterial infections, 
malaria or tuberculosis each year [444]. It is unquestionable that we are at a critical 
point to take global measures against antimicrobial resistance. However, 
development of novel antibiotics has slowed down since 1990s [445], and typically 
bacteria quickly develop resistance to new antibiotics within a few years after their 
introduction. 
In the meantime, increasing understanding of bacterial virulence factors and their 
functions motivates the research on antivirulence strategies, which aim to interfere 
with the virulence of bacteria instead of killing them or inhibit their growth. The 
number of publications on antivirulence compounds and targets has increased 
rapidly over the past decades (Figure 4.1). The most significant advantage of 
antivirulence drugs seems to be the weaker evolutionary pressure they impose on 
bacteria compared to antibiotics. Adhesion, toxin, secretion system, biofilm and QS 
system have been considered as promising antivirulence targets and intensively 
studied in various antibiotic resistant pathogens such as P. aeruginosa, S. aureus, 
Klebsiella pneumoniae, A. baumannii, Clostridium botulinum and Enterobacter [446-
448]. However, most of these compounds with antivirulence potential are not yet 
widely tested in the clinical settings, and more efforts are needed to prove their 
putative advantages and effectiveness.  
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Figure 4.1 Increased numbers of antivirulence publications and citations over time. The total number 
of publications on Web of Science is given as a baseline (red), scaled to the number in 2015, which is 
indicated in parentheses. [446] 
2. QS as antivirulence target in infections: promises and challenges 
Compared to other antivirulence targets, the most encouraging potential of QS is the 
possibility to prevent the production of multiple virulence factors. In the case of P. 
aeruginosa, QS regulates the production of pyocyanin, protease, HCN, rhamnolipid 
and other virulence factors, and it also affects the process of iron uptake and biofilm 
formation, which makes QS an attractive target to reduce the full virulence of P. 
aeruginosa during infections [449]. Although study on QS of A. baumannii is still in an 
early stage, biofilm formation and motility of A. baumannii were shown to be affected 
by QS [360]. QS systems in other pathogens such as S. aureus, Burkholderia 
cenocepacia and E. coli also play an important role in their virulence [425, 426]. In 
addition, due to the regulatory role of QS in biofilm formation, QS inhibition has been 
considered as a possible way to increase the efficiency of antimicrobials against 
pathogens such as P. aeruginosa [352] in treating biofilm-related infections. 
Different strategies for QS inhibition have been proposed based on the general QS 
circuits, including blocking the signal production, degrading signal molecules and 
disrupting the signal reception. Various enzymes and compounds have been 
identified with QS inhibition activities targeting different QS systems in pathogens 
(See Chapter I). In Chapter III Paper 1, we showed that the AHL-degrading enzyme 
MomL can reduce biofilm formation of P. aeruginosa and A. baumannii, and MomL in 
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combination with antibiotics resulted in fewer biofilm cells compared to antibiotic 
treatment alone. In Paper 2, the QS inhibitor coumarin was shown to inhibit QS-
regulated virulence factors, biofilm formation and virulence to L. sericata maggots in 
P. aeruginosa. In Paper 3, promising QSIs were identified which can reduce biofilm 
formation, motility and virulence to G. mellonella in A. baumannii. These results prove 
the antivirulence and antibiofilm potential of both QQ enzymes and QSIs, and some 
QSIs showed promising results not only in vitro but also in in vivo models. 
However, several questions have also been raised during the exploration of QS 
inhibition as an effective antivirulence approach, and these questions were well 
discussed with P. aeruginosa as an example [413]. 
Firstly, in addition to its role in regulating virulence genes, QS also influences the 
global metabolism. Davenport et al. compared the metabolites produced by a lasI rhlI 
double mutant and wild-type P. aeruginosa, and found changes in approx. one third 
of the metabolites tested including tricarboxylic acid (TCA) cycle intermediates, 
amino acids and fatty acids [450]. Our RNA-sequencing results on coumarin-treated 
biofilms of P. aeruginosa (Chapter III Paper 2) also showed that expression of 
multiple genes related to metabolisms were altered, such as glycogen phosphorylase 
(glgP), glycogen branching enzyme (glgB) and glycogen synthase (PA2165, glgA) 
which are related to carbohydrate metabolism and are positively controlled by QS 
[78]. How these changes could affect the growth and fitness of P. aeruginosa under 
different nutritional conditions remains to be determined. QS is also involved in the 
regulation of primary metabolism in Burkholderia species and in Yersinia pestis [451]. 
The possible implications of such metabolic changes on QS inhibition therapy are still 
unexplored. Therefore when we focus on the inhibition of virulence factors by 
interfering with QS, the accompanied changes on metabolism of these pathogens 
should not be ignored. Otherwise these changes may lead to unexpected outcomes 
by affecting growth and competition of pathogen populations in vivo. 
Secondly, QS may positively or negatively regulate different virulence factors in 
certain pathogens. For P. aeruginosa, most virulence factors are positively regulated 
by QS, but the expression of T3SS has been reported to be negatively affected by 
QS [412]. Although transcriptome analysis on coumarin and 6-gingerol treated 
biofilms revealed that T3SS was repressed along with their QS inhibition effects 
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(Chapter III Paper 1, [328]), another study on curcumin treated P. aeruginosa showed 
six genes related to T3SS were upregulated [437]. In S. aureus, the Agr system 
positively regulates many toxins and degradative exoenzymes, but several 
colonization factors and biofilm formation are negatively regulated by Agr, and this 
becomes a noticeable problem when developing Agr blockers [67]. For A. baumannii, 
the interactions between QS and other virulence factors are not yet well established, 
and these need to be understood better for a solid scientific basis of QS inhibition 
therapy in A. baumannii. 
Furthermore, variations between different clinical strains may also render QS 
inhibition therapy fall short of expectations. Our results in Chapter III Paper 1 and 
Paper 2 indicated that the effect of either QQ enzyme or QSI may be strain 
dependent. MomL inhibits the biofilm formation of A. baumannii LMG 10531 and 
LMG 10520, but biofilm formation of three other A. baumannii strains is not reduced 
by MomL treatment. Inhibitory effects of coumarin on virulence and biofilm formation 
vary in different P. aeruginosa strains tested. These variations were also observed in 
a study of Guendouze et al., which evaluated the effect of QQ enzyme SsoPox and 
QSIs (furanone C30 and 5-fluorouracil ) on P. aeruginosa clinical strains [256]. The 
effect of QSIs on growth also varies between different strains. García-Contreras et al. 
showed that furanone C30 displayed highly variable QS inhibition activity and growth 
inhibition in 50 P. aeruginosa isolates from cystic fibrosis patients, and some of these 
strains even produced higher amounts of the virulence factors when exposed to C30 
[409].  
Although LasR in P. aeruginosa has been considered as a pivotal factor in the QS 
network, lasR mutants are frequently found in at least one third of the chronically 
infected cystic fibrosis patients, and these mutants are associated with worse lung 
function [452]. Fitness advantages of lasR mutants are indicated by several studies, 
such as the ability to grow on nitrate and aromatic amino acid sources and higher 
resistance to alkaline stress [453-455]. lasR mutants have also been shown to induce 
exaggerated host inflammatory responses in respiratory epithelial cells with 
increased accumulation of proinflammatory cytokines and neutrophil recruitment, and 
might directly contribute to the pathogenesis and progression of chronic lung disease 
[456]. These results raise concerns about the effects of inhibitors targeting LasR, and 
indicate that host immune responses and types of infections should also be 
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considered when developing QS inhibition agents of remarkable complex pathogens 
as P. aeruginosa. 
In addition, one underlying assumption for effective QS inhibition therapy is that the 
immune systems of patients can clear the bacteria in infections upon QS inhibition 
treatments [413]. However, opportunistic pathogens such as P. aeruginosa and A. 
baumannii primarily infect patients with compromised immune systems, and whether 
the bacteria can be get rid of or not with single QS inhibition therapy is yet to be 
demonstrated. If these bacteria are not cleared thoroughly, the question whether they 
will become a potential ‘time bomb’ in patients after removing the QS inhibition 
agents needs to be considered. 
In this dissertation, we also found that the effect of QQ enzymes and QSIs might fall 
short of expectation under certain in vivo-like conditions or in multi-species biofilms. 
These results indicated that the role of QS should be better understood in a specific 
type of infections before we consider QS as a promising target to inhibit biofilm 
formation and virulence. In the case of wound infections, it has been shown that 
albumin can bind and sequster 3-oxo-C12-HSL produced by P. aeruginosa, 
indicating that the las system in P. aeruginosa might be largely inhibited in a an 
albumin-rich environment such as chronic wounds [457]. On the other hand, in 
peripheral blood during burn trauma with reduced level of albumin, the function of QS 
in P. aeruginosa  is probably only slightly affected [457]. In addition, the presence of 
PONs in the serum can also lead to less functional QS systems in P. aeruginosa 
during infections. These factors affecting the las system might partially explain the 
less pronounced effect of MomL and coumarin on P. aeruginosa in the wound model, 
as activation of the las system is considered to precede the activation of RhlR or 
PqsR and a non-functional las system can lead to QS-deficient phenotypes in well-
studied P. aeruginosa lab strains. However, increasing evidence shows that RhlR 
can be functional in a las-independent manner in clinical isolates during infections 
[458]. Therefore, the in vivo effect of QQ enzymes and QSIs targeting not only las but 
also rhl or even the PQS system during wound infections needs to be further studied.  
Considering the fact that wound infections are often colonized by multiple species 
including C. albicans, S. aureus, P. aeruginosa, E. coli, Bacteroides spp., the 
treatment by QQ enzymes and QSIs can be more challenging. QS inhibition targeting 
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one pathogen might influence the population of other species. For instance, QS-
regulated virulence factors of P. aeruginosa severely impair the growth of S. aureus 
[459, 460]. It is possible that QQ enzymes or QSIs targeting P. aeruginosa can lead 
to an increased population of S. aureus in polymicrobial infections and might be less 
helpful in reduce the burden of infections. A similar situation may also occur with P. 
aeruginosa and C. albicans. AHLs produced by P. aeruginosa can inhibit the yeast to 
hyphal switch, an important process for the virulence of C. albicans [461]. PQS and 
pyocyanin are also involved in the interaction between P. aeruginosa and C. albicans 
[462]. Therefore, QS inhibition of P. aeruginosa may result in increased virulence of 
C. albicans. Evaluating the effects of QQ enzymes and QSIs in delicate designed 
polymicrobial model may help us to study these possibilities that could happen in in 
vivo wound infections. 
In summary, QS may be an attractive antivirulence target in P. aeruginosa and other 
pathogens, but more research is needed to understand the relationship between QS, 
virulence and physiology in different pathogens. Discovery of QSIs with different 
mechanisms of QS inhibition may also help to identify the truly effective ones that 
may ultimately be used in the clinic. 
 
3. Plants as abundant sources for natural QSIs 
Natural products from plant have long been studied as sources of lead compounds 
for modern drug discovery, and now plant extracts have also become an abundant 
source for QSIs. It is assumed that plants (which have no sophisticated immune 
system) may rely on cellular and biochemical defense systems and produce natural 
QS inhibition compounds to defeat pathogens [463]. As discussed in Chapter I, a 
variety of phenolic compounds show QS inhibition activity, and several flavonoids 
comprise a well-studied group. In Chapter III Paper 3, we showed that quercetin, a 
typical flavonoid found in many fruits, vegetables, leaves, and grains, can 
successfully inhibit biofilm formation and virulence of A. baumannii. Another 
promising QSI against A. baumannii identified in our study, curcumin, is a natural 
phenol primarily found in turmeric (Curcuma longa). 
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Figure 4.2 Coumarins with anti-biofilm or anti-QS activities. Compounds for which anti-biofilm 
properties have been established are presented on the left, while those with dual activity are 
presented on the right [391]. 
Coumarins are another family belonging to the phenolic compounds, and they are 
composed of fused benzene and α-pyrone rings. Their potential to inhibit QS and 
biofilm formation in different pathogens has just begun to be studied (Figure 4.2). 
Esculetin and esculin were the first coumarins reported as QSIs in a virtual QS 
inhibitor screen [416]. The QS inhibition activities of other coumarins have been 
reported subsequently, including that of  coumarin itself [391, 392]. However, none of 
these coumarins have been tested in vivo, and the mechanisms of their QS inhibition 
effects remains unknown. In Chapter III Paper 2, we provided a thorough analysis 
with transcriptomic data on the QS inhibition effect of coumarin in P. aeruginosa, and 
H3CO 
Chapter IV. Broader international context, relevance, and future perspectives 
119 
surprisingly found that coumarin can also interfere with type III secretion and c-di-
GMP signaling in P. aeruginosa. These results indicated that coumarin may be 
promising in treating P. aeruginosa infections. Further studies on other coumarin 
compounds and chemical modifications of these compounds might help us to identify 
more potent QSIs. In addition, although a reference dose (acceptable daily exposure 
level for a lifetime) of 0.64 mg/kg/day coumarin has been proposed as a conservative  
value, the clinical database suggests that most humans can tolerate far higher 
exposures to coumarin without any adverse effects [391, 464]. 
However, there is an on-going debate about the therapeutic use of several natural 
products including curcumin, quercetin and polyphenols. In the case of curcumin, it 
can hit many targets and might not have favorable pharmacokinetic properties  [465]. 
Other drawbacks of curcumin include the low oral bioavailability and toxicity under 
specific conditions [466]. These negative properties of curcumin and other 
polyphenols should also be considered when further developing them as effective 
QSIs. 
4. Methods used in QS inhibition studies 
4.1 Biosensor strains 
Genetically engineered bacterial whole-cell biosensors are useful tools in the 
detection of QS signal molecules as well as to determine the activity of QQ enzymes 
and QSIs. Generally, a QS biosensor strain harbors QS systems of interest coupled 
with easily detectable and quantifiable reporter genes. Reporter genes generates 
different classes of readable output such as fluorescence, color pigments and 
luminescence [293, 467]. These biosensors have been developed with a wide range 
of bacteria including E. coli, P. aeruginosa, A. tumefaciens and Chromobacterium 
violaceum. The type of AHLs that can be detected and the detectable concentration 
range are different for biosensors based on their mechanisms. In Chaper III Paper 1, 
the biosensor A. tumefaciens A136 was used to detect the residual AHL 
concentrations after degradation by MomL. A. tumefaciens A136 expressed β-
galactosidase in the presence of AHLs, and is widely used in many studies due to its 
broad detection range of AHLs and high sensitivity [367, 468]. In Chaper III Paper 2, 
P. aeruginosa QSIS2 was used to confirm the QS inhibitory effect of coumarin. This 
biosensor is useful in identifying QSIs targeting the QS circuit of P. aeruginosa, as 
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QS inhibition is quantified directly by the cell growth of P. aeruginosa in the presence 
of sucrose [395]. However, there are also limitations with these biosensors. For 
example, the concentrations of AHLs produced by A. baumannii strains are too low to 
be detected by the biosensor used in our study, and in such case analytical methods 
as HPLC and mass spectrometry can be used to quantify the AHL levels. In addition, 
false positive results in identifying QSIs with biosensors might happen as the 
detected phenotype is often co-dependent on other factors and/or the metabolic 
activity of the cells [435]. Therefore, these biosensors can be used as a fast, 
convenient tool in primary identification of QSIs, but a series of verification tests are 
needed to confirm  QS inhibition. 
4.2 Inhibition of QS-regulated virulence 
Reduced production of virulence factors controlled by QS is a strong evidence for QS 
inhibition in pathogens as P. aeruginosa, and also has important implications for 
reduced virulence of these pathogens in in vivo infections. Pyocyanin, protease and 
rhamnolipid are commonly tested QS-regulated virulence factors in P. aeruginosa, as 
well as biofilm formation which is under the tight control of QS systems [181]. Crystal 
violate staining is widely used to quantify biofilm biomass in microtiter plates. Plating 
and resazurin staining are also used in our study to quantify live cells in biofilms. 
Fluorescence and confocal microscope are useful to detect changes in biofilm 
structures after QSI treatment. In addition, model systems of biofilm are also useful to 
study the effect of QSIs on biofilms, such as continuous-flow reactors for biofilm 
formation  [314, 469] and the wound model used in our study. 
4.3 Analysis of expression of QS-regulated genes 
Quantitative real-time PCR (RT-qPCR) is commonly used to detect changes in the 
expression of selected core genes in QS systems to confirm the QS inhibition activity. 
However, transcriptome analysis by microarray analysis or RNA-sequencing might 
better indicate the overall effect of QSIs on the QS network and virulence, especially 
for QSIs with undefined mechanisms and for pathogens as P. aeruginosa with 
complex QS network. 
4.4 Virulence in in vivo models 
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Many studies on QQ enzymes and QSIs go one step further and investigate their 
effects on in vivo virulence of pathogens. As discussed in Chapter I, C. elegans and 
G. mellonella are simple infection models used in QSI studies. The advantages of 
these models are the small sizes and simple experiment operations. Despite the 
simplicity of these models, C. elegans and G. mellonella give valuable information 
about the effectiveness of QQ enzymes and QSIs under in vivo conditions. Different 
mouse models are also commonly used in studies for QS inhibition to mimic the 
conditions in various types of infections, such as foreign-body implant model [331], 
pulmonary mouse model [314] and urinary tract infections model [333].  
 
5. Comparison of transcriptome studies on QS inhibition in P. aeruginosa 
Transcriptome analysis has been shown to be a valuable tool to study QS regulons 
and the influence of QSIs in P. aeruginosa. To identify QS-regulated genes in P. 
aeruginosa, several groups performed transcriptome analysis with lasI rhlI mutants. 
Wagner et al. identified that 394 genes are positively regulated and 222 genes are 
negatively regulated by QS in P. aeruginosa [411]. Schuster et al. showed that 315 
genes are QS-induced and 38 genes are QS-repressed [78]. In another study, 
Hentzer et al. reported that 163 genes can be activated by QS [314]. Approximately 
100 common QS-regulated genes were found in all three studies and the dominant 
functional class of these genes is secreted factors including toxins and extracellular 
enzymes [79]. Due to the differences in data analysis and experimental conditions, 
most of QS-regulated genes were not simultaneously reported in all three studies. In 
addition, growth medium and oxygen availability can affect the transcript abundance 
of many QS-regulated genes [411]. In another study using a semi-defined medium 
that limits the final densities of P. aeruginosa, only 79 genes were found to be 
activated by QS [470]. 
Similarly, the number of genes targeted by the different QSIs also varies a lot (Table 
4.1), and this variation might also be due to different mechanisms of QSIs, as well as 
different concentrations and treatment times used in these studies. Most QSIs affect 
the expression of a considerable number of genes in P. aeruginosa, except ajoene 
which only down-regulated 11 genes related to production of LasA protease, 
chitinase and rhamnolipids. Interestingly, changes in QS-controlled virulence genes 
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such as lasA, lasB, rhlAB, phzC-G, katA and chiC were found to be more significant 
compared to the changes in core QS genes, indicating that minor changes in core 
QS genes may be able to repress these virulence factors. Correspondingly, no 
significant changes were shown in core QS genes when cells were exposed to QSIs 
such as ajoene and patulin, but QS-regulated virulence genes were significantly 
down-regulated by these QSIs. An explanation offered in several studies for these 
observations is that some QSIs might interfere with QS regulators at the post-
transcriptional level instead of inhibiting the transcription of genes in the central part 
of QS circuit [304, 314]. However, it could also be possible that changes in 
expression of core QS genes were not detected due to the experimental and 
statistical analysis methods used in these studies. In the case of 6-gingerol, no 
changes in the expression of lasI, lasR and rhlI were found by microarray analysis, 
but the RT-qPCR results in the same study showed that these genes were also 
significantly repressed by 6-gingerol [328]. In addition, transcriptome analysis on the 
same QSI in different studies may lead to quite distinct results. In the case of 
azithromycin (2 μg/mL), Nalca et al. showed that 29 and 78 genes were down- and 
up-regulated in P. aeruginosa PAO1 (Table 4.1), whereas in the study of Skindersoe 
et al. 227 and 49 genes were down- and up-regulated [320]. The different results in 
these two studies might be partly explained by the different origins of P. aeruginosa 
PAO1 and the different media used [320]. 
Despite the variations in transcriptome studies, most QSIs are reported to repress 
multiple QS-regulated virulence factors, such as LasA protease, LasB elastase, 
rhamnolipids, pyocyanin, hydrogen cyanide and chitinase either in planktonic or 
biofilm cells. Transcriptome analysis on biofilm cells treated with 6-gingerol and 
coumarin indicated that more genes might be affected by QSIs in biofilm compared to 
the planktonic cells. Indeed, in the study of Hentzer et al., 254 genes were found to 
be induced by AHL in P. aeruginosa biofilms, whereas 163 genes were induced in 
planktonic cells [314]. In addition, 86% of genes highly induced by AHLs in planktonic 
cells were also found to be induced in biofilm cells. These results suggest that QS 
might regulate more genes in biofilms compared to planktonic cells, but the 
commonly identified QS regulons [79] might be consistent in planktonic and biofilm 
cells. 
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Table 5.1 Transcriptome studies of P. aeruginosa treated by various QSIs 
QSIs Cell types 
Number of genes affected Down-regulated 
core QS genes 
Reference 
Down-regulated Up-regulated 
Furanone C30 Planktonic 
cells 
85 8 phnAB [314] 





502 214 lasI [437] 
mBTL Planktonic 
cells 






11 5 None [298] 
Azithromycin Planktonic 
cells 





136 10 None [320] 
Ciprofloxacin Planktonic 
cells 
223 58 None [320] 
Patulin Planktonic 
cells 
157 in total None [304] 
Penicillic acid Planktonic 
cells 
300 in total None [304] 
Protoanemonin Planktonic 
cells 
37 45 None [471] 





6. Will QS inhibition lead to resistance? 
Another intensely discussed issue about QS interference therapy is that there is 
increasing evidence showing that resistance to QS inhibition can develop. The 
possibility for bacteria to evolve resistance to QS inhibition was first systematically 
discussed by Defoirdt et al. [290], based on the observation that variations between 
different stains exist in core QS genes related to production and reception of signal 
molecules. Besides, selective stress might also be induced under the conditions that 
QS inhibition may affect the fitness of pathogens. 
Subsequently, resistance to furanone C30 was reported to arise rapidly in P. 
aeruginosa through mutations related to efflux pumps when functional lasR was 
needed for growth on adenosine in minimal medium [472]. Another study showed 
that furanone C30 resistant P. aeruginosa strains were selected in the presence of 
C30 and oxidative stress [473], indicating that stress might result in strong selection 
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for bacteria resistant to QS inhibitors as QS may enhance the stress response [474]. 
This result suggests that reactive oxygen species released by the host immune 
systems during infection might accelerate the selection of resistant strains against 
QS disruption.  
Several competition studies with QS-deficient and QS-proficient strains have been 
performed to explore if QS inhibition resistant strains can be selected [474]. Gerdt et 
al. demonstrated that two barriers might impede the spread of QSI resistance: 
insufficient native QS signal levels prevent QS-regulated gene expression in QSI-
resistant bacteria, and QSI sensitive strains can exploit the group-beneficial QS-
regulated products by social cheating [475]. These results support the promise of 
QSIs as a resistance-proof therapy. 
However, it is also noteworthy that many known QSIs exhibit both antimicrobial and 
antivirulence effects depending on the concentrations, and this is particularly true for 
several antibiotics used in sub-inhibitory concentrations as QSIs. In the case of 
azithromycin, although its QS inhibition and antivirulence effects have been 
demonstrated in vitro [321, 476] and the therapeutic efficacy of azithromycin in cystic 
fibrosis patients has been proven in many clinical trials [341, 477], it is difficult to 
assess the contribution of these activities to the efficacy of azithromycin in vivo 
because of concomitant antivirulence and bactericidal effects under certain 
conditions [478]. Even used in sub-inhibitory concentrations, resistance can possibly 
be selected [479, 480], and this may also happen with other QSI compounds with 
antimicrobial activity. In addition, the growth inhibitory effect of QSIs on different 
bacterial species varies greatly. As indicated by the results in Chapter III Paper 2 and 
Paper 3, coumarin affected the growth of A. baumannii at 250 μM, while the growth 
of P. aeruginosa strains is not significantly affected by 1 or 2 mM coumarin [392]. In 
another study, Vibrio splendidus was treated with 6.75 mM coumarin and no 
significant effect on cell growth was observed [393]. Therefore, if the concentration is 
not properly chosen, treatment with QSIs in multi-species infections may induce 
higher selective stress on certain species and lead to the emergence of resistance in 
these species.  
Nevertheless, based on the current knowledge, it is still not possible to conclude 
whether resistance against QS inhibition can be wide-spread under drug selection 
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and how fast the QSI resistance can evolve, as different outcomes are possible 
depending on the specific conditions at the site of infections [291, 474, 481]. Further 
evolution studies in appropriate models may give us a better understanding on this 
issue. 
 
7. Comparison of QQ enzymes and QSIs as antivirulence therapy 
QQ enzymes and QSIs are two major approaches for QS inhibitions. In the current 
study, we showed that both QQ enzymes and QSIs are promising agents to inhibit 
biofilm formation and virulence in P. aeruginosa and A. baumannii. The effectiveness 
of QQ enzyme and QSIs are seldom compared under the same experimental 
conditions. In a recent study, the effect of engineered lactonase SsoPox was 
compared with furanone C30 and 5-fluorouracil against several clinical P. aeruginosa 
isolates at their optimized concentrations, respectively [256]. Their results showed 
that SsoPox is more active in reducing the production of pyocyanin and protease and 
inhibiting biofilm formation in 16 P. aeruginosa strains, whereas the well-
characterized QSI furanone C30 only slightly inhibited the protease production in five 
strains, the pyocyanin production in two strains and biofilm formation in one strain. 
Many strains even showed higher production of virulence factors when treated with 
C30. Although we cannot conclude that the use of QQ enzymes is a better anti-
virulence approach compared to QSIs based on this study alone, their results initiate 
the thinking that QQ enzymes might have advantages over some QSIs under certain 
conditions. 
QQ enzymes degrade signal molecules extracellular instead of targeting intracellular 
receptors, and it might not be possible to induce resistance mechanisms such as 
increased efflux pumps against them. QQ enzymes are less toxic compared to QSIs 
such as C30, and might be safer to be used in human. However, resistance 
mechanisms against QQ enzymes may emerge by degrading the QQ enzymes, 
increasing the production of signal molecules or decreasing the detection threshold 
of signal molecules. Currently, the physiological function of various QQ enzymes in 
nature remains largely unknown, therefore unexpected outcomes might occur when 
applied in vivo. QQ enzymes that can degrade a broad range of AHLs must be 
assessed with great care, as they might affect other commensal bacteria in complex 
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communities. In addition, the large-scale production, the stability under in vivo 
environment and the tolerance to industrial process also needs to be solved before 
further applications of QQ enzymes.  
Compared to QQ enzymes, QSIs can be easily modified by synthetic methods. Some 
QSIs are designed to target receptors in specific pathogen, and this may minimize 
the effect of these QSIs on non-pathogenic bacteria. QSIs with low molecular weights 
can easily be administered orally or intravenously as other drugs. In addition, QSIs 
identified from known drugs (‘repurposing’) may facilitate their future application in 
the clinic.  
8. Future perspectives for QS inhibition studies 
8.1 Future perspectives for QQ enzymes 
Currently, a large number of QQ enzymes have been identified from different origins. 
This diversity of QQ enzymes provides valuable resources to obtain modified QQ 
enzymes that are more active and stable. QQ enzymes with a broad substrate range 
may be useful in treating multi-species infections, but engineered QQ enzymes with 
high specificity towards AHLs can help us develop a more selective QS inhibition 
strategy targeting certain pathogens. Development of QQ membranes and catheters 
with immobilized QQ enzymes gets one step further towards the application of QQ 
enzymes in medical devices. Topical application with a QQ enzyme containing gel in 
combination with ciprofloxacin has been showed to reduce mortality against P. 
aeruginosa in a burn infection model on mice [269]. Therefore, future development of 
dressings and bandages with QQ enzymes may be a promising way to treat wound 
infections. 
Meanwhile, more efforts are needed to elucidate the physiological role of QQ 
enzymes either in bacteria or in the complex natural communities. Recently, the AHL-
acylase from Acidovorax sp. was found to degrade a wide range of β-lactams [239]. 
This result reminds us to be cautious with the possible overlooked functions of QQ 
enzymes in future studies. In addition, evaluating the QQ enzymes on different 
clinical strains and in different in vivo models might give a deeper understanding on 
their effects during infections. 
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8.2 Future perspectives for QSIs 
Although increasing numbers of QSIs have been reported, the continuous search for 
novel QSIs is important for future studies to get more effective and reliable QSIs 
targeting different pathogens. In the meantime, the current knowledge of known QSIs 
needs to be enriched, including their targets and mechanisms, as well as their 
influences on other physiologic process in bacteria except QS. For complex 
pathogens as P. aeruginosa, continued basic research about their QS network in 
natural human habitats will promote the identification of truly effective QSIs, and 
more efforts are needed to understand the interactions of QSIs with the core QS 
systems, various QS regulons and environmental stress in vivo. Further metabolomic 
and proteomic studies may shed more light about the effect of QSIs under in vivo 
conditions. 
Combination of QSIs and antibiotics has been studied as a possible way for the 
further application of QSIs. Besides, combination of QSIs with other anti-virulence 
agents targeting biofilms and secretion systems might also be an effective approach 
to be proved in future studies. 
8.3 Future perspectives for QS inhibition therapy in clinic 
Although promising results with QQ enzymes and QSIs have constantly been 
reported in vitro and in vivo, there is still a long distance from the bench to the clinic 
for QS inhibition therapy. Besides those fundamental questions regarding the 
effectiveness of QS inhibition and possible resistance mechanisms, other problems 
related to drug delivery, stability and toxicity are yet to be solved for successful 
application of QQ enzymes and QSIs. However, we are pleased to see that several 
small-scale clinical trials with specific QSIs have been performed [341, 342]. As our 
knowledge on QS inhibition therapy expands, we will get closer to broad-scale clinical 
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QS systems of many clinical relevant pathogens are involved in regulating various 
processes associated with virulence. This allows bacteria to achieve a coordinated 
attack on the host at a high population density and overcome the host defense 
successfully. Therefore, QS inhibition either by QQ enzymes or QSIs has been 
considered as an attractive therapeutic strategy to treat infections caused by 
pathogens such as P. aeruginosa and A. baumannii. In this dissertation, we explored 
the effects of typical QQ enzyme and QSIs on P. aeruginosa and A. baumannii, 
aiming to identify promising QS inhibition agents to reduce virulence and biofilm 
formation of P. aeruginosa and A. baumannii. 
In the first part of this dissertation, we purified the QQ enzyme MomL and evaluated 
its effect on biofilms of P. aeruginosa and A. baumannii strains. MomL reduced 
biofilm formation and increased biofilm susceptibility to different antibiotics in biofilms 
of P. aeruginosa PAO1 and A. baumannii LMG 10531 formed in microtiter plates in 
vitro. However, MomL showed no effect on the overall cell number in a mixed species 
biofilm formed by P. aeruginosa and A. baumannii, and the same disappointing 
results were obtained in biofilms formed in wound model system. The virulence of A. 
baumannii in the C. elegans infection model was not affected by MomL. Additionally, 
the effect of MomL on biofilm formation of Acinetobacter strains seems to be strain-
dependent. No effects of MomL on biofilm formation were detected for three out of 
five Acinetobacter strains tested. These results indicated that although promising 
anti-biofilm effect of MomL was observed against P. aeruginosa and A. baumannii 
biofilms formed in microtiter plates, the effect of MomL and other QQ enzymes on 
biofilm formation under conditions more likely to mimic the real-life situation might be 
much less pronounced or even absent. 
In the second part, we focused on the effect of QS inhibitor coumarin on biofilms and 
virulence of P. aeruginosa in the context of wound infections. The QS inhibition 
activity of coumarin was confirmed in the biosensor P. aeruginosa QSIS2. The 
production of pyocyanin and protease was reduced by coumarin in several P. 
aeruginosa wound isolates. Coumarin also inhibited the biofilm formation of all six P. 
aeruginosa strains tested in microtiter plates; three strains showed reduced biofilm 
formation in would model when treated with coumarin. We further evaluated the 
effect of coumarin on the virulence of P. aeruginosa to L. sericata maggots, 
significantly increased survival was observed against two P. aeruginosa strains with 
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coumarin treatment. RNA-sequencing results on P. aeruginosa biofilm cells showed 
that several key genes involved in the las, rhl, PQS and IQS systems were down-
regulated by coumarin, as well as genes responsible for the QS-regulated virulence 
factor such as alkaline protease, hydrogen cyanide, LasA protease, LasB elastase, 
phenazine, siderophores and rhamnolipids. Intriguingly, coumarin down-regulated 
genes related to type III secretion system in P. aeruginosa planktonic and biofilm 
cells. The cellular level of c-di-GMP was also decreased by coumarin through the up-
regulation of tpbA. These results indicated that coumarin might reduce biofilms and 
virulence of P. aeruginosa by affecting QS, type III secretion and c-di-GMP levels, 
and might be promising in treating P. aeruginosa infections. 
Finally, we evaluated the effects of 12 known QSIs on A. baumannii. Among these 
compounds, baicailin hydrate, curcumin and quercetin significantly reduced biofilm 
formation of two A. baumannii strains without affecting planktonic cell growth. (+)-
Catechin hydrate, curcumin, indole and quercetin were found to inhibit the twitching 
motility of A. baumannii. Only two QSIs, curcumin and quercetin, significantly 
inhibited both biofilm formation and twitching motility of A. baumannii. We further 
evaluated the effect of curcumin and quercetin on the virulence of A. baumannii in a 
G. mellonella infection model. The survival of infected larvae was increased by 
approx. 30% and 50% when treated by quercetin and curcumin, respectively. 
Therefore, curcumin and quercetin might be effective QSIs to inhibit biofilm formation 
and virulence of A. baumannii. 
To conclude, our data demonstrated that QQ enzyme and QSIs can effectively inhibit 
virulence and biofilms of P. aeruginosa and A. baumannii under certain conditions. 
However, their effects can be strain dependent and might be reduced in the more 
complex environment encountered in vivo. Discovery of novel QSIs and further 
reseach on the mechanism of known QSIs may help us to identify truly potent QSIs 
targeting P. aeruginosa and A. baumannii. Evaluation of QQ enzyme and QSIs in 
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Quorum sensing (QS)-systemen van veel klinisch relevante pathogenen zijn 
betrokken bij het reguleren van verschillende processen geassocieerd met virulentie. 
Hierdoor kunnen bacteriën bij hoge celdensiteit een gecoördineerde aanval op de 
gastheer uitvoeren en de verdedigingsmechanismen van de gastheer met succes 
overwinnen. Daarom wordt inhibitie van QS door enzymen met quorum quenching 
(QQ) activiteit en conventionele QS-inhibitoren (QSI's) beschouwd als een 
aantrekkelijke therapeutische strategie voor de behandeling van infecties veroorzaakt 
door pathogenen zoals Pseudomonas aeruginosa en Acinetobacter baumannii. In dit 
proefschrift hebben we de effecten onderzocht van een QQ-enzym en verschillende 
QSI's op P. aeruginosa en A. baumannii, met als doel veelbelovende QS-remmende 
middelen te identificeren om virulentie en biofilmvorming van deze organismen te 
verminderen. 
In het eerste deel van dit proefschrift hebben we het QQ-enzym MomL opgezuiverd 
en het effect op biofilms van P. aeruginosa en A. baumannii-stammen geëvalueerd. 
MomL verminderde de biofilmvorming en verhoogde de biofilmgevoeligheid voor 
verschillende antibiotica in biofilms van P. aeruginosa PAO1 en A. baumannii LMG 
10531, gevormd in microtiterplaten in vitro. MomL had echter geen effect op het 
totale aantal cellen in een gemengde biofilm gevormd door P. aeruginosa én A. 
baumannii, en dezelfde teleurstellende resultaten werden verkregen in biofilms 
gevormd in een wondmodelsysteem. De virulentie van A. baumannii in het 
Caenorhabditis elegans-infectiemodel werd niet beïnvloed door MomL. Bovendien 
lijkt het effect van MomL op de biofilmvorming van Acinetobacter-stammen 
afhankelijk van de stam; er werd immers geen effecten van MomL op biofilmvorming 
gedetecteerd voor drie van de vijf geteste Acinetobacter-stammen. Deze resultaten 
gaven aan dat,  alhoewel een veelbelovend anti-biofilmeffect van MomL werd 
waargenomen tegen P. aeruginosa en A. baumannii biofilms gevormd in 
microtiterplaten, het effect van MomL en andere QQ-enzymen op biofilmvorming 
onder in vivo-achtige omstandigheden veel minder uitgesproken of zelfs afwezig kan 
zijn. 
In het tweede deel hebben we ons gericht op het effect van QS-remmer coumarine 
op biofilms en virulentie van P. aeruginosa in de context van wondinfecties. De QSI 
activiteit van coumarine werd bevestigd in de biosensor P. aeruginosa QSIS2. De 
productie van pyocyanine en protease werd gereduceerd door coumarine in 
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verschillende P. aeruginosa wondisolaten. Coumarine remde ook de biofilmvorming 
van alle zes P. aeruginosa-stammen die werden getest in microtiterplaten; drie 
stammen toonden verminderde biofilmvorming in dit model wanneer behandeld met 
coumarine. We evalueerden verder het effect van coumarine op de virulentie van P. 
aeruginosa in Lucilia sericata-maden; hierbij werd een significant verhoogde 
overleving waargenomen bij twee P. aeruginosa-stammen na coumarinebehandeling. 
Resultaten van RNA-sequencing op P. aeruginosa biofilmcellen toonden aan dat 
verschillende sleutelgenen betrokken bij de las-, rhl-, PQS- en IQS-systemen down-
gereguleerd waren door coumarine, evenals genen die verantwoordelijk zijn voor de 
productie van QS-gereguleerde virulentiefactoren zoals alkalische protease, 
waterstofcyanide, LasA-protease, LasB-elastase, fenazine, sideroforen en 
rhamnolipiden. Intrigerend zijn coumarine down-gereguleerde genen gerelateerd aan 
type III secretiesysteem in P. aeruginosa planktonische en biofilmcellen. Het 
cellulaire niveau van c-di-GMP werd ook verlaagd door coumarine door de 
opregulatie van tpbA. Deze resultaten gaven aan dat coumarine biofilmvorming en 
virulentie van P. aeruginosa zou kunnen verminderen door QS, type III-secretie en c-
di-GMP-niveaus te beïnvloeden, en dus mogelijk bruikbaar zou kunnen zijn bij de 
behandeling van P. aeruginosa-infecties. 
Ten slotte evalueerden we de effecten van 12 bekende QSI's op A. baumannii. Van 
deze verbindingen verminderden baicailinehydraat, curcumine en quercetine de 
biofilmvorming van twee A. baumannii-stammen zonder de groei van planktoncellen 
te beïnvloeden. (+) - Catechinehydraat, curcumine, indool en quercetine bleken de 
motiliteit van A. baumannii te remmen. Slechts twee QSI's, curcumine en quercetine, 
remden significant de vorming van zowel biofilm als twitching motility van A. 
baumannii. We evalueerden verder het effect van curcumine en quercetine op de 
virulentie van A. baumannii in een Galleria mellonella-infectiemodel. De overleving 
van geïnfecteerde larven werd verhoogd met ongeveer 30% en 50% wanneer 
behandeld werd met respectievelijk quercetine en curcumine. Daarom kunnen 
curcumine en quercetine effectieve QSI's zijn om biofilmvorming en virulentie van A. 
baumannii te remmen. 
Onze data toonden aan dat het QQ-enzym MomL en diverse QSI's onder bepaalde 
omstandigheden effectief virulentie en biofilms van P. aeruginosa en A. baumannii 
kunnen remmen. De effecten ervan kunnen echter afhankelijk zijn van de stam en 
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kunnen worden verminderd in de meer complexe omgeving die in vivo wordt 
aangetroffen. Ontdekking van nieuwe QSI's en verder onderzoek naar het 
mechanisme van bekende QSI's kan ons helpen om echt krachtige QSI's te 
identificeren die zich richten op P. aeruginosa en A. baumannii. Evaluatie van QQ-
enzymen en QSI's in relevante(re) modelsystemen en op klinische stammen is hierbij 
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